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Resistance to antibiotics is an increasing problem in the developing world. 
Resistance genes in the normal gut flora may act as a reservoir from which 
pathogens may acquire resistance. Trimethoprim is an important drug in the 
treatment of a wide range of infections but resistance has increased in recent years 
particularly in the developing world. 
A survey was conducted in Vellore, south India, to determine the rate of carriage 
of antibiotic resistant enterobacteria in the normal gut flora of a sample of the 
population. Very high rates of resistance were encountered to the widely used 
antimicrobials, ampicillin, chloramphenicol and trimethoprim. The trimethoprim 
resistant strains were analyzed further, 35 % were capable of plasmid- mediated 
transfer of trimethoprim resistance by different plasmid types, as identified by 
restriction endonuclease digestion. Resistance to a variety of other agents was co- 
transferred. Transferable trimethoprim resistance was shown, by DNA 
hybridization, to result from the presence of three different drug resistant 
dihydrofolate reductase (dhfr) genes. The dhfrV was present in 50% of 
transconjugants, associated with either the transposon Tn21 or only with the 
integrase -like open reading frame (orf) of this transposon; 31% possessed the dhfrl, 
associated with the integrase orf of Tn 7 and 19% had dhfrlV . 
The dihydrofolate reductase (DHFR) enzyme type IV has only ever been identified 
in this area of India, in 1984. The enzyme mediates only low level resistance, as 
measured by conventional tests, but it is inducible, a unique property in the 
DHFRs. It has persisted in this area despite a seemingly poor resistance 
mechanism. The DHFR typelV enzymes characterized during this survey were also 
inducible. It was demonstrated that the induction mechanism will produce over 
100 -fold greater resistance if the cells are challenged prior to determination of 
resistance level. This mechanism was shown to be mediated by a lack of thymine 
and to be dependant on cell phase and density. A plasmid characterized in this 
study also mediated resistance to ampicillin as a result of the presence of the 
IEM -1 ¡3- lactamase. This enzyme was also inducible, a property not observed 
before for this enzyme or for any other plasmid mediated 0- lactamase in Gram - 
negative bacteria, producing increased resistance to the widely used amoxycillin- 
clavulanic acid combination. The induction of both enzymes was cross -reactive, 
both trimethoprim and the 0- lactam drugs induced both mechanisms. The 
metabolic impact of the ß- lactams must be triggering the induction mechanism. 
This cannot, however, be by the same pathway as trimethoprim. 
The high rates of carriage of normal gut flora resistant to antimicrobials are 
probably the result of selection by antimicrobials which are freely available without 
prescription combined with poor hygiene and sanitation. The evolution of such 
unusual induction mechanisms may have resulted from the prevailing low level of 
antimicrobials or frequent exposure to low levels of drug as a consequence of self - 
dosing. High rates of resistance in normal flora and the evolution of such resistance 
mechanisms is serious because of their impact on the development of resistance and 
in the testing for resistance, when such induction mechanisms may disguise true 
resistance levels. 
The DNA sequence of the dh&IV was also determined and was shown to be only 
distantly related to the chromosomal dhñ- and other plasmid mediated dhfrs. 
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Ag Amoxycillin /clavulanic acid combination, in 2:1 ratio 
Ap Ampicillin 
bp Base pair 
BSA Bovine serum albumin 
C Cytosine 
CCCP Carbonyl cyanide m- chlorophenyl hydrazone 
cfu Colony forming units 
Cm Chloramphenicol 
Cp Cephaloridine 
dATP 2' deoxyriboadenosine triphosphate 
dCTP 2' deoxyribocytidine triphosphate 
DHF Dihydrofolate 
DHFR Dihydrofolate reductase 
dhfr Dihydrofolate reductase gene 
DM Davis Mingioli minimal salts medium 
DNA Deoxyribonucleic acid 
DSTA Diagnostic sensitivity test agar 
dTMP 2' deoxyribothymidine monophosphate 
dUMP 2' deoxyribouridine monophosphate 
EDTA Ethylenediaminetetraacetic acid 
foJA Chromosomal dihydrofolate reductase gene 
G Guanine 
ID50 Dose giving 50% inhibition 
IEF Isoelectric focusing 
In Integron 




MIC Minimum inhibitory concentration 
Mr Relative molecular size 
Mtx Methotrexate 
Na Nalidixic acid 
NADP Nicotinamide adenine dinucleotide phosphate (oxidized) 
NADPH Nicotinamide adenine dinucleotide phosphate (reduced) 
O.D. Optical density 
pABA Para -amino benzoic acid 
PAGE Polyacrylamide gel electrophoresis 
R Purine 
r Resistant 
RNA Ribonucleic acid 
RUHSA Rural unit for health and social administration 
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TD50 Time at 45 °C, in minutes, giving 50% inhibition 
TEMED N, N, N' ,N' -tetramethyl- ethylenediamine 
THE Tetrahydrofolate 




The standard single and three letter abbreviations are used for the amino acids. 
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Antimicrobial agents remain one of the few chemotherapeutic regimes that can 
effect a total cure of the disorder afflicting the patient. Trimethoprim, despite over 
24 years of use, is still a potent drug in many infections. Its low cost has made 
trimethoprim an important agent in the treatment of a wide range of infections 
especially in the developing world. In many areas, however, particularly in the 
developing world, the use of trimethoprim is being compromised by high rates of 
resistance among enterobacteria (Levy et al 1987; Elwell and Fling 1989). 
THE BEGINNING OF MODERN ANTIBACTERIAL 
CHEMOTHERAPY AND BACTERIAL RESISTANCE 
1.1.1. The Early Development of Antibacterials 
The development of trimethoprim (2,4- diamino -5- (3,4,5, -trimethoxybenzyl) 
pyrimidine) can be seen as leading directly from work done in the early years of 
antimicrobial chemotherapy by Woods on the sulphonamide antimetabolites 
(Woods 1940). The dye prontosil had been discovered earlier by Gerhard Domagt 
(1935) but had been shown to possess poor anti -bacterial activity. It was 
subsequently shown, by Tréfouel et aí(1935) that the colourless metabolite of the 
drug, the sulphonamide component, was the active agent. Woods proposed that the 
sulphonamide produced, when the dye prontosil was metabolised, competed with 
p- aminobenzoic acid (PABA) in the formation of folic acid. Thus the site of action 
of the drug was identified (figure 1). 
Exploitation of Fleming' s famous discovery of penicillin (Fleming 1929) by Florey 
and Chain (Abraham 1983) switched the main thrust for the treatment of bacterial 
infections towards the true antibiotics produced by micro -organisms. There had 
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been previous reports of the inhibition of the growth of bacteria by moulds, and by 
other bacteria, by Pasteur and Joubert (1877) and as early as 1874 by William 
Roberts, who observed the inhibition of bacteria by Penicillium glaucum. These 
observations could not be exploited because the technology of the time was too 
limited. It was only after Fleming's report that the time was right for the 
exploitation of the antibiotic. Penicillin was purified and characterized by Florey 
and Chain (Abraham 1983) and production on a large scale was undertaken by 
large American chemical companies. This started the search for more and more 
antibiotics which were chemically modified and subsequently synthesized to 
improve efficacy and production. 
1.1.2. The Development of Resistance 
Very soon after the introduction of penicillin into clinical use, resistance mediated 
by penicillinases began to appear (Abraham and Chain 1940; Kirby 1944). This 
has been a continuing theme in antimicrobial chemotherapy. The introduction of 
greater and greater numbers and varieties of antibiotics has been met by the 
evolution of resistance mechanisms in the bacteria (Goldstein et al 1974). The 
development of such resistance mechanisms has not always been by stepwise 
mutations of the chromosome but has involved extra -chromosomal genetic 
material. The role of plasmids in the transfer of resistance between organisms was 
first identified by Akiba et al (1960) as cited by Watanabe (1963), and has since 
been shown to be relevant in most groups of antibiotics. More recently other 
molecular mechanisms have been described which are capable of mediating the 
movement of resistance genes between the replicons of host organisms, 
chromosomes and plasmids, revealing the enormous potential for the exchange of 
resistance genes between organisms and the development of resistance. 
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TRIMETHOPRIM AS AN ANTIBACTERIAL AGENT 
1.2.1. The Action of Trimethoprim 
The site of action of trimethoprim is the bacterial dihydrofolate reductase 
(DHFR) [5,6,7,8- tetrahydrofolate:NADP+ oxido- reductase, EC 1.5.1.3], which is 
selectively inhibited, whilst the mammalian DHFR is not (Burchall and Hitchings 
1965). The selective inhibition of the bacterial DHFR by trimethoprim in 
comparison to the mammalian enzyme, with 100,000 -fold higher affinity for the 
drug, has been shown, by X -ray crystallography, to be the result of a much better 
"fit" of the trimethoprim molecule in the DHF binding site of the bacterial enzyme 
(Matthews et al 1986). The biochemical pathway upon which both trimethoprim 
and sulphonamides act is that which leads to the formation of tetrahydrofolate 
(THF), an essential co- factor in the synthesis of several amino acids, purines and 
pyrimidines (Burchall 1973; Hitchings 1973), particularly thymine (Amyes and 
Smith 1974a). Bacteria cannot take -up pre -formed folate molecules, therefore 
trimethoprim acts selectively against bacterial cells. 
The sulphonamides inhibit the action of dihydropteroate synthetase, thus blocking 
the condensation of dihydropterate from pABA and dihydropteridine. Dihyrofolate 
is then synthesised from dihydropteridine and dihydropteroate by the action of 
dihydrofolate synthetase. Dihydrofolate reductase then catalyses the reduction of 
dihydrofolate to tetrahydrofolate. Trimethoprim is a competitive inhibitor of 
dihydrofolate reductase, being an analogue of dihydrofolate (Brown 1971) 
(figure 1). 
The metabolic effect on the cell of the inhibition of dihydrofolate reductase is wide 
ranging. Tetrahydrofolate serves as a carrier of one carbon units for the 
biosynthesis of methionine, formyl methionine tRNA and purines and is thus 
central to extensive metabolic processes. A product of THF, 5,10- methylene THF 
is involved in thymine biosynthesis. As well as donating the single carbon moiety, 
5,10- methylene THF also donates 2 hydrogen atoms, this oxidation process 
regenerates DHF. (Figure 2). DHF is inactive in this metabolic cycle and must be 
reduced to the tetrahydrofolate state. Trimethoprim blocks the reduction to the 
"active" reduced form (Hitchings 1983). 
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Figure 1. The biosynthetic pathway of tetrahydrofolate inhibited by trimethoprim 
and the sulphonamides. 
Dihydropteridine ABA 
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Figure 2. The pathway of 5,10- methylene THF formation from THF on which 
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The bactericidal effect of trimethoprim is the result of thymine starvation (Then 
and Angehrn 1973). Bacteria are almost universally capable of utilizing exogenous 
purines and amino acids; however, they cannot take -up thymine. Thus in the 
presence of amino acids and purines, available in tissues, the bacteria grow in an 
unbalanced way resulting in the rapid depletion of thymine and subsequent death of 
the cell (Then and Angehrn 1973). Bacteria are capable of utilizing thymidine, the 
ribonucleoside of thymine, the presence of which will antagonise the effect of 
trimethoprim, but this is only present in very low amounts in normal tissue. 
It has been shown that the amino acids methionine and glycine together with a 
purine contribute to thymineless death. Amyes and Smith (1974a) demonstrated 
that in minimal media trimethoprim has a bacteriostatic effect; however, in the 
presence of the amino acids methionine and glycine plus a purine the effect of 
trimethoprim is bactericidal. These three metabolites, which are all products of the 
THF pathway inhibited by trimethoprim, act on the pathway which converts THF 
to 5,10- methylene THF. This molecule, as described above, is involved in thymine 
metabolism, being the methyl donor in the formation of dTMP from dUMP (figure 
2). The provision of these three metabolites acts to conserve THF in the presence 
of trimethoprim, thus preventing the formation of 5,10- methylene THF and the 
biosynthesis of thymine (Amyes and Smith 1974a). 
The provision of a purine in the growth media acts in three ways. 1) It will inhibit 
the purine biosynthetic pathway, thus inhibiting the formation of 10- formyl THF 
and 5,10- methenyl THF (Miovic and Pizer 1971). 2) Purines act directly on 5,10 - 
methylene dehydrogenase; this inhibits the reaction 5,10- methenyl THF a 5,10 - 
methylene THF (Sibler and Mansouri 1971). 3) 10- formyl THF is a precursor of 
formyl methionine tRNA as well as purine biosynthesis. Thus, if a purine is 
provided, 10- formyl THF will be conserved for the formation of formyl met RNA 
and the initiation of protein synthesis (Dickerman 1971). Protein synthesis is 
necessary for the bactericidal effect of trimethoprim (Miovic and Pizer 1971); the 
conservation of formyl met tRNA is therefore important in the action of 
trimethoprim. 
The addition of glycine in the media will push the reversible serine a glycine 
reaction, catalysed by serine hydroxymethyl transferase, in the direction of serine 
formation. This will act to conserve THF and deplete 5,10- methylene THF. 
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Methionine has two effects on 5,10- methylene THF formation. 1) Methionine has 
been shown to inhibit serine hydroxymethyl transferase; thus the formation of 
glycine and 5,10 -methylene THF will be inhibited, as above, but in the presence of 
glycine this will have no further metabolic effect (Sibler and Mansouri 1971). 2) 
Methionine inhibits its own biosynthesis by inhibiting 5,10- methylene THF 
reductase. This enzyme catalyses the reaction 5- methyl THF a 5,10- methylene 
THF (Katzan and Buchanan 1965). The homocysteine a methionine equilibrium is 
strongly biased in favour of methionine, therefore the addition of methionine to the 
media does not greatly influence the flux of THF --> 5,10- methylene THF (Amyes 
and Smith 1974a). 
The addition of all three metabolites is required to produce the observed 
bactericidal effect (Amyes and Smith 1974a). They act in concert to prevent the 
formation of 5,10- methylene THF, and thus the formation of thymine, and to 
maintain protein synthesis. The organism undergoes thymineless death resembling 
that of a thymine requiring auxotroph in thymine deficient media (Amyes and 
Smith 1974a). Of course in the absence of trimethoprim the formation of THF 
from DHF must be sufficient to drive the pathway towards 5,10- methylene THF. 
1.2.2. Trimethoprim in combination 
Trimethoprim, first described in 1962 (Roth et al 1962), was formulated against a 
background of increasing resistance to the antibiotics. It was developed as an anti - 
metabolite acting on the same metabolic pathway as the sulphonamides (Figure 1) 
and was thus contrived as a potentiator of the sulphonamides (Bushby and 
Hitchings 1968). It was argued that the inhibition of DHFR by trimethoprim at a 
stage further along the pathway leading to folic acid synthesis would lead to 
synergy with the sulphonamides by "sequential blocking" (Hitchings 1969). It has 
also been argued that the sulphonamides themselves inhibit bacterial DHFR since 
sequential blocking of the same pathway could not produce an effect greater than 
that of the most active single inhibitor (Brown 1962). So trimethoprim and 
sulphonamide must act together on the DHFR in order to produce a synergistic 
effect (Poe 1976). It would seem likely, however, that the inhibition of 
dihydropteroate synthetase by the sulphonamides acts by limiting the supply of 
DHF, the substrate for dihydrofolate reductase; thus trimethoprim will be more 
effective, being in competition with lower levels of DHF (Hitchings 1973). This 
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results in increased bacteriostatic and bactericidal activity in vitro, and subsequent 
decrease in MIC ( Bushby 1973). Besides the synergistic benefits in the use of both 
drugs together, it was hoped that the combination would act to delay the onset of 
resistance (Hitching s 1973). 
1.2.3. The Use of Trimethoprim as a Single Agent 
Despite the observed synergy of trimethoprim and the sulphonamides in vitro 
(Hitchings 1969; Bushby 1973), it has been argued that synergy will not occur in 
vivo. Sulphonamides act to lower the MIC of trimethoprim; thus synergy is seen 
only at trimethoprim concentrations below the MIC (Lacey 1979). Trimethoprim, 
because it inhibits the bacterial DHFR to such an extent, would need to be at sub - 
inhibitory levels and the sulphonamide at very high levels for synergy to be shown. 
Levels of trimethoprim found in tissue are usually much greater than the MIC for 
the infecting organism (Lacey 1979). The maximum synergistic effect is seen at 
ratios of trimethoprim to sulphonamide of 1:20 or 1:25 (Bergan and Brodwall 
1972). This ratio is only observed in serum (Bergan and Brodwall 1972; Kaplan et 
al 1973); in other tissues trimethoprim is at much higher levels (Wilkinson and 
Reeves 1979) than this "ideal" ratio and will therefore be exerting the major if not 
all the effect of the combination. 
It has been shown that there is no difference in the clinical efficacy of the 
combination over trimethoprim used as a single agent (Lacey et al 1980). In vitro 
models of urinary tract infection (UTI) have produced results in agreement with 
these findings. Levels of sulphonamide achievable in the bladder are not 
sufficiently high to contribute to the action of trimethoprim (Greenwood and 
O'Grady 1976; Greenwood 1979). Laboratory findings did, however, indicate that 
exposure to trimethoprim alone resulted in greater mutation to resistance when 
compared with exposure of bacteria to the combination (Darrel et al 1968). Results 
of clinical trials, however, reported no difference in cure rates or the emergence of 
resistance between trimethoprim, as a single agent, and the combination (Lacey et 
al 1980). A study conducted by Amyes, Doherty and Wannacot (1986) found no 
significant difference between the two regimes in the treatment of respiratory tract 
infections. 
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Some consensus has arisen that the combination has not delayed the development 
of resistance to either trimethoprim or to sulphonamide (Lacey 1982), as had 
originally been suggested. This probably resulted from the widespread resistance to 
sulphonamides before the introduction of trimethoprim. Many of these resistance 
genes were situated on promiscuous and widespread mobile genetic elements 
(Bissonnette and Roy 1992). 
Trimethoprim as a single agent has been available in the UK since 1979. Towner 
and Slack (1986) reported an increase in the proportion of trimethoprim resistant 
sulphamethoxazole -sensitive Enterobacteriaceae from UTI after the introduction 
and increasing use of trimethoprim as a single agent. The authors also concluded 
that this had not resulted in a great increase in resistance to trimethoprim. In 
Finland trimethoprim has been available as a single agent since 1973 and 
increasingly high rates of resistance to trimethoprim have been reported associated 
with high levels of consumption of the drug (Huovinen et al 1986). General rates 
of resistance in Finland do not, however, seem to be higher than those reported in 
other western countries. Resistance in three Finnish cities was reported as between 
14% and 19% in 1988 (Heikkilä et al 1990a). This compares to a rate of just 
below 20% in France (Goldstein and Acar 1990), where the combination is used 
extensively. Thus, the benefits in the use of trimethoprim alone, i.e. fewer adverse 
reactions, may outweigh the benefits of the use of the combination, which seem at 
best debatable in vivo. The argument may have swung away from the prevention of 
the onset of resistance, by the combination, to the suggestion that the combination 
may produce selective pressures that produce a linkage between the widespread 
sulphonamide resistance genes and trimethoprim resistance genes (Sundström et al 
1988; Sundström and Sköld 1990). 
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THE EPIDEMIOLOGY OF TRIMETHOPRIM RESISTANCE 
The introduction of trimethoprim has been followed by an increase in resistance 
found in clinical isolates as monitored in many regions (Goldstein and Acar 1990). 
However comparisons between studies are often difficult because of a number of 
factors such as patient groups, type of specimen and methodology may differ 
(Goldstein Papadopolou and Acar 1986; Amyes 1989) and there are local 
variations within areas (Elwell and Fling 1989). General trends can be seen, 
however, and sequential studies have provided useful information at a number of 
centres (Towner and Slack 1986; Towner 1982; Towner et al 1991; Heikkilä et al 
1990a). With improved techniques more information is becoming available about 
the dissemination and mechanisms of resistance. The most striking feature in the 
epidemiology of trimethoprim resistance is the contrast between the developed 
world, where rates of resistance are generally low, and the developing world, 
where rates of resistance are considerably higher. 
Enteric and diarrhoeal disease represents a major problem in many developing 
countries. Resistance in the bacterial pathogens causing such infections is a serious 
threat to the ability to combat such life threatening diseases (Farrar 1985). 
Resistance to trimethoprim is of particular importance, since organisms such as 
Shigella, Salmonella and Vibrio remained sensitive to trimethoprim whilst 
resistance has developed to ampicillin and chloramphenicol. This then represented 
a cheap and effective oral antimicrobial, with a long shelf life, with which to treat 
infections caused by bacteria which are increasingly resistant to the conventional 
therapy, ampicillin and chloramphenicol (Levy et al 1987; Shahid et al 1985). 
1.3.1. Resistance to Trimethoprim in the Developed World 
There have been numerous reports pointing to a general trend towards increasing 
rates of resistance to trimethoprim which seems to have stabilized in recent years 
(Goldstein and Acar 1990). From 1971 -82, Gruneberg (1984) reported an increase 
in hospital isolates, in London, resistant to trimethoprim from 3.2 to 14.3 %. 
Similar rates of resistance were seen in other studies centred in London hospitals, 
13% in studies by both Brumfitt et al (1983) and Chirnside et al (1985). Similar 
figures were published for urinary tract isolates in Edinburgh over the period 1982- 
4 where overall resistance was 16.5% (Amyes, Doherty and Young 1986). 
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Hamilton -Miller and Purves (1986) reported an increase from 6 to 19% resistance 
to trimethoprim over the period 1981 to 1985. In a sequential study by Towner and 
Slack (1986) of Enterobacteria in UTI there was some increase in resistance to 
trimethoprim in E. coli, Proteus spp., Klebsiellae and Enterobacter in the 
community and hospitals in the Nottingham area. For example E. coli resistant to 
trimethoprim and sulphamethoxazole increased from 0.3% in 1978 to 11.3% in 
1984 and 9.3% in 1985, in the community; and from 2.0% in 1974 to 14.0%and 
12.0% in 1984 and 1985 respectively, in hospital isolates. As mentioned above the 
authors also noted an increase in the isolation of trimethoprim resistant 
sulphamethoxazole sensitive isolates concomitant with an increase in the use of 
trimethoprim as a single agent. Similar studies have been carried out in Finland 
with similar results. In Helsinki from 1978 -1988 resistance in enterobacteria rose 
from 3 to 19 %, and from 1980 -1988 in Turku and Ronvaniemi the increase was 5 
to 16% and 3% to 14% respectively ( Heikkilä et al 1990a). However, Huovinen et 
al (1986) reported an increase of 8% to 35% during 1971 to 1984 associated with 
heavy use of trimethoprim in a Finnish hospital. In the USA resistance to 
trimethoprim is low, being reported at between 4% and 6% (Murray et al 1985). 
There are also variations in patient populations; 40% resistance was reported in a 
Finnish geriatric hospital (Heikkilä et al 1990c), which compares to similar figures 
for geriatric wards in a British hospital of 50% in ward acquired infections but 
only 26% in infections acquired prior to admission (Bendall et al 1989). Amyes, 
Doherty and Young (1986) reported 64% of urinary bacteria resistant to 
trimethoprim from patients in a long -stay hospital in Edinburgh, compared to 
16.5% in the general hospital population. These results probably reflect the 
nosocomial basis of the resistance in these situations and perhaps the high use of 
the drug to treat infections common in these patients. 
Although there has been an increase in resistance to trimethoprim since the mid 
1970s in western countries it is generally seen to be below 20 %, besides 
exceptional patient populations. 
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1.3.2. Trimethoprim Resistance in Developing Countries 
The situation in developing countries is quite different, with numerous reports of 
high rates of resistance (Goldstein, Papadopolou and Acar 1986). In a study of 
urinary pathogens in Vellore, south India, 64% of isolates were reported as being 
resistant to trimethoprim (Young et al 1986a). Similar figures were obtained in a 
study of trimethoprim resistance from Nigeria. 63.3% of urinary tract isolates were 
found to be resistant to trimethoprim, 93.3% of which had associated resistance to 
sulphamethoxazole (Lamikanra and Ndep 1989). In a three centre, study 44% 
resistance was reported in Santiago, Chile; 40% in Bangkok, Thailand, and 48% in 
Honduras (Murray et al 1985). A study in Chile reported 34% resistance occurring 
in Enterobacteria mostly from UTI, before the introduction of the drug, 78% of 
which was plasmid mediated (Urbina et al 1989). The authors speculated that other 
resistance determinants on the plasmids concerned were co- selecting for resistance 
to trimethoprim. In Tanzania 36% of E. coli were reported as being resistant to 
trimethoprim (Young and Amyes 1986b). 
Murray and Matthewson (1990) demonstrated that resistant faecal flora was quickly 
acquired by visitors to developing countries; of 13 US students, previously clear of 
trimethoprim resistant faecal flora, 7 were shown to have acquired trimethoprim 
resistant faecal flora after a visit to Mexico, an area where resistance to 
trimethoprim is high (Murray and Matthewson 1990). Although this is only a very 
small study group it does demonstrate a route of transmission of resistance genes 
from third world areas to the developed world, especially given the increase in 
world travel. 
Thus a contrast can be seen between the situation in developed and developing 
countries in the prevalence of resistance to trimethoprim. This is reflected in the 
increase in resistance to trimethoprim in those pathogens associated with enteric 
and diarrhoeal disease, a great problem in the developing world. 
1.3.3. Trimethoprim Resistance in Shigella 
Barada and Guerrant (1980) suggested trimethoprim as the drug of choice in the 
treatment of shigellosis resistant to ampicillin. Resistance to trimethoprim in 
Shigella had been virtually unknown until the late 1970s, when Bannatyne et al 
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(1980) reported that 3% of Shigella isolated in Ontario were resistant to 
trimethoprim. Other western countries showed similar increases. Between 1979 and 
1983 Shigellae resistant to trimethoprim rose from 1.3% to 17% in England and 
Wales (Gross et al 1984). Spain in particular had a very high rate of resistance 
amongst Shigellae, 89% resistance was reported in 1983 (Palenque et al 1983). 
Recent reports from the Netherlands also show high rates of resistance in species of 
Shigella, resistance to trimethoprim amongst S. sonnei rose from 16% to 46 %, in 
S. flexneri from 8 to 25 %, in the period 1984 -89 (Voogd et al 1992). In Finland it 
has been reported that resistance in shigellae that was only 3.0% had risen to 
43.8% by 1988 (Heikki lä et al 1990b). A recent survey, again from Ontario 
demonstrated increasing resistance among shigellae, from the 3% previously 
reported to 26.7% in S. boydii, and 39.4% in S. Bexneri (Harnett 1992) . In the 
USA, however, general rates of resistance in shigellae are low, 7 %, but higher 
rates were seen in people who had recently been abroad (Tauxe et al 1990). 
Rates of resistance in shigellae reported in the developing world are considerably 
higher. In Bangladesh resistance rose rapidly after trimethoprim was introduced on 
a large scale in 1981 (Shahid et al 1985). Resistance among shigellae rose from 
5% in 1979 to 83% in 1983 (Zaman et al 1983). There was also a concomitant 
switch in the dominant cause of shigellosis from S. flexneri to S. dysenteria type I 
(Shiga's bacillus) which had become resistant more rapidly than other species. This 
was a serious turn of events since S. dysenteria is a much more dangerous 
organism (Shahid et al 1985). 
There have been similar reports from Zaire where therapy for shigellosis was 
switched from tetracycline to trimethoprim resulting in a rapid increase in 
resistance to 83% (Frost et al 1982). A similar situation was seen in India where 
100% sensitivity to trimethoprim - sulphamethoxazole was described in 1981 
amongst S. dysenteria; this, however, rose rapidly to 94% resistance in 1984 
(Macaden and Bhat 1985). In Vellore, south India, 84% of S. flexneri and 88% of 
S. shigae were found to be resistant to trimethoprim, most as the result of 
transferable resistance (Jesudason et al 1989). 
Trimethoprim resistance on a Navajo Indian reservation in the USA rose from 3% 
to 21 % among shigellae. A correlation was also shown between those receiving 
antimicrobials and those infected by resistant organisms. Resistant faecal flora were 
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also shown in 28% of children who presented with symptoms but no single 
promiscuous plasmid could be identified as mediating resistance (Griffin et al 
1989). The in vivo transfer of resistance to trimethoprim- sulphamethoxazole 
between E. coli and Shigella was also demonstrated in the same reservation. The 
index patient was shown to be a woman being treated prophylactically with the 
drug for a persistent urinary tract infection. An E. call resistant to the combination 
was isolated from the urine and, subsequent to the development of shigellosis, a 
Shigella was isolated that was resistant to trimethoprim -sulphamethoxazole. Both 
organisms were found to harbour very similar resistance plasmids indicating that 
the E. coli was the source of resistance in the Shigella (Tauxe et al 1989). 
1.3.4. Trimethoprim Resistance in Salmonella 
Trimethoprim- sulphamethoxazole was shown to be as effective as ampicillin or 
chloramphenicol in the treatment of salmonellosis (Butler et al 1982), and, like 
Shigellae, resistance was not widespread, especially in S. typhi, before the late 
1970's (Threlfall et al 1983). However, among S. typhimurium resistance to 
trimethoprim was 7 %, largely as the result of the spread of a single phage type, 
204c, (Threlfall et al 1980b), and the carriage of multi -resistant plasmids (Threlfall 
et al 1986), the acquisition of which was probably the result of the successive use 
of different antimicrobials to counter S. typhimurium in cattle ( Threlfall et al 
1986). 39% of cattle isolates and 4% of human isolates were phage type 204c, 
drug resistant strains. 
The acquisition of drug resistance by S. typhi has been shown to be less likely 
(Paramasivan et al 1977). However, Tn 7 probably mediating DHFR type I (the 
most commonly isolated of the plasmid- encoded trimethoprim resistant DHFRs), 
has been encountered in S. typhi (Richards and Datta 1982). In Peru 14% of S. 
typhi were trimethoprim resistant (Taylor et al 1985); in Mexico a similar figure, 
16 %, was reported by Solorzano et al (1987). 
1.3.5. Trimethoprim Resistance in Vibrio 
Reports of trimethoprim resistance in Vibrio have been fairly infrequent. It was 
first demonstrated in a multi -resistant plasmid from Vibrio cholerae, in Dacca, 
Bangladesh (Threlfall, Rowe and Huq 1980). Again in the Indian subcontinent, 
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resistant Vbrio cholerae was reported in 1984 (Sunderan and Murthy 1984). More 
recently, transferable trimethoprim resistance in V cholerae has been reported in 
Vellore, south India (Jesudason and John 1990). 
The DHFR type II has been recorded as mediating trimethoprim resistance in V 
cholerae in Thailand (Tabtieng et al 1989). It has been reported that plasmid 
mediated resistance to trimethoprim in V cholerae is limited to the Inc 6 -c 
incompatibility group (Goldstein, Gerbaud and Courvalin 1986). 
Young and Amyes (1986b) demonstrated the presence of a plasmid, in 10 strains of 
Vibrio cholerae el tor Inaba from Tanzania, that encoded a resistance mechanism 
that was biochemically very much like the DHFR type Ia. The plasmid was thought 
to be derived from the plasmids of the Enterobacteriaceae that were prevalent in 
the area. The DHFR type I has also been shown integrated into the V cholerae 
chromosome as part of Tn 7 (Goldstein, Gerbaud and Courvalin 1986). 
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TRIMETHOPRIM RESISTANCE IN NORMAL 
FAECAL FLORA 
1.4.1. The Relevance of Resistance in Normal Faecal Flora to 
Disease States 
Resistance in normal gut flora may be relevant to the occurrence of resistance in 
clinical isolates, for two reasons: 1) The gut flora themselves may cause an 
infection. 2) The gut flora may contribute to a gene pool of antibiotic resistance 
genes which may be acquired by pathogenic organisms (Hawkey 1986; Levy et al 
1988). The transfer of R- factors in vitro is well documented, however, plasmid 
transfer in vivo in the gut is not (Anderson et al 1973). These authors demonstrated 
that, although they could not achieve transfer between two marked strains in the 
gut of volunteers in the absence of antibiotic, when therapeutic doses of antibiotic 
were administered transfer of the R- factors could be demonstrated. It seems likely, 
however, that under normal conditions R- plasmid bearing strains are eliminated 
from the gut after antimicrobial chemotherapy is ended, the resistant organisms do 
not persist in the gut, although it would seem that the organism itself is eliminated 
not the plasmid from the cell (Anderson 1974; Bennet and Linton 1986). Tauxe et 
al (1989) demonstrated the acquisition of a trimethoprim- sulphamethoxazole 
resistance plasmid by a Shigella from an E. coli, causing a urinary tract infection, 
which had previously been treated with trimethoprim. 
Resistant strains may be passed from one person, receiving antimicrobials, to 
another who is not. Petroceilou et al (1977) reported that tetracycline resistant 
strains of E. coli, of the same serotype, could be isolated from a woman receiving 
long -term tetracycline therapy and her husband who received no antimicrobials. 
The same tetracycline resistance plasmid was also isolated in a different serotype of 
E. coli, that had not been carrying the plasmid at the onset of the study 
(Petroceilou et al 1977). This group had also previously demonstrated the transfer 
of R- factors in the gut of two healthy volunteers (Petroceilou et al 1976). In a 
follow -up study, cross -infection continued. Following long -term therapy with 
tetracycline, the woman was also treated with ampicillin. The tetracycline resistant 
organisms were eliminated to be replaced by ampicillin resistant E. coli. However, 
after all therapy had been stopped the tetracycline resistant organisms became 
dominant again. These strains persisted until they were replaced by tetracycline 
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sensitive E. coli of the same serotype as the resistant strain. This strain was also 
found to have a plasmid identical to the tetracycline resistance plasmid except for a 
1Md insert which had stopped expression of tetracycline resistance (Petroceilou et 
al 1979). The curtailment of resistance expression confers an advantage on the cell 
when no challenge is present but the plasmid itself is maintained. 
Thus it seems likely that normal flora carrying resistance genes can transfer these 
genes to other organisms and can spread between hosts, and that a background use 
of antimicrobials facilitates this process. However, doubt has been cast on the 
ability of normal faecal E. coli to cause infection, with the finding by Siitonen 
(1992) that such organisms isolated from healthy individuals did not possess the 
virulence factors found in organisms that cause infection. It was proposed that 
invasive organisms do not arise from the normal flora of the patient but are caused 
by organisms that first invade and colonize the gut and then infect other areas such 
as the urinary tract. 
1.4.2. Surveys of Resistance in Normal Faecal Flora 
In 1969, Datta reported 52% of admission samples at a London hospital contained 
organisms that were resistant to at least one antimicrobial, although resistance to 
any particular drug was not more than 38 %, in the case of sulphamethoxazole. 
Linton et al (1970) showed 67% of children and 46% of adults harbouring resistant 
organisms. The rate in a rural sample was higher, at 63% of adults, presumably 
because of the use of antimicrobials in animal husbandry. The resistance was 
shown to be R- factor mediated in 61 % of strains. 
In a study conducted in Boston, 60% of isolates from normal faecal samples were 
resistant to one or more antimicrobial agents. Resistance to ampicillin was the 
highest; 40% of the samples contained E. coli resistant to ampicillin (Levy et al 
1988). In a comparative study between Boston, Caracas, Peru, and Qin Pu, China, 
great differences were observed between the resistant organisms carried by children 
in Boston and children in the cities of the developing countries. 21 of 39 children 
had antimicrobial resistant E. coli in faecal samples, as opposed to 40 of 41 in 
Caracas and 51 of 53 in Qin Pu. In Boston, 1 of the 39 carried a trimethoprim 
resistant E. coli, but 25 of 41 in Caracas and 34 of 53 in Qin Pu had E. coli 
resistant to trimethoprim. None of the isolates from Boston were resistant to more 
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than six antibiotics but 6% in Caracas and 20% in Qin Pu were. These figures 
were directly reflected in the proportions of resistant organisms isolated from 
clinical specimens in these cities, demonstrating the link between resistance in 
normal and pathogenic flora (Lester et al 1990). 
A study in the Sudan also showed high rates of resistance in the normal flora of 
children in developing countries. 96% carried ampicillin- and 77% trimethoprim- 
resistant E. coli; 19 of 40 tested possessed R- factors mediating resistance (Shears et 
al 1988). 
In a study of students from the Netherlands, 25% of normal faecal samples 
contained E. coli resistant to trimethoprim, 86% to sulphamethoxazole and 76% to 
ampicillin (Bonten et al 1990). In a recent study the same group presented similar 
high figures for resistance in two industrial centres in the Netherlands; 89% 
resistance to ampicillin and 28% resistance to trimethoprim (Bonten et al 1992). 
These figures are high and high rates of resistance amongst pathogenic organisms 
have also been reported in the Netherlands. Resistance to ampicillin in Shigella 
flexneri was reported at 53% and resistance to trimethoprim in S. sonnei at 46% 
(Voogd et a1 1992). 
Under circumstances where faecal contamination is high, because of poor hygiene, 
spread of resistant organisms is high, as reported in the study of a children's day- 
care centre by Reves et al (1990). Twenty eight percent of samples contained 
trimethoprim -resistant E. coli, and 65% contained ampicillin- resistant E. coli. 
These centres, it was suggested, could represent important foci for the 
dissemination of resistant organisms (Reves et al 1987). It has subsequently been 
demonstrated that members of the families of children harbouring resistant strains 
also have trimethoprim resistant strains in their normal flora (Fornasini et al 1992). 
High rates of resistance in normal flora will be reflected in resistance in clinical 
isolates since these arise directly, or may acquire resistance factors from, normal 
flora (Lester et al 1990). Thus, monitoring of resistance in normal flora may give 
important indications of resistance in clinical isolates (Bonten et al 1992). 
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1.4.3. Conditions Supporting the Development of Resistance 
Life threatening enteric pathogens are capable of rapid acquisition of resistance. 
This represents a considerable problem in developing countries where such 
infections are far more common and much more dangerous. The emergence and 
spread of resistance is supported by overuse and misuse of antimicrobial drugs 
(Griffin et al 1989; Levy et al 1987). The causes of such misuse are complex and 
many. Some of the factors involved are: Poor diagnosis through lack of resources 
and education resulting in poor selection of antimicrobial agents in the treatment of 
infections; misconceptions of the efficacy of antimicrobials, there is a pervading 
attitude that antimicrobials are "wonder- drugs" that can cure many ailments; 
promotion by drug companies can often be misleading, forceful and very 
persuasive. These factors lead to a "shot -gun" approach to the use of antimicrobials 
with considerable sub -optimal use. Restrictions on the purchase of antimicrobials, 
whether de facto or de jure, are fewer in developing countries which results in over 
the counter purchase and self -dosing (Levy et al 1987). 
The spread of resistant organisms is also assisted by poor hygiene, over -crowding, 
poor general health and living conditions (Griffin et al 1989; Levy et al 1987). 
This can result in the constant circulation of resistant organisms from those who 
are taking antimicrobials. 
In some areas, reduction in drug use, switch to support therapy for mild infections 
and better hygiene may be possible (Griffin et al 1989). However, the problems of 
third world regions are considerable. The appropriate use of antimicrobials must 
not be discouraged since the need is great in regions where bacterial infections are 
widespread and much more dangerous (Levy et al 1987). 
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MECHANISMS OF RESISTANCE TO TRIMETHOPRIM 
The novel and synthetic nature of trimethoprim has presented an ideal opportunity 
to observe the development of resistance to an antibacterial from day zero (Amyes 
and Towner 1990). The antibiotics such as penicillin are derived from natural 
products, thus resistance to such compounds will be extant in the bacterial gene 
pool. There was no such background in the development of resistance to 
trimethoprim since it was a totally novel agent. 
The bacteria have not disappointed us in their response to trimethoprim. The target 
site of the drug was novel and the subsequent evolution of the organisms has been 
as novel. Five responses conferring protection from the effects of trimethoprim on 
the cell have been characterized. 
1. Thymine auxotrophy. 
2. Impermeability. 
3. Mutation in the chromosomal DHFR structural gene. 
4. Hyperproduction of chromosomal DHFR. 
5. Production of a second DHFR with low affinity for the drug. 
1.5.1. Thymine Auxotrophy 
Trimethoprim was used to produce thymine requiring auxotrophs in vitro by Stacey 
and Simson (1965) and Bertino and Stacey (1966) by growing organisms in the 
presence of trimethoprim and thymidine. These mutants are highly resistant to 
trimethoprim (Amyes and Smith 1975). Thymidylate synthetase is non -functional, 
thymine is acquired directly from the medium. This effectively "shortcircuits" the 
THE pathway, the action of trimethoprim can no longer produce thymineless 
death. Obviously, this is only an effective resistance mechanism as long as thymine 
is present in the medium. Thymine is not usually present in normal tissue and 
therefore the occurrence of such mutants in this case is not possible (Maskell et al 
1978). There have, however, been several reports of such mutations arising during 
trimethoprim therapy (Okubadejo and Maskell 1973; Hayek and Netherway 1976). 
Acar and Goldstein (1982) reported that 1.5% of trimethoprim resistant strains 
were thymine requiring auxotrophs. For these mutants to arise there must be an 
underlying source of thymine or a derivative which supports the growth of the 
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auxotrophs. Dead pus cells or bacteria in renal calculi are possible sources of 
thymine (Maskell et al 1976). 
1.5.2. Impermeability 
Pseudomonas aeruginosa is intrinsically resistant to trimethoprim despite 
possessing a chromosomal DHFR which is sensitive to the drug. It has, therefore, 
been argued that there must be a permeability barrier preventing trimethoprim from 
entering the cell (Burchall et al 1982). Resistance to trimethoprim as a result of 
reduced penetration into P. aeruginosa has been reported (Werner and Goeth 1984) 
but the relevance of impermeability to resistance to trimethoprim has been 
questioned (Scudamore and Golder 1989). Permeability mutants of strains normally 
sensitive to trimethoprim have also been reported. Mutants of Klebsiella 
pneumoniae were isolated that possessed cross -resistance to nalidixic acid, 
chloramphenicol and trimethoprim following exposure to any of the drugs; it was 
speculated that the cross -resistance could be the result of a permeability barrier 
(Smith 1976). This phenomenon has also been reported in Serratia and 
Enterobacter but has not been demonstrated in Escherichia coli or Proteus (Acar 
and Goldstein 1982). On examination of the outer -membrane proteins, these strains 
of Serratia and Enterobacter were found to be deficient in proteins corresponding 
to porins. There was also a concomitant reduction in the uptake of [3H]- glucose 
and [14C]- chloramphenicol indicating a change in the permeability of the cell wall 
(Gutmann et al 1985). It appears likely that this is a true impermeability resistance 
mechanism produced in vitro. Thirty such mutants were also isolated from patients 
(Gutmann et al 1985). However, the epidemiological significance of such a 
mechanism is a matter of debate; impermeability is often sited when no other 
mechanism can be identified to account for the observed resistance (Hamilton - 
Miller 1979). 
1.5.3. Alteration in the Chromosomal Dihydrofolate Reductase 
Mutations in the DHFR structural gene, that result in reduced affinity of the 
enzyme for the drug rendering cells more resistant, as measured by higher DHF K; 
values in the presence of trimethoprim, can be produced by chemical mutagenesis 
or the selection of spontaneous mutants, in vitro (Smith et al 1982). These 
mutations in the structural gene are often accompanied by changes in the regulation 
of production of the enzyme resulting in higher levels of DHFR with a reduced 
sensitivity (Sheldon 1977). Smith et al (1982) found that mutations occurred in two 
specific amino acids at a highly conserved region associated with DHF binding 
(Freisheim et al 1978). 
Although these mutations have been studied in detail in laboratory mutants their 
clinical significance has not been widely investigated. Thirteen highly resistant 
strains of P. cepacia were shown to have an altered DHFR resulting in decreased 
drug sensitivity. However, this could not solely account for the high level 
resistance observed and permeability or hyper- production may have been involved 
(Burns et al 1989). Degroot et al (1991) have reported decreased chromosomal 
DHFR combined with hyper -production of the enzyme as being responsible for 
trimethoprim resistance amongst isolates of Haemophilus infuenzae. A survey of 
133 strains reported chromosomal DHFRs with reduced sensitivity in Enterobacter 
spp. and Klebsiella aerogenes (Grey et al 1979). There are no methods for the 
rapid detection and analysis of altered chromosomal DHFR. The purification and 
biochemical analysis of enzyme samples is extremely time- consuming; the 
performance of any meaningful survey would thus be a practical impossibility. 
1.5.4. Hyper -production of Dihydrofolate Reductase 
Resistance to trimethoprim by the over -production of the chromosomal DHFR is 
rare amongst clinical isolates (Elwell and Fling 1989). The constitutive over- 
production of DHFR would probably result in an imbalance which would seriously 
disrupt the metabolism of the cell (Koch 1981). Such mutations have, however, 
been produced in vitro. Sheldon (1977) produced three mutants that were resistant 
to trimethoprim having DHFRs that were hyper -produced, 10 -fold, and had 
reduced affinity for trimethoprim. It has been suggested that DHFR is responsible 
for its own regulation, by autogenous control of the promoter, because alterations 
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in the structural gene can lead to over -production, suggesting that the DHFR must 
be acting as an operator on its own promoter (Goldberger 1974). This seems an 
unlikely scenario since the regulation of DHFR has been shown to be cis -acting 
and it is improbable that DHFR is an autogenous cis -acting regulator (Sheldon and 
Brenner 1976). Sheldon (1977) proposed alternative explanations; mutations for 
increased DHFR production and reduced affinity for trimethoprim occurred at 10-8 
or 10-9 suggesting a single event so, unless DHFR is a cis -acting regulator, the 
mutation must act to increase the efficiency of initiation of translation. 
Tennhammar -Ekman et al (1986) reported resistance in a clinical strain of E. coli 
as the result of over -expression of chromosomal DHFR. The enzyme was over- 
produced 200 -fold and also had reduced affinity for trimethoprim. The production 
of the enzyme was also increased by the addition of trimethoprim to the medium; 
higher levels of enzyme were induced three minutes after the addition of the drug 
to exponentially growing cells at a cell density of 2x108 cells /ml. This process was 
dependent on protein synthesis and was not produced by thymine starvation with 
the addition of the uridine analogue 5- fluorouracil; although this was not tested 
directly by the use of thymine auxotrophy or the addition of thymine to the 
medium to antagonise the effect of trimethoprim. Over -production of the DHFR 
has subsequently been shown to be the result of more efficient transcription and 
translation of the fol gene through 1) mutations in the ribosomal binding region 
leading to increased homology with the 16S ribosomal subunit, 2) lengthening the 
distance between this region and the start codon and 3) mutations in the promoter 
region. These changes all result in increased transcription and translation 
(Flensburg and Sköld 1987). Smith et al (1982) found similar changes in 
constitutive "promoter -up" mutations produced in the laboratory. However, these 
findings do not explain the induction by trimethoprim of further increases in the 
production of DHFR. No mechanism has been suggested for the induction of the 
chromosomal enzyme (Tennhammar -Ekman et al 1986). 
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1.5.5. Resistance Mediated by the Presence of a Second 
Dihydrofolate Reductase with Reduced Affinity for 
Trimethoprim 
The most important mechanism of resistance is that mediated by the production of 
a second insensitive DHFR, thus by- passing the block imposed by the action of 
trimethoprim on the sensitive enzyme (Amyes and Smith 1974b; Sköld and Widh 
1974). 
Table 1. The biochemical properties of the plasmid mediated DHFRs. 











la 57.0 4.4 0.5 5.6 7.4 35 > 1000 
lb 32.0 2.8 1.2 11.0 41 24.5 >1000 
IIa 70000.0 1100.0 >12 4.6 6100 35 >1000 
IIb 80000.0 750.0 >12 8.3 150 35 > 1000 
IIc 20000.0 1000.0 >12 4.2 400 34 >1000 
IIIa 2.0 0.2 > 12 0.4 0.019 16.9 64 
IIIb 2.0 0.2 > 12 9.5 0.4 17 128 
IIIc 3.0 0.007 8 3.1 0.5 22 256 
IV 0.2 0.02 >12 37.0 0.063 46.7 10 
V 20.0 2.3 * 15.4 3.2 §5 > 1000 
VI 200.0 7.25 0.4 31.2 75.0 10 >1000 
VII 30.0 3.0 1.5 20.0 7.0 11.5 > 1000 
VIII - - - - - - >1000 
IX 0.01 - - - - 19.86 250 
X - - - - - 21.2 500 
XII - - - - - - > 2000 
S1 50.0 0.002 >12 10.8 11.6 19.7 >1000 
* Dependent on protein concentration. 
§ Apparent molecular weight by Sephadex gel filtration. 
Plasmid mediated resistance to trimethoprim was first described in 1972 by 
Fleming et al. It has subsequently been shown to be mediated by a variety of 
mobile genetic elements (Sundström et al 1988: Bissonnette and Roy 1992). A 
number of plasmid mediated DHFRs, insensitive to the action of trimethoprim, 
have been described and classified, initially based on their biochemical properties 
(Amyes 1989; Huovinen 1987). Those enzymes recently described have been 
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classified solely on their DNA sequences and hybridisation with known gene 
probes, nothing being known of their biochemical properties (Amyes et al 1992). 
1.5.5a. The Type I Dihydrofolate Reductase 
Sköld and Widh (1974) described the by -pass resistance mechanism in relation to 
the enzyme produced by the plasmid R483. The enzyme was subsequently 
designated the DHFR type I ( Pattishall et al 1977). The enzyme was found to be 
moderately resistant to trimethoprim; Tp ID50 (the concentration of drug required 
to reduce activity by 50 %) was shown to be 57µM. The enzyme is, however, 
produced in 10 -fold greater quantities than the chromosomal enzyme, rendering the 
cell resistant to high levels of drug. It was also shown to be heat labile (Pattishall 
et al 1977). The enzyme has a dimeric subunit structure, each subunit having a 
molecular weight of 18,000 (table 1). This in contrast to the monomeric structure 
of the chromosomal enzyme, although this has a molecular weight of 18,000 
equivalent to that of the single subunit of the type I (Fling and Elwell 1980). When 
the DNA sequence of the subunit is aligned with that of the chromosomal enzyme, 
homology can be seen between the two enzymes, greatest homology occurring 
around the substrate binding site (Fling and Richards 1983). Recent analysis puts 
the similarity between the two enzymes at 57% with 37% identity (Singh et al 
1992). Such homology points to a common ancestor or the resistant enzyme has 
been introduced from a species very close to E. coli (Fling and Richards 1983). 
The DHFR type I is the most commonly isolated of the trimethoprim resistant 
DHFRs. It is located on the transposon Tn 7 (Barth et al 1976), although it has also 
been isolated in association with Tn21 (Sundström and Sköld 1990). The 
transposon Tn 7 inserts into a specific site in the E. coli chromosome, the Tn 7 
attachment site (attTn 7) , with very high frequency and in one orientation, although 
it will also transpose at lower frequency to other sites in the chromosome and other 
replicons (Lichtenstein and Brenner 1981; 1982). Thus, Tn 7 and DHFR type I 
have a tendency to become fixed in the chromosome of E. coli, integrated at the 
attTn7 site (Heikkilä et al 1991). So the DHFR I has become more frequently 
identified in the chromosome of clinical isolates (Towner et al 1980; Kraft et al 
1986; Steen and Sköld 1985 Heikkilä et al 1991). 
26 
The DHFR type I is the dominant DHFR found in resistant isolates, especially in 
the industrialised world. Towner et al (1991) reported 86.4% of trimethoprim 
resistant E. coli from Nottingham harboured the DHFR type I in 1978 -83; this, 
however, dropped to 62.3% in 1987 -88. In a survey in Finland, 73% of resistant 
isolates were found to have the DHFR type I, mostly integrated in the host 
chromosome (Heikkilä et al 1991). In a wider survey of trimethoprim resistance in 
Finland, although it was less frequently identified, the DHFR type I was still the 
dominant resistance mechanism, and increased from 51% of resistant isolates in 
1984 to 63 % in 1987 (Heikkilä et al 1990a). A recent report of a survey in 
Taiwan reported 45.4% of resistance to trimethoprim mediated by the DHFR type 
I (Chang et al 1992). Of trimethoprim resistant Shigella spp. in Finland, 85% of 
resistance was mediated by the DHFR type I, the enzyme being present in 35% of 
all Shigella spp. (Heikkilä et al 1990b). The gene has also been detected in 
Shigella dysenteriae, both on plasmids and in the chromosome, in isolates from 
various parts of south east Asia (Haider et al 1990). Similarly Tn 7 has been shown 
to mediate trimethoprim resistance in Salmonella typhi (Richards and Datta 1982). 
Tn 7 -like transposons have also been implicated in trimethoprim resistance in Vibrio 
spp., both integrated in the chromosome (Goldstein et al 1986) and in plasmid 
mediated resistance in Vibrio cholerae el tor inaba (Young and Amyes 1986). 
The DHFR type I has also been recently reported as a "gene- cassette" inserted into 
Tn21 and thus linked to the sulphonamide resistance gene which is associated with 
this element (Sundström and Sköld 1990). It has been reported in this new location 
in 6 of 75 isolates in Finland (Heikkilä et al 1991). This gives a new twist in 
trimethoprim resistance conferred by the type I DHFR, provided by "gene- 
cassette" structures and integrons. 
A DHFR with similar but distinct properties to the DHFR type I (table 1), has also 
been characterized and designated as the type lb DHFR (Young and Amyes 1985). 
It was originally purified from a strain of E. coli isolated in Edinburgh but until 
recently no DNA probe was available so little is known of its epidemiology 
(Qumsieh and Young 1991). 
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1.5.5b. The Type II Dihydrofolate Reductases 
The type II DHFRs are a group of three related enzymes showing significant 
homology at the DNA level (Flensburg and Steen 1986; Stone and Smith 1979; 
Swift et al 1981) and very similar biochemical properties (Pattishall et al 1977), 
which must share a common origin. The type II enzyme of the plasmid R388 was 
the first identified instance of trimethoprim resistance mediated by production of a 
second DHFR insensitive to the drug (Amyes and Smith 1974b); the enzyme has 
since been designated as the type Ilb. The type IIa, of plasmid R67, was shown to 
be almost completely insensitive to the action of trimethoprim, the IDso being 
70mM compared to 57µm for the DHFR type I (table 1) (Pattishall et al 1977). 
These enzymes all have molecular weights of 35,000, having a tetrameric subunit 
structure, each subunit being Mr 8,000 (Joyner et al 1984). Sequence analysis has 
confirmed these findings and shown that the subunits are homogeneous (Flensburg 
and Steen 1986; Stone and Smith 1979; Swift et al 1981). Sequence analysis has 
also shown the types IIa, b, and c to be completely unrelated to the other DHFRs. 
This would account for the very high resistance of the enzymes to trimethoprim 
and has provoked speculation that these enzymes are oxido- reductase enzymes that 
have assumed DHFR function (Elwell and Fling 1989). 
The type II DNA probe was initially generated from R67 providing an 850bp probe 
(Mayer et al 1985). However, this probe contains a portion of the widespread 
transposon Tn21 and produces frequent false positives (Towner 1990). An 
alternative is the 280óp fragment in pWZ280 derived from R388 (Zolg and Hangii 
1978). The probes can be used in the detection of any of the three type II DHFRs 
because of the high degree of homology that they share. 
The prevalence of the type II DHFRs in Europe is low; 1.5% of trimethoprim 
resistant E. coli (Towner et al 1991), and only 3 isolates of 1300 resistant 
Enterobacteriaceae in Finland (Heikkilä et al 1990), carried a type II enzyme. A 
report from Greece, however, showed the type II DHFRs to be the dominant form 
of trimethoprim resistant DHFRs in species other than E. coli, i.e. Klebsiella, 
Enterobacter and Serratia spp., although the type II was also reported in a small 
number of E. coli (Tsakris et al 1993). This seemed to be the result of the spread of 
related plasmids amongst these species (Tsakris et al 1992); the authors speculated 
that the plasmids carrying the two different genes had different evolutionary origins 
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(Tsakris et al 1993). Both of these surveys employed the small probe fragment and 
could be considered reliable. Other reports outside Europe have also reported high 
prevalence of type II DHFRs. These have, however, employed the large type II 
probe and false positives may have been counted. Thirty two percent of 
trimethoprim resistant Shigella spp. and 50% of enterotoxigenic E. coli harboured 
type II DHFRs, compared to 9% and 14% carrying the DHFR type I 
(Chatkaemorakot et al 1987). Sixty per cent of trimethoprim resistance in Chile 
(Murray et al 1985), and 26% in a worldwide selection of enterobacteria (Fling et 
al 1982) was type II mediated. Tabtieng et al (1989) reported trimethoprim 
resistance in an outbreak of Vibrio cholera as the result of two plasmids carrying 
type II dihydrofolate reductase. 
The type II DHFRs, despite the presence of the IIc on a transposon (Shapiro and 
Sporn 1977), seem to have a localized distribution and occur only as plasmid 
mediated resistance ( Tsakris et al 1992; Papadopolou et al 1986). 
1.5.5c. The Type III Dihydrofolate Reductases 
The type III DHFR was first identified by Fling et al (1982), after a small 
mobilisable plasmid conferring low level trimethoprim resistance in Salmonella 
typhimurium failed to hybridize with either the type I or II probes. The enzyme 
carried by this plasmid was shown to be sensitive to low levels of trimethoprim, 
reflected in the ID50 1.5µM. High affinity for the substrate, however, shown in the 
low DHF Km (table 1), confers a moderate level of resistance on the cell. The 
minimum inhibitory concentration is 64mg /L. It is a monomeric protein of Mr 
16,900; this structure, size and high level of DNA homology, 51% identity, 
reflects a close relationship to the chromosomal DHFR of E. coli (Fling et al 
1988). 
Despite being originally isolated on a broad host range plasmid of incompatibility 
group Inc Q (Hedges 1987), and speculation that this would lead to rapid spread of 
the enzyme (Joyner et al 1984), reports of the type III have remained few. Its 
presence in the UK has been confirmed (Thomson et al 1990) and there has been a 
report of increasingly frequent detection of the type III gene in Nottingham, from 
1.2% in 1978 to 20.3% in 1987 -88 in trimethoprim resistant E. coli (Towner et al 
1991). The low frequency of detection of the type III DHFR may be as a result of 
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the less frequent testing of low level trimethoprim resistant strains for 
transferability or the presence of insensitive DHFRs. It is often assumed that 
resistance of this low level is chromosomal in origin. It has been noted that the 
presence of low level transferable resistance to trimethoprim means that it is 
important to test such isolates for the presence of transferable trimethoprim 
resistance (Towner and Pinn 1981). 
More recently two enzymes have been identified in the US. that have been 
designated as the types IIIb and IIlc DHFRs because of their close biochemical 
similarities to the original type III, the IIIa. Both of the enzymes were identified in 
plasmids from Shigella sonnei outbreaks (Barg et al 1990). Moderate levels of 
resistance is conferred by these enzymes which have only slightly raised 
insensitivity to trimethoprim and very similar ID50 figures (2.0µM and 3.0µM) to 
that of the type IIIa. However, they have less affinity for the substrate (table 1), 
and did not hybridize with the type IIIa probe (Barg et al 1990). 
The N- terminal sequence of the IIIb has been elucidated and shown not to be 
directly related to the type IIIa, notwithstanding the similarities in biochemical 
properties (Thomson, Barg and Amyes 1990). The nucleotide sequence of IIIc has 
also recently been detemined and again shares little homology with the IIIa. 
Although it shares some homology with the E. coli chromosomal DHFR it seems 
most closely related to the DHFR of Halobacteria volcannii (S. G. B. Amyes 
personal communication). 
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1.5.5d. The Type IV Dihydrofolate Reductase 
During a survey of urinary pathogens from Vellore, India (Young et al 1986a), a 
group of plasmids were identified that conferred unusually low resistance to 
trimethoprim in Isosensitest agar or minimal agar containing methionine, glycine 
and adenine, MIC 5mg /L, but showed increased resistance when tested on minimal 
agar, MIC 160mg \L (Young et al 1986b). 
It was speculated that the presence of the metabolites were having an effect on the 
expression of the type IV DHFR (Young et al 1986b) by their influence on the 
metabolic pathway leading from THF to 5,10- methyl THF and the formation of 
thymine (as described previously). It has been shown that the presence of the 
DHFR IV in E. coli K12 J62 -2 allows the cells to grow in the presence of 10mg /L 
trimethoprim in minimal media, but cell death occurs in this concentration of drug 
if methionine, glycine and adenine are present (Young et al 1993). The DHFR was 
subsequently shown to be inducible at trimethoprim concentrations of greater than 
10mg /L; up to 600 -fold increase in production of the enzyme is seen, a unique 
property of this DHFR (Young and Amyes 1986a). It has been speculated that it is 
the over -production of the enzyme that confers resistance on the cell since the 
enzyme is not very resistant to trimethoprim (table 1)(Thomson, Young and Amyes 
1993). 
The induction mechanism itself also appears to be less than straightforward. 
Induction of the enzyme does not seem to be a direct response to the presence of 
the drug but rather a response to the metabolic effect imposed by trimethoprim. 
Induction of the enzyme does not occur until between 5 and 14 hours after 
inoculation of broth containing trimethoprim (Thomson et al 1993). The induction 
of the enzyme has also been shown to be dependant on the presence of methionine, 
glycine and adenine (Thomson et al 1993). This would seem to contradict the MIC 
results. The MIC is lower in media containing methionine, glycine and adenine 
than in minimal media; it might then be expected that the enzyme will be induced 
in minimal media but be lower in media containing methionine, glycine and 
adenine. The presence of thymidine completely abolishes the effect and cell death 
and morphological changes associated with thymine starvation can be observed in 
the cells prior to induction of the DHFR. Thymine deficiency, therefore, seems to 
play a role in mediating the induction of the enzyme (Thomson et al 1993). 
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The enzyme has been shown to be larger than the other DHFRs, Mr 46,000, 
although this may be an over estimate and the actual Mr may be only 36,000 
(Thomson Young and Amyes 1990), and it is only partially resistant to 
trimethoprim, ID50 0.2µM (Young and Amyes 1986a). 
This induction mechanism seems to be quite unlike the chromosomal induction 
mechanism described by Tennhammar -Ekman et al (1986) and Flensberg and 
Sköld (1987), in which the response to trimethoprim is immediate and thymine is 
not thought to influence expression. 
The type IV DHFR has not been encountered elsewhere but this may be because, 
as with the case of the type III, low level trimethoprim resistance is not followed 
up as closely as high level resistance. This may be even more applicable to the type 
IV given the very low levels of resistance shown on convential media. A DNA 
probe is available for this enzyme and, although this includes large regions outside 
the structural gene, little cross -hybridisation is seen with the other standard 
DHFR -carrying plasmids (Towner et al 1988). 
1.5.5e. The Type V Dihydrofolate Reductase 
The DHFR type V was originally isolated in Sri Lanka where it was shown to be 
the most common enzyme mediating plasmid -borne trimethoprim resistance 
(Sundström et al 1987). It has since been isolated sporadically in Europe and the 
US. Less than 0.3% of trimethoprim resistant enterobacteria were reported to 
harbour the type V in a study conducted in Finland ( Heikkilä 1990a), while 4% of 
enterobacteria from a children's day care centre in the US carried this enzyme and 
Towner et al (1991) reported only slightly higher levels in Nottingham at 9.9% in 
the period 1978 -83 and 5.8% in 1987 -88. However, a study in Sicily reported that 
all Shigella sonnei from an outbreak of trimethoprim resistant shigellosis harboured 
only the DHFR type V. This was mediated by the spread of only two plasmids and 
these plasmids or the original infection may have originated in Sri Lanka (Agodi 
et al 1990), indicating a localized spread of the enzyme. An investigation of 
trimethoprim resistant Shigella spp. in Finland reported that in only 5 of 175 
strains was the DHFR type V implicated; in four of these cases the patients had 
recently returned from Sri Lanka (Heikkilä et al 1990a). 
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The enzyme itself has biochemical properties very similar to the type I DHFR 
(Towner et al 1990) (table 1). When sequenced it was shown to be closely related 
to the type I, having 84% similarity and sharing 75% identity (Sundström et al 
1988; Singh eta/ 1992). 
The DNA probe for this gene is 500óp long and is comprised of almost only the 
structural gene, providing a very specific probe which under conditions of high 
stringency shows no hybridisation to the other DHFRs, even the closely related 
type I (Towner et al 1988). 
The dhfrV gene is found in the transposon Tn21 and as such is associated with 
sulphonamide resistance, an enormous genetic advantage if the trimethoprim- 
sulphonamide combination is in use. As part of the Tn21 -like transposon group the 
dhfrV has been identified as a "gene- cassette" in an integron structure (Sundström 
et al 1988). Although the distribution of the DHFR type V has been wide its 
prevalence remains low in most parts of the world. 
1.5.5f. The Type VI Dihydrofolate Reductase 
There has been only one reported report of this gene, in a strain of Proteus 
mirabilis from South Africa (Wylie et al 1988). It is similar to the type I in 
sequence, sharing 63% homology with the type I and the type V, (Wylie and 
Koornhof 1991). It does not, however, cross -hybridise with the other DHFR gene 
probes (Towner 1990). It is also more resistant to trimethoprim, reflected in a 
higher Tp ID50 and K; (table 1) (Wylie et al 1988). The DNA probe for this gene 
has not been available so nothing is known of its epidemiology. 
1.5.5g. The Type VII Dihydrofolate Reductase 
Originally identified in a porcine isolate of E. coli, the type VII DHFR is similar 
to the type Ia, Ib and V DHFRs in its biochemical properties (Amyes et al 1989). 
An intragenic DNA probe has been produced which is 300bp in length and which 
shows some degree of cross -hybridisation with the types I and V indicating close 
similarity of the enzymes at the DNA level (Towner and Carter 1990). The 
nucleotide sequence of the dhfr 
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VII gene, located on transposon Tn5086, has recently been determined and has 
been shown to be related to the types I, V and VI, having between 64 and 71% 
homology with these dhfr genes (Sundström et al 1993). 
Although originally identified in an animal isolate, there is evidence of a shared 
pool of R- factors in animal and human bacteria (Towner et al 1986) and the type 
VII has subsequently been identified at low frequency in human isolates from 
Finland (Heikkilä et al 1990a) and seems to be increasing in prevalence in 
Nottingham, where it was first identified, from 1.2% of trimethoprim resistant E. 
coli in 1978 -83 to 7.2% in 1987 -88 (Towner et al 1991). The enzyme was also 
isolated in Scandinavia where it has been sequenced and shown, as predicted by 
biochemical and hybridisation data, to be closely related to the types I and V 
(Sundström et al 1993). This gene, like the dhfrI and dhfrV, is associated with a 
transposon. The dhfrVII has been shown to be part of the Tn21 -like transposon 
Tn5086, which like Tn21 has an associated integron which may have been 
responsible for the location of dhfrVII in the transposon. The transposon also 
mediates resistance to quaternary ammonium compounds, mercuric ions and 
sulphamethoxazole. The dhfrVII, and the transposon have been shown on a 
plasmid, R22259, isolated originally in Sweden in 1974 (Sundström et al 1993); 
thus despite its recent characterization the gene has been in existance for almost 20 
years. 
1.5.5h. The Type VIII Dihydrofolate Reductase 
The type VIII mediating high level resistance has been reported only once. It has a 
sequence that marks it as being different from the type I -like enzymes, the V, VI 
and VII (Sundström 1989) 
1.5.5i. The Type IX Dihydrofolate Reductase 
Like the type VII, this DHFR was originally isolated in a porcine strain. It was 
initially identified in two distinct plasmid types in Sweden (Jansson and Sköld 
1991). This enzyme mediates only moderate levels of resistance to trimethoprim, 
MIC 250mg /L, even though it has an ID50 of 20µM compared to 57µM for the 
type I; it was speculated that the lower resistance was as a result of lower 
expression of the gene (Jansson and Sköld 1991). The type IX shares some 
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homology with the type I (29 %), the type III (31 %), and the E. coli chromosomal 
enzyme, and seems to represent an intermediary resistance mechanism (Jansson and 
Sköld 1991). It has, so far, been isolated in only one human strain but was 
reported in 11% of porcine trimethoprim resistant E. coli, in Sweden; 
approximately 60% of resistance was the result of the presence of the type I 
enzyme (Jansson, Franklin and Sköld 1992). Its wider spread into human bacteria 
may be limited because of the success of the type I DHFR. 
1.5.5j. The Type X Dihydrofolate Reductase 
The type X DHFR has recently been isolated in Australia. It has been sequenced 
and appears to be located on an unusual integron, In7, and as such is associated 
with sulphonamide resistance. It shows homology with other DHFRs, up to 28% 
identity, 45% similarity. The putative enzyme has a molecular weight of 21,000 
and from the sequence data appears not to directly related to any other DHFRs, 
although it may have a similar molecular weight. The spread of the gene is being 
monitored and a probe derived from the sequence will be available (Parsons et al 
1991). 
1.5.5k. The Type XII Dihydrofolate Reductase 
The last of the recently isolated dhfr genes in gram- negative rods, isolated from an 
E. coli strain in the normal flora of children from a child day care centre in Texas, 
has also only been characterized by its sequence (Singh et al 1992). Like the type 
X nothing is known of the biochemical properties of the enzyme. The gene shares 
some homology with the other dhfs, 60% similar, 35% identical to the type III; 
59% similar, 39% identical to the type V; 56% similar, 32% identical to the 
type I; and 57% similar, 36% identical to the E. coli chromosomal enzyme; it 
would again seem not to be directly related to any of the other dhfis (Singh et al 
1992). It confers resistance at an MIC of 500mg /L and in the study was reported to 
be fairly widespread in the sub -population under investigation, being present in 
21% of the trimethoprim resistant E. coli (Singh et al 1992). 
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1.5.51. The Type SI Dihydrofolate Reductase in Staphylococcus 
The only DHFR resistant to trimethoprim so far identified in Staphylococci is the 
type S1 (Amyes and Tait 1990). First identified and characterized (Young et al 
1987) in an Australian Multi- resistant S. aureus (MRSA), the enzyme confers high 
level resistance, being produced in high quantities and is resistant to trimethoprim, 
ID50 50j. M. It has a molecular weight equivalent to that of the staphylococcal 
chromosomal enzyme (Young et al 1987). A plasmid mediated DHFR from 
Staphylococci was also isolated in the US (Coughter et al 1987), and this has also 
been demonstrated to be a type 51 (Tait and Amyes 1989). The Si has also been 
demonstrated in strains from Eastern Europe (Hartmann et al 1988), London 
(Amyes and Tait 1990) and in other species of Staphylococci (Tait and Amyes 
1989). 
The DNA sequence has shown the gene to be related to the chromosomal enzyme 
(Hartmann et al 1988; Rouch et al 1989) and is associated with insertion sequences 
responsible for transposition into the chromosome (Rouch et al 1989) where it is 
expressed at a reduced level (Amyes and Tait 1990). 
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TRANSPOSONS AND INTEGRONS 
1.6.1. Transposons 
The first report by Fleming in 1972 that trimethoprim resistance was plasmid 
mediated has been followed by many studies that have demonstrated the increasing 
prevalence and dissemination of trimethoprim resistance (Towner 1982; Kraft et al 
1986; Amyes 1989). However, four years after the initial demonstration of plasmid 
mediated trimethoprim resistance, it was shown that the dhfr I gene, of R483, was 
located on a transposon, Tn 7 (Barth et al 1976). Transposition of antibiotic 
resistance genes was first demonstrated in ampicillin resistance by Hedges and 
Jacob (1974). Since then transposons have been shown to be widespread and 
responsible for numerous resistance mechanisms (Grinsted 1986), and are perhaps 
responsible for the acquisition of resistance by clinical plasmids (Datta and Hughes 
1983). 
Two classes of transposon have been shown to mediate resistance in gram- negative 
rods; class I, or composite, and class II, or complex transposons, that differ in 
both structure and function (Galas and Chandler 1981; Harshey and Bukhari 1981; 
Schmitt 1986). The class I transposons are a heterogeneous group of elements that 
carry a variety of resistance mechanisms but share little homology at the DNA 
level (Grinsted 1986). Their structure is relatively simple. They are formed from 
two insertion sequences (IS), the basic transposable element, that occur in either 
direct or indirect repeats between which is situated the resistance gene. IS elements 
are the regions that code for the transposase, the enzyme responsible for 
recombination (Schmitt 1986). These elements are flanked by inverted or direct 
repeat sequences of between 8 and 40 base pairs (bp) and provide recognition 
sequences for the transposase, thus four repeat sequences are available as 
recombination sites so a number of conformational outcomes are possible (Grindley 
and Reed 1985). 
A conservative mechanism of action has been proposed for the transposition of 
class I elements (Morisato and Kleckner 1984; Schmitt 1986) in which the 
transposon is excised from the donor replicon at the repeat sequences and 
integrated at the target site, destroying the donor in the process. However, a 
process has also been proposed in which donor and target replicons form a co- 
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integrate; replication of this structure then takes place before resolution of the 
replicated transposons, leaving a complete transposon in both replicons (Shapiro 
1979). However, this seems a more likely mode of action of the class II or 
complex transposons (Schmitt 1986). The entire class II element is flanked by 
inverted repeat sequences of between 30 and 40 bp, that again serve as recognition 
sequences for the transposase. The enzymes responsible for transposition are not 
found flanking the resistance genes but are found to one end. The transposition 
enzymes are the products of genes tnpA, the transposase, and tnpR, the resolvase 
responsible for the resolution of the replicated co- integrate of donor and target 
DNA formed by the transposase at a site res (Kleckner 1981); a third gene tnpM is 
involved in regulation of transposition (Schmitt 1986). 
1.6.2. Integrons 
Recently it has been recognized that a number of antibacterial resistance 
mechanisms are present in the same, or closely related class II transposons, 
forming a group of transposons like Tn21(Wiedemann et al 1986; Martinez and de 
la Cruz 1988). These transposons, together with the Tn3 family, are the major 
contributors to multi- resistance plasmids (Grinsted et al 1990). Resistance to 
sulphamethoxazole is usually present; OXA and PSE ß- láctamases are frequently 
present (Lafond et al 1989) as are a variety of transferase genes mediating 
resistance to aminoglycosides (Wohileben et al 1989; Hall and Vockler 1987). 
Resistance to mercuric compounds is also a common feature of these structures 
(Brown et al 1986). The trimethoprim resistance genes dhfr IIc (Fling and Elwell 
1980) and dhfr V (Sundström et al 1988) were both identified in Tn21 -like 
transposons. 
It is not immediately obvious how so many different resistance mechanisms can be 
located in the same transposon. Tn21 and similar elements are capable of acquiring 
novel resistance mechanisms and resistance to new drugs, indicating a greater level 
of sophistication (Zuhlsdorf and Weidemann 1992). It has been recognized that 
these structures have been formed by the insertion of resistance genes into already 
existing transposons by a recA independent recombination system known as 
integration (Martinez and de la Cruz 1988). 
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In the transposons, and plasmids carrying similar structures without the presence of 
the transposon, e.g. R388 and R46 (Sundström et al 1988), highly conserved 
regions are found in sequences immediately surrounding the structural gene. 
Flanking the structural gene for antimicrobial resistance are GTTRRRY sequences 
which mark the insertion points for the resistance gene and represent 
recombinational "hot- spots" for cross -over of genes, forming "gene- cassette" 
structures (Schmidt et al 1989; Martinez and de la Cruz 1990). At the 5'end of the 
resistance gene there is a conserved region that contains a common promoter 
immediately upstream of the insertion site, thus any inserted genes are transcribed 
from this common promoter (Stokes and Hall 1989), and 5' to this is an open 
reading frame (ORF) which codes for a protein which shares homology with both 
transposon resolvases and phage site - specific integrases (Oullette and Roy 1987; 
Mahillon and Lereclus 1988). This integrase has been designated int (Stokes and 
Hall 1989) or tnpl (Mercier et al 1990). 
At the 3'end is the active site for the insertion of new genes by the integrase 
(Martinez and de la Cruz 1990) and in the correct orientation for transcription from 
the common promoter (Collis and Hall 1992). This is an imperfect palindromic 
region of about 59 bp, the structure of which has been shown to be quite variable 
in length and sequence (Zuhlsdorf and Weidemann 1992), which has at its 3'end 
the "hot- spot" GTTRRRY sequence, into which the new gene will insert by cross- 
over at the GTTRRRY sequences of the in- coming "gene- cassette" and the target 
sequence (Collis and Hall 1992). 
These elements have been called integrons (Stokes and Hall 1989) and appear to be 
responsible for the accumulation of many resistance genes in plasmids and Tn21- 
like transposons (Bissonnette and Roy 1992). Evidence of an ancestral integron has 
been found in plasmid pSV1, a plasmid of P. aeruginosa. This consists of only the 
integrase region and a single GTTRRRY cross -over point (Bissonnette and Roy 
1992). This "primitive" integron lacks the 59bp region, which may indicate that 
this region was initially associated with an in- coming resistance gene (Bissonnette 
and Roy 1992), since this is necessary for the integration of new genes (Martinez 
and de la Cruz 1990). This will only have been necessary once, future genes being 
integrated into this site by the action of the integrase, which can act in trans 
(Grinsted et al 1992). 
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There is evidence that the integration of the sul gene was an early event in the 
formation of antimicrobial resistance integrons, this being highly conserved in 
these structures, probably as a response to the early use of sulphonamides 
(Bissonnette and Roy 1992). This has been followed by the evolution of these 
structures, not only by the action of integrases but by homologous recombination 
and location in transposons (Bissonnette and Roy 1992), leading to the diversity 
seen in the Tn21 group of transposons (Zuhlsdorf and Weidemann 1992). 
1.6.3. Trimethoprim Resistance Genes Associated with 
Transposons and Integrons 
Trimethoprim resistant dhfr genes have been found associated with transposons and 
integrons, leading to a variety of genetic backgrounds for the trimethoprim 
resistant DHFR enzymes (Sundström et al 1988; Sundström and Sköld 1990; 
Heikkilä et al 1991). The dhfrV was initially described in association with Tn21 
and was observed to be flanked by regions similar to those flanking the dhfrlI of 
R388 (Sundström et al 1988). These regions have been shown to be associated with 
integron function, the dhfrV forms a "gene- cassette" (Sundström et al 1988). Thus, 
these DHFRs have been linked to sulphonamide resistance, an advantageous event 
if the trimethoprim -sulphonamide combination is present. The dhfrI has also been 
identified located in a Tn21 -like transposon, again linked with sulphonamide 
resistance (Sundström et al 1988). The dhfil also forms a "gene- cassette" structure, 
flanked by GTTA sequences like the GTTRRRY sequences previously reported, as 
part of Tn 7 which also seems to possess integron related sequences, a 59bp region 
and an integrase ORF (Sundström and Sköld 1990). The integration of other 
resistance genes in Tn 7 has been observed (Tietze et al 1987) and spectinomycin 
resistance in Tn 7 is also associated with a gene -cassette, so Tn 7 may have, 
although it has not been directly observed, an integron function which is similar to 
that of Tn21 (Sundström and Sköld 1990; Sundström et al 1991). 
The dhfrVlI, which is very similar in properties and sequence to the types I and V 
(Thomson 1990; Towner and Carter 1990; Sundström et al 1993) is also associated 
with a Tn21 -like integron system (Sundström 1993; Bissonnette and Roy 1992). 
The dhfrVII is located on a Tn21 -like transposon Tn5086, which also encodes 
resistance genes to quaternary ammonium compounds, mercuric ions and 
sulphamethoxazole. The dhfrVII is found as a gene- cassette, like the dhfrl and 
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dhfrV, which seems to have replaced the aadAl gene -cassette for 
spectinomycin /streptomycin resistance. Tn5086 also differs from Tn21 in having a 
deletion of approximately 4.2Kb upstream of the dhfr gene, a region in which 
deletions and rearrangements are frequently seen (Sundström et al 1993). The 
dhfrX has been characterized as part of an integron, In 7, which also has the 
sulphonamide resistance gene (Parsons et al 1991). Transposon and integron 
mediation of trimethoprim resistance has contributed to the evolution and 
dissemination of the mechanisms of resistance, and the evolution of these mobile 
elements, particularly integrons, may be the result of antibiotic pressure. 
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INDUCIBLE RESISTANCE MECHANISMS IN 
GRAM -NEGATIVE RODS 
1.7.1. The Inducible Chromosomal ß- lactamases 
Pseudomonas aeruginosa and most enterobacteria have chromosomal ß- lactamases. 
In Enterobacter spp., Citrobacter spp., Providencia spp., Morganella, indole 
positive Proteus spp. and P. aeruginosa these enzymes are inducible (Sykes and 
Matthews 1976). The chromosomal ß- lactamases of the enterobacteria share 
considerable homology but have quite different substrate profiles (Sykes and Smith 
1979). The various ß- lactams differ in their ability to induce the enzymes and in 
their lability to hydrolysis by them (Livermore 1987). Ampicillin, the first 
generation cephalosporins and benzylpenicillins are strong inducers at 
concentrations well below the MIC (Livermore 1987). When induction occurs high 
levels of resistance are seen, in vivo and in vitro. High MICs are produced in both 
broth and solid media. The increase in enzyme synthesis occurs, in exponentially 
growing cells, immediately after addition at sub -inhibitory levels of the drug; high 
levels of enzyme expression are seen after four hours (Minami et al 1980). 
The induction mechanism has not been fully elucidated; . however, a number of 
genes seem to be involved in the control of ampC, the ß- lactamase structural gene 
(Korfmann and Sanders 1989). Adjacent to the ampC gene is ampR, these genes 
have promoters which are divergent and over -lapping. The ampR gene product 
binds to this region in an inactive form in the absence of inducer, regulating itself 
and ampC (Lindquist et al 1989). In the presence of inducer, the ampR product is 
activated by a ligand, that seems to be provided by a third gene product, ampG 
(Korfmann and Sanders 1989), which increases the transcription of ampC 
(Lindquist et a/ 1989). In the absence of inducer, this ligand, so far unidentified, is 
inactivated by the ampD gene product (Korfmann and Sanders 1989). Thus ampC 
is negatively controlled by the action of ampD ( Korfmann and Wiedemann 1988). 
The expression of ampD is somehow controlled by the inducer; it seems unlikely 
that this is by direct action of the ß- lactams since there is no evidence that these 
agents can penetrate into the cytoplasm. Another protein, probably a trans - 
membrane protein, must be involved in transmitting the signal to increase ampD 
expression. There is some evidence that PBP2 is involved in the regulation of 
ampD (Oliva et al 1989). 
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1.7.2. The Induction of Tetracycline Resistance 
Tetracycline resistance in the enterobacteria is mediated by a inducible mechanism 
situated on transposons Tn 10 and Tn 1712, which have been shown to be related 
(Chopra 1986). The resistance determinant in these transposable elements consists 
of two regions, a membrane bound protein of Mr 36,000 which mediates active 
efflux of the drug, and a repressor protein. There are two operators that control the 
over -lapping promoters for the repressor and the membrane protein (Chopra 1986). 
The repressor sensitive operators thus control transcription of the resistance 
determinant and the repressor (which is thus autogenously controlled). The 
repressor will act in trans to the operator region (Klock et al 1985) and is sensitive 
to the presence of tetracycline. Thus tetracycline directly effects the expression of 
resistance. 
Phenotypically high level resistance is seen in vivo and in vitro, MICs are high in 
broth and agar dilution methods. This system probably evolved in the wild to deal 
with tetracycline produced by streptomyces, having evolved separately in both 
Gram -negative and Gram -positive organisms (Chopra 1986). 
AIMS OF THIS THESIS 
Young et al (1986a) found very high levels of resistance to trimethoprim and 
ampicillin amongst urinary tract pathogens isolated in Vellore, south India. A 
survey was conducted in Vellore, in conjunction with the Christian Medical 
College and Hospital; to establish the rates of carriage of resistant faecal flora, for 
the commonly used antimicrobials, trimethoprim, ampicillin, chloramphenicol and 
nalidixic acid in the population of the town of Vellore and rural villages 
surrounding the town. It could then be established whether the normal faecal flora 
could be acting as a reservoir of resistant bacteria and resistance genes. 
Those strains that were resistant to trimethoprim will be investigated further. The 
mechanisms responsible for trimethoprim resistance will be established, and the 
presence of these mechanisms on plasmids, transposons or integrons will be 
investigated. Any novel resistance mechanisms to trimethoprim will be identified 
and characterized. The DHFR type IV has been shown to be peculiar to this region 
of India; it has not been identified anywhere else. The continued presence of this 
unusual trimethoprim resistance mechanism will be established and the nature of 
the mechanism of action investigated further. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1. REAGENTS 
Chemicals and reagents were all supplied by Sigma chemicals 
(Poole, Dorset) unless other wise indicated. 
2.2. BACTERIAL STRAINS 
The standard laboratory strains used were as follows: 
Table 2. Bacterial strains. 
Strain Requirements Sited in: From: 
E. coli K12 prototroph Bachmann 1972 S.G.B. Amyes 
E. coli K12 J62 -2 pro, his, trp Bachmann 1972 S.G.B. Amyes 
E. coli DH5a thi Hanahan 1983 H -K. Young 
E. coli JM101 thi, pro Messing 1979 J. Moss 
F' [pro +] 
S. typhimurium LT2 S.G.B. Amyes 
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2.3. MEDIA 
2.3.1. Minimal Media 
Minimal salts medium was prepared as double strength solution as described by 
Davis and Mingioli (DM) (1950) (table 3). To prepare diluent for the dilution of 
cell suspensions, an equal volume of distilled water was added. For the preparation 
of minimal salts growth media, any auxotrophic requirements were added, 
aseptically, at the concentrations given in table 4, along with any selective agent 
and D- glucose to a final concentration of 0.28 %. To make a liquid medium the 
volume was made up with sterile distilled water; for solid media the salts solution 
was added to sterile molten agar immediately before the plates were poured. 
Table 3. Double strength Davis and Mingioli minimal salts. 
SALT For IL (g) 
K2HPO4 14.0 
KH2PO4 6.0 
tri -sodium citrate 1.0 
MgSO4.7H2O 0.2 
(NH4)25O4 2.0 
The salts were dissolved in the order given and made up to 1L in distilled 
water. Then sterilised by autoclaving at 121 °C for 15 minutes. 
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L- Histidine 5g \L 50mg /L steam 
L- proline 5g /L 50mg /L steam 
L- tryptophan 2g /L 50mg /L steam 
L- methionine 5g /L 50mg /L steam 
glycine 5g /L 50mg /L steam 
thymidine 5g /L *Varied filtration 
adenine 5g /L 50mg /L filtration 
Steaming was carried out for 30 minutes. Filtration was through a Millipore 
filter with a 0.22µm pore size. 
*The concentration of thymidine used for each experiment is given in the 
Results. 
2.3.2. Complex Media 
The following complex media were used: Isosensitest Broth (CM473), Nutrient 
Broth No. 2 (CM67), Isosensitest Agar (CM471) and MaConkey Agar (CM7b), all 
Oxoid (Basingstoke, Hants). Modified Mueller- Hinton agar, for the selection of 
trimethoprim resistant, lactose fermenting organisms was made up as follows: 
Mueller- Hinton agar (Difco, East Molesey, Surrey) containing 1% lactose, 0.5% 
bile salts, neutral red 75mg /L. LB agar and LB broth were supplied by Gibco -BRL 
(Paisley, Scotland). All media were made to the manufacturers instructions and 
sterilized at 121 °C for 15 minutes. 
SOB medium was made up as follows, for one litre: 
20g Bacto tryptone (Difco): 5g Bacto yeast extract (Difco): 0.5g NaCI: 10m1 of 
0.25M KC1. The pH was adjusted to 7.0 with NaOH. SOC was made up as SOB 
but 20mM glucose was added. 
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2.4. ANTIMICROBIAL AGENTS 
Antimicrobial agents were either supplied as sterile powders from the manufacturer 
or were sterilized by filtration through a 0.22µm pore membrane (See table 5). In 
susceptibility testing, and other experiments, involving the amoxycillin -clavulanic 
acid combination a 2:1 ratio of amoxycillin : clavulanic ratio was used. 
Table 5. Antimicrobial agents. 








Amoxycillin } Ag 
Clavulanic acid } 
Ciprofloxacin 



























2.5. SURVEY OF ANTIBIOTIC RESISTANCE IN THE 
NORMAL GUT FLORA OF VOLUNTEERS 
Volunteers from the urban population of Vellore, a town of some 60,000 
inhabitants about 120 km from Madras in Tamil Nadu, south India, were identified 
and recruited by the community health unit of the Christian Medical College and 
Hospital (CMCH), in Vellore. Volunteers from three rural villages, about 40 km 
from Vellore, were identified by the Rural Unit for Health and Social 
Administration (RUHSA), a unit of the hospital which operates in the rural 
communities around Vellore. Three villages were used: Kilvayattarankuppam, a 
roadside village with good communication with other areas and the town; Kavanur 
a riverside village with less contact with outside areas; and Melmoil, situated in the 
nearby foothills, which was fairly remote. 
The volunteers were each issued with a sterile bottle and asked to provide a faecal 
specimen for collection the next day. They were also asked a few relevant 
questions concerning their diet, health, sanitary arrangements and recent 
medication. Those who had received antimicrobial chemotherapy in the two weeks 
prior to taking the sample were eliminated from the study. After collection the 
samples were taken to the laboratory for processing. 
The samples were plated out on Oxoid MaConkey agar containing ampicillin, 
chloramphenicol or nalidixic acid, 10mg /L, and on the modified Mueller- Hinton 
agar, described above, containing of trimethoprim, 10mg /L. The plates were 
incubated overnight at 37 °C after which resistant lactose fermenting gram- negative 
rods were selected, colony types and the specimens which had contained them were 
noted. The strains were then purified on the same media prior to storage in nutrient 
agar slopes. 
2.6. STORAGE OF CULTURES 
All strains were stored at -70 °C, in cryovials (Alpha laboratories, Eastleigh, 
Hants). The bacteria were grown overnight, after which an aliquot was added to a 
vial and mixed with glycerol, to a final concentration of 5%, before freezing. 
Strains were always sub -cultured from the stock and not passaged. 
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2.7. ANTIBACTERIAL SUSCEPTIBILITY TESTING 
Minimal inhibitory concentrations (MIC), and break -point susceptibility testing 
were performed on ISTA agar, or on minimal media where indicated. MICs were 
determined using agar double dilution of the antibacterial. The agar was inoculated 
with a 2µL spot, delivered from a multipoint inoculator (Denley, Billinghurst, 
Surrey), of a 1 in 104 serial dilution of a fresh overnight culture in nutrient broth. 
The same procedure was followed for break -point testing but only one drug 
concentration was used. The concentrations used in break -point testing were as 
stated in the Results. 
2.8. VIABLE COUNTS 
Serial, 1 in 10, dilutions were made of the test suspension or culture; 0.1m1 
aliquots of the dilutions were then spread onto IST agar plates and incubated 
overnight at 37 °C. 
2.9. TRANSCONJUGATIONAL TRANSFER OF PLASMIDS 
From fresh overnight cultures in nutrient broth, 0.1m1 of the donor strain and 
1.0m1 of the recipient strain were added and gently mixed in 4.5ml of warmed 
nutrient broth. The mixture was incubated at 37 °C for six hours; the cells were 
then spun down in a Heraeus Christ labofuge and washed in single strength D M. 
Serial 10 -fold dilutions were prepared before spreading 0.1m1 of the dilutions on 
minimal agar containing the appropriate auxotrophic requirements of the recipient 
and selective drugs. The plates were incubated for 48 hours; any transconjugants 
were verified by checking auxotrophic requirements and resistance markers. 
To select E. coli K12 J62 -2 trimethoprim resistant transconjugants, media 
containing the requirements of this strain, proline, histidine and tryptophan, along 
with rifampicin, 25mg /L, and trimethoprim, 10mg /L, was used. In transfers, from 
E. coli K12 J62 -2 to E. coli K12 and S. typhimurium LT2, the transfer frequency 
was calculated thus: 
No. transconjugants /ml of final mix 
Transfer frequency = No. donors in original culture /ml 
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2.10. ENZYME PREPARATION AND ASSAY 
2.10.1. Preparation for Dihydrofolate Reductase Assays 
Crude cell lysates were prepared from overnight cultures in Isosensitest broth, 
either 200 ml for induction studies, or 1L to prepare cell lysate enzyme for further 
purification and gel filtration chromatography. The cells were harvested by 
centrifugation at 6,000r.p.m. for 15 minutes (Sorval RC -5B, DuPont Stevenage, 
Herts.); the cells were then washed in cold buffer A (50mM sodium phosphate 
buffer pH 7.4, 10mM ß- mercaptoethanol, 1mM EDTA). The cells were finally 
resuspended in cold buffer A; after this stage all procedures were performed on ice 
or at 4 °C. The cells were disrupted by sonication; two 30 second pulses separated 
by a 30 second cooling period at 8µm (MSE Soniprep). 
This crude enzyme preparation could then be used to assay the enzyme's specific 
activity, being the amount of DHFR activity as a proportion of the total protein 
present, thus giving an expression of the DHFR produced by the cells. 
To examine the biochemical properties of the enzyme, further purification was 
necessary. Nucleic acids were removed by precipitation with the addition of 0.1 
volume of 10% streptomycin sulphate, followed by centrifugation at 12,000g for 
30 minutes. Dihydrofolate reductase was precipitated from the lysate by the 
addition of ammonium sulphate to 50% and 80 %, with the recovery of each 
precipitate by centrifugation at 12,000r.p.m. for 30 minutes. The resulting 50% to 
80% precipitate was then resuspended in a minimum volume of buffer A (about 
2m1). The activity was assayed and the preps could then be frozen at -20 °C until 
required. 
2.10.2. Preparation of Cell Lysates for ß- lactamase Assay 
These preparations were carried out in the same way as above, but 50mM sodium 
phosphate buffer pH 7.0 was substituted for buffer A. To prepare lysates for both 
assays from the same culture, after the initial harvest, the cells were resuspended in 
Davis and Mingioli medium; this suspension was split into two. The cells were 
harvested and the two extracts were then treated as appropriate for the enzyme 
assay to be performed. 
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2.10.3. Dihydrofolate Reductase Assays 
This was performed as described by Osborn and Huennekens (1958). A Perkin 
Elmer lambda 2 spectrophotometer, with heated cuvette carriage at 37 °C, was used 
to measure decrease in absorbance at 340nm. This is caused by the oxidation of 
NADPH to NADP and the reduction of dihydrofolate (DHF) to tetrahydrofolate, 
by the action of the DHFR. 52% of this combined fall in absorbance is a result of 
the reduction of DHF, when both substrates are acted upon stoichiometrically 
(Matthews et al 1963). With this qualification, the rate of enzyme activity is 
expressed in molar terms of DHF reduced to THF. 
The reaction was performed in 1 ml quartz cuvettes containing: 
40mM sodium phosphate buffer pH 6.0 
10mM ß- mercaptoethanol 
0.08mM NADPH 
enzyme 
distilled water to a volume of 0.95m1 
A blank was also prepared but contained no NADPH. Both this and the test were 
placed in the spectrophotometer and allowed to equilibrate for four minutes. 
Dihydrofolate was then added to both cuvettes; the absorbance was read for 10 
minutes or until it had reached zero. If a decrease in absorbance was recorded 
before the addition of DHF, this was taken as DHF -independent NADPH oxidase 
activity. The final rate of DHFR activity was taken as the total rate of change in 
absorbance less that of any DHF -independent oxidase activity. 
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2.10.4. Measurement of Activity of ß- lactamase 
This was measured as a change in O.D. 384nm of nitrocephin (Glaxo laboratories, 
Middlesex) at a concentration of 100µM and O.D. 238nm of ampicillin (Sigma 
Chemicals) at a concentration of 10mM, in sodium phosphate buffer at a final 
volume of three ml. Crude extract was added to the test cuvette and the decrease in 
absorbance over time was taken with reference to a blank containing substrate but 
no enzyme. 
The activity of the sample was then determined by: 
AOD x n x extract dilution 
R= 
LOD1 x time 
R= µM of substrate hydrolysed minute' ml' extract. 
DOD= change in optical density. 
n= µM substrate in the cuvette. 
OD1= optical density of the intact substrate. 
2.10.5. Protein Estimations 
Estimations of protein concentrations in crude lysates were determined by the 
method of Waddell (1956). The samples to be tested were initially diluted in 
distilled water. The absorbance was then measured at 215 and 225nm. The 
concentration of protein could then be ascertained with reference to a previously 
prepared standard curve. Specific activity was determined from the activity of the 
sample divided by the total protein concentration. 
2.10.6. Purification of Dihydrofolate Reductase Samples by 
Gel -Filtration 
Fine grade Sephadex G75 (Pharmacia, Uppsala Sweden) was swollen in buffer A 
by maintaining at 100 °C for three hours. After allowing the gel to settle, excess 
buffer was decanted and fresh buffer added. The slurry was poured in an Amicon 
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acrylic column (2cm2x90cm) which was maintained at 4 °C in an LKB mini cold 
lab. When fully packed, a peristaltic pump was attached (Pharmacia) and buffer A 
was washed through the column at a flow rate of approximately 2m1 in ten 
minutes; this was continued for about 48 hours. 
Samples were applied to the column and eluted with buffer A at 2ml in 10 minutes, 
until at least one column volume had been passed. Fractions were collected in an 
LKB Ultrorac fraction collector. After elution the column was washed for 12 hours 
before further use. 
2.10.7. Determination of Protein Molecular Weight 
The sephadex column was calibrated essentially by the method of Andrews (1964). 
Three proteins of known molecular weight were applied to the column in 1 ml 
aliquots of 5mg /ml. These were eluted at approximately 2m1 in 10 minutes, 2ml 
fractions were collected and the elution volumes of the proteins were determined 
by measuring the absorbance of the fractions. A standard curve was then plotted of 
elution volume against molecular weight with which to compare the peak activity 
of the test elution volume. 
2.11. ENZYME KINETICS 
After determining the peak activity of the eluted fractions from the column, those 
fractions containing the most activity were pooled. 
Inhibition of enzyme activity by trimethoprim and methotrexate was determined in 
DHFR assays similar to those described above except that they were conducted in 
the presence of increasing concentrations of drug. 
Temperature sensitivity was determined by pre- treating the enzyme at 42 °C for 
increasing time spans up to 12 minutes. The activity was then assayed. 
To establish the enzyme's Michaelis constant (K,,,) for dihydrofolate, a measure of 
the affinity of the enzyme for the substrate, the activity was determined in 
conditions of partial saturation with DHF. The results were then analyzed by the 
method of Lineweaver and Burk (1934). The reciprocal of the substrate 
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concentration, 1 /[s], was plotted against the rate of enzymic reaction, 1 /v. When 
extrapolated, the interception on the abscissa gives the negative reciprocal of the 
Michaelis constant, this being the concentration of substrate at which the rate of 
reaction is half the maximum velocity. 
The inhibitor constant (K;) for the competitive inhibition of an enzyme was 
determined by repeating the assays for the Km but in the presence of trimethoprim. 
The 1 /[s] and 1/v are plotted as before. The competitive inhibition of the reaction 
by trimethoprim means that the line crosses the ordinate at the same point as the 
Km plot, but the interception with the abscissa is nearer to the origin because the 
reaction is slowed. This point gives the negative reciprocal of the apparent Km in 
the presence of inhibitor, the Kp .The K; is calculated from: 
ti K = t 
i K 
p m 
2.12. ANALYTICAL ISOELECTRIC FOCUSING OF 
ß- LACTAMASES 
Table 6. Composition of analytical IEF gel. 




Sigma 0.2 0.25mg /I 
40% ampholines(pH3.5 -10) Pharmacia 2.0 2% w/v 
33% acrylamide/ 




acrylamide 75g /L 
bis -acrylamide 2g /L 
Riboflavin (20mg /1) Sigma 4.0 2mg /m1 
Stock solutions were made up in sterile distilled water. 
ß- lactamases were focused on horizontal thin layer polyacrylamide gels containing 
carrier ampholines of pH 3.5 -10.0, by the method of Matthews et al (1975). The 
composition of the gels is given in table 6. To assess the quantity of sample to be 
loaded on the gel, an empirically derived assay was used to ascertain the activity of 
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the sample. 3Oµ1 of sample were added to l00µ1 of nitrocephin (50mg /L). The 
time taken for a colour change to occur could be used as an indication of the 
activity in the sample. The corresponding volume, in µl, to the time taken in 
seconds, was used to load the gel. 
The samples were loaded near the anode and run at one Watt overnight. The gels 
were stained with nitrocephin (500mg /L) to allow detection of the focused enzyme. 
2.13. DNA TECHNIQUES 
2.13.1. Mini- Preparations of Plasmid DNA 
Small scale plasmid extractions were carried -out by the alkaline lysis method of 
Takahashi and Nagano (1984) on 4.5ml of cells grown overnight in nutrient broth 
at 37 °C with vigorous shaking. The extracted DNA was subjected to 
electrophoresis at 60V overnight in 0.6% agarose in 40mM Tris- acetate pH 8.0, 
2mM EDTA electrophoresis buffer (Takahashi and Nagano 1984), in a Gibco -BRL 
(Paisley, Scotland) Horizon 20.25 horizontal gel tank. 
The DNA was visualized by staining for one hour in 50µg /L ethidium bromide and 
viewed on a U.V. transilluminator (U.V. Products, Cambridge). 
2.13.2. Large -Scale Plasmid DNA Preparations 
To prepare vector plasmids and plasmids carrying probe inserts, large scale DNA 
preparations were performed by the polyethylene glycol precipitation method of 
Sambrook et al (1989). Concentration and purity of DNA was assessed by reading 
the optical density at 260nm and 280nm. 
One absorbance unit at 260nm = 50µg /ml for double stranded DNA. The ratio 
between the O.D. 260nm and O.D. 280nm provides an estimate of purity; the ratio 
1:1.8 is an indication of pure double stranded DNA. 
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2.13.3. Restriction Endonuclease Digests 
Restriction enzymes were supplied by Gibco -BRL Life Sciences. DNA was 
digested as recommended by the manufacturer in the "REact" buffer system 
supplied with the enzyme. Electrophoresis was performed with the buffer and tanks 
specified above, but 0.8% agarose was used for the analysis of "wild -type" 
plasmids. For the analysis or separation of cloned or probe inserts in vector 
plasmid, a Pharmacia GNA -100 mini -tank was used; an appropriate concentration 
of agarose was used according to the fragments to be separated or extracted. 
2.13.4. Sizing of DNA Fragments and Plasmids 
The distance migrated by linear DNA during electrophoresis through an agarose 
gel is inversely proportional to the log of its molecular weight. A standard curve 
can be drawn from the distance migrated by DNA fragments of known size against 
the log of their molecular weight; the unknown can be derived from this curve. 
Lambda phage DNA digested with HindIII was the standard used. The molecular 
weight of plasmids was derived from the sum of the fragments produced on 
restriction endonuclease digestion. 
2.13.5. Southern Blotting 
Plasmid DNA was blotted onto Hybond -C Extra membrane (Amersham plc. 
Amersham, UK), nitrocellulose combined with nylon, by the capillary blotting 
method recommended by the manufacturer. After overnight blotting the membrane 
was baked at 80 °C under vacuum for two hours. 
2.13.6. Colony Blotting 
This was carried -out by the procedure of Sundström et al (1987). Fresh overnight 
cultures were picked onto nitrocellulose membrane which was placed on top of an 
IST agar plate. The patches were allowed to grow for 5 hours. They were then 
placed on filter paper saturated with the following solutions, with intervening 
drying on filter paper; 0.5M NaOH for seven minutes; 0.1M NaOH, 1.5M NaCI 
for 10 minutes; 1M Tris -HCI (pH 7.5) twice for two minutes each; 0.5M Tris -HC1 
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(pH 7.5), 1.5M NaC1 for four minutes. The filter was then air dried before baking 
at 80 °C for two hours under vacuum. 
2.13.7. The Preparation of DNA Probes 
DNA probes were prepared from those plasmids given in table 7. The plasmids 
were digested with the appropriate enzymes and the fragments were separated on 
gels as outlined previously. The probe DNA fragments were extracted from the gel 
by the Prepagene DNA purification kit (Biorad, Hemel Hempstead, Herts.). Purity 
and concentration of the fragment was assessed by electrophoresis and comparison 
with DNA of known concentration. 
The DNA probes were labelled with biotin -14 -dATP (Gibco -BRL), or [32P1 -dCTP 
(Amersham) with the Gibco -BRL Nick Translation kit, following the 
manufacturer's instructions. 
Table 7. Probes used, and their origin. 
Probe for Derived 
from 















integrase -like pLKO26 
ORF of Tn21 
integrase -like pRSSO11 








Aval, HpaI 1700bp 
BamHI, KpnI 1289bp 
Fling & Richards 1983 
Mayer et al 1985 
(Gifted by K.J. Towner) 
Towner et al 1988 
Towner et al 1988 










The plasmids were purified 
the text. 
and fragments separated and labelled as described in 
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Table 8. Control plasmids 
Plasmid Identified by Enzyme Originally characterized in 
R6K Datta and Kontimichalou TEM-1 Hedges et a11974 
1965 
R483 Hedges et al 1972 DHFRIa Sköld and Widh 1974 
R67 Acar et al 1977 DHFRIIa Pattishall et al 1977 
R388 Datta and Hedges 1972 DHFRIIb Amyes and Smith 1974b 
R751 Jobanputra and Datta 1974 DHFRIIc Fling and Elwell 1980 
pAZ1 Joyner et al 1984 DHFRIIIa Fling et al 1982 
pUKI 123 Young et al 1986 DHFRIV Young and Amyes 1986a 
pUN433 Towner and Carter 1990 DHFRV Thomson et al 1990 
pUN1043 Towner et a11990 DHFRVII Amyes et al 1989 
The above plasmids (table 8) were used, in southern blotting, to confirm the 
specificity and efficacy of the dhfr and other gene probes listed in table 7. 
2.13.8. Hybridisation of DNA Probes with Southern Blots 
Prior to hybridisation with the probe, the membrane was incubated with pre - 
hybridisation solution, in Gibco -BRL hybridisation bags, for two hours at 42 °C. 
After the removal of the pre -hybridisation solution, hybridisation solution was 
added containing the probe which had been de- natured by boiling for 10 minutes. 
Hybridisation was carried -out overnight at 42 °C in the solution given in table 10, 
with overnight incubation. These are as recommended by Gibco -BRL, the 
manufacturer of both the labelling and detection kits. 
High stringency post- hybridisation washes of the membrane were as follows: 
1. 2 x SSC, 0.1% SDS for three minutes at room temperature, repeated twice. 
2. 0.2 x SSC, 0.1% SDS for three minutes at room temperature, repeated twice. 
3. 0.16 x SSC, 0.1% SDS for 15 minutes at 50 °C, repeated twice. 
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All were done with gentle agitation. The membrane was then washed twice with 2 
x SSC. Positive hybridisation signals were then detected by means of the BluGene 
biotin detection kit (Gibco -BRL), following the procedure recommended by the 
manufacturer. Stock solutions for hybridization mixes were as given in table 9. 
Table 9. Stock solutions. 
20 x SSC 100 x Denhardts 
3.0M NaCI 





in 3 x SSC 
Table 10. Stock solutions, pre -hybridisation and hybridisation solutions. 
Stock solutions Pre -hybridisation Hybridisation 
*100% Formamide 50% 45% 
20 x SSC 5x 5x 
100 x Denhardts 5x 1 x 
500mM Sodium phosphate (pH 6.5) 50mM 20mM 
10% SDS 0.1% 0.1% 
10mg /m1 sheared herring sperm DNA lmg /ml 0.5mg /m1 
20% Sodium Dextran Sulphate 5% 
All stock and final solutions were made up with de- ionized distilled water. 
*Formamide was deionised before use with Amberlite Monobed resin M. B.1 
(Merck, Poole, Dorset). 
*Stocks stored frozen at -20 °C. 
2.13.9. Cloning DNA Fragments 
The vector and target DNA were digested with an appropriate enzyme and the 
digests were checked by electrophoresis. The DNA was then extracted with phenol 
and precipitated with ethanol. The ligation reactions were carried -out in 20µ1 
reaction volume, containing ligation mix (Gibco -BRL), digested vector and target 
DNA, to which was added 0.1 unit of T4 DNA ligase (Gibco -BRL). The mix was 
59 
incubated at 12 °C overnight after which a sample was transformed into the host 
cell. 
To ligate an EcoRI linker molecule (Boehringer Mannheim) to an extracted DNA 
fragment, 0.5µg of the linker was incubated with 3µg of the target fragment in a 
101.l final volume with 2 units of ligase and incubated overnight at 4 °C. This 
mixture was then digested with EcoRI and purified with the Prepagene kit before 
ligation into the vector plasmid and transformation of a host. 
2.13.10. Transformation 
The cells to be transformed were grown overnight in 10m1 of SOB broth containing 
10mM MgCl2; 0.5ml of this culture was then inoculated into 50m1 of SOB broth 
containing 10mM MgC12, the cells were then grown at 37 °C with vigorous shaking 
to approximately mid -log phase. The cells were then harvested by centrifugation at 
2,000g, for 12 minutes, at 4 °C (RC -5B Sorval) and resuspended in 12ml ice -cold 
50mM CaC12; the cells were then stored on ice for 15 minutes. The cells were 
centrifuged as before then resuspended in 4m1 of ice -cold 50mM CaC12 and 
dispensed in 0.2ml aliquots. The DNA, 5µ1 of the ligation mix, was added to the 
cells and gently mixed before storing on ice for 30 minutes. The cells were 
subjected to a 42 °C heat pulse for one minute, after which they were returned to 
the ice and 800µl of SOC broth was added. They were then allowed to recover by 
incubation for one hour at 37 °C. The cells were then spread onto IST agar 
containing the appropriate antibiotics. To test the efficiency of transformation, a 
known concentration of pUC18 DNA was transformed and the number of 
transformants on agar containing ampicillin, 10mg /L, counted. 
The above procedure was used for the transformation of DH5a. To transform J62- 
2 the same procedure was followed except that purified plasmid DNA from a 
previously transformed strain was used. This modification was required because 
the efficiency of transformation of J62 -2 was not sufficient to allow direct 
transformation with the ligation mix. 
For M13 subcloning the same procedure was followed except 200141 of SOC was 
substituted for the 8000 of SOB. The cells were then added to 3m1 of soft LB agar 
(Gibco -BRL) containing 40µ1 of X -gal (20mg /ml), 4µ1 of IPTG (200mg /m1) and 
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0.2ml of an overnight culture of the host cells (JM 101). This was gently mixed 
before pouring over an LB agar plate (Sambrook et al 1989). Clear plaques were 
identified and used to transfect stock cultures. Possible recombinants were sub- 
cultured onto selective plates followed by plasmid preparation and analysis by 
restriction digestion. 
2.14. VECTOR PLASMIDS 
The plasmids used in cloning were pUC 18 (Gibco -BRL), pSU 18, chloramphenicol 
resistant (Bartolomé et al 1991) and pSC101 (S.G.B. Amyes) a low copy plasmid 
which carries chloramphenicol and kanamycin resistance. M13mp19 (Gibco 
BRL)(Yanisch - Perron et al 1985) was also used as a vector prior to sequencing. 
2.15. DNA SEQUENCING 
Single and double stranded DNA sequencing was carried -out with the Sequenase 
system (Cambridge Bioscience, Cambridge UK) and 135S! -dATP label 
(Amersham). The M13 -40 forward primer and the M13 -40 reverse primer were 
supplied by Cambridge Bioscience. 
A specific primer, ACATCATGATTGGTATGAT, which was taken from a region 
immediately upstream of the dhfrlV structural gene, was supplied by Edinburgh 
University Department of Chemistry, Kings Buildings, Edinburgh. The sequence 
for this primer was kindly given by Dr H -K Young, Dundee University School of 
Biological Sciences. 
Double stranded DNA, pUK1227, was prepared by the Qiagen midi -plasmid DNA 
preparation kit (Qiagen, Chatsworth, California). Single stranded viral DNA was 
prepared by the polyethylene glycol precipitation of Sambrook et al (1989). 
Hydrolink, "Longer- ranger ", polyacrylamide gel (Hoeffer, Newcastle- Under- 
Lyme) made up to the manufacturers recommendations was used to run the 
sequencing reactions on a Biorad sequencing apparatus. Autoradiography was 
carried -out with an Amersham autoradiography cassette and Amersham Hyperfilm 
MP, with 24 hour exposure at room temperature. The development of the film was 
kindly performed by the X -ray department at the Edinburgh Royal Infirmary. 
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CHAPTER 3. 
RESULTS FROM THE SURVEY OF 
RESISTANCE IN NORMAL FAECAL 
FLORA 
3.1. ANTIBIOTIC RESISTANCE IN AEROBIC LACTOSE 
FERMENTING GRAM- NEGATIVE RODS FROM 
NORMAL FAECAL SAMPLES 
3.1.1. The Results of the Survey of Normal Faecal Samples 
Faecal samples provided by populations from the town of Vellore and three nearby 
villages, Kilvayatarrankuppam, Kavanur and Melmoil, were surveyed, as outlined 
in Materials and Methods, for the carriage of gram- negative lactose- fermenting 
rods resistant to trimethoprim, ampicillin, chloramphenicol and nalidixic acid. The 
rate of carriage of resistant organisms in these populations was then determined 
before the isolated organisms and the resistance mechanisms carried by them were 
characterized further. 
Very high levels of resistance were recorded in both the rural and urban 
populations to the commonly used antimicrobials trimethoprim, ampicillin and 
chloramphenicol. Almost every volunteer in the study carried lactose- fermenting 
gram -negative rods resistant to these agents. Resistance to nalidixic acid was 
encountered far less frequently in both rural and urban groups; the rural group 
showed comparatively few members harbouring nalidixic acid resistant bacteria. 
The urban population had rather more bacteria resistant to nalidixic acid, but not to 
the same extent as the other agents. 
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Table 11. Percentage of survey population harbouring resistant gram- negative 
lactose- fermenting rods. 









KVK 43 97.7 93.0 16.3 95.5 
Kavanur 46 95.6 100.0 19.6 95.6 
Melmoil 38 97.4 97.4 2.7 97.4 
Average 96.9 96.8 12.9 96.0 
Urban 
Vellore 95 100 98.9 34.7 98.9 
KVK is Kilvayatarrankuppam 
There was no difference between the villages, despite the various locations, nor 
was there a significant difference in the rate of carriage of resistant organisms 
between the urban and rural populations, except in the case of nalidixic acid. 
Carriage of organisms resistant to trimethoprim, ampicillin and chloramphenicol 
was the same in the two sample populations (table 11). 
Table 12. Average number of different resistant colony types in each specimen. 
Trimethoprim Ampicillin Nalidixic acid Chloram- 
phenicol 
Rural village 
Kilvayattarrankuppam 2.1 1.6 0.3 1.6 
Kavanur 1.8 1.8 0.2 1.7 
Melmoil 1.3 1.9 0.0 1.6 
Average 1.7 1.8 0.2 1.6 
Urban 
Vellore 1.8 2.1 0.5 1.9 
Not only were the levels of carriage of resistant organisms very high but the 
samples themselves frequently had more than one distinguishable resistant strain 
identifiable by differences in colony type. On average each sample carried more 
than one type of gram- negative rod resistant to the antimicrobial tested, with the 
exception of nalidixic acid (table 12). 
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3.1.2. Possible Contributory Factors to the High Rates of Carriage 
of Resistant Organisms 
General levels of hygiene and sanitary provision in this part of the world are low. 
Drinking water came from bore -holes or wells in the rural villages and from 
municipal supplies from taps in the town of Vellore, although wells were also 
used. In the villages there was no sewage or waste disposal facilities; the villagers 
used the fields. In the town, open sewers were the rule and were obvious in most 
streets. 
In the questionnaires that were filled -out, many of the volunteers reported illness 
and various symptoms; these are summarized in table 13. According to the local 
workers with RUHSA, this incidence of illness is quite usual in both urban and 
rural populations. Specific symptoms are listed; the miscellaneous symptoms 
ranged from back -ache to diabetes mellitus. A wide range of diseases are obviously 
prevalent in this area, many of which may be bacterial in origin given the high rate 
of enteric disease in this region. This may contribute not only to a reduced level of 
general health but also to the spread of resistant organisms. 
Other factors such as diet, i.e. whether the volunteer was vegetarian or not, did not 
seem to make any difference. In the village of Melmoil, for instance, no 
vegetarians were reported but there was no apparent difference in the carriage of 
resistant organisms. The amount of meat eaten by each group was, however, very 
similar. Melmoil also had the lowest density of people per household; this also 
seemed to make little difference to the carriage rate of resistant organisms, 
although it is interesting to note that Melmoil did have only one person who carried 
an organism resistant to nalidixic acid. The average age or sex of the volunteers 
does not seem to be important; the average age of the urban group was higher than 









































































































his is the num
ber of volunteers w
ho had received therapy, other than antibiotics, in the w
eek before sam
pling. Illnesses or 
sym
ptom
s had occurred in the previous m
onth before sam
pling. 
As part of the study the availability of antimicrobials in "over the counter sales" 
was assessed. It was ascertained that it was possible to buy many antimicrobials 
without prescription, except 2nd and 3rd generation cephalosporins but including 
the newer fluorinated 4- quinolones. Drugs that were freely available included 
trimethoprim, co- trimoxazole, ampicillin, cephalexin, nortloxacin, ciprofloxacin, 
tetracycline, chloramphenicol and erythromycin. These antimicrobials could be 
bought singly or in doses, thus there was no control over the dosing in those taking 
the drugs. Commensal flora and pathogens will be subject to challenge from 
antibacterials in uncontrolled self -dosing. 
Table 14. Details of the population sample recorded in the questionnaires. 
Location Total 
No. of males 








KVK 43 11 14 26.6 7.0 4.1 
Kavanur 46 17 5 14.2 6.2 4.3 
Melmoil 38 27 0 18.8 4.8 4.3 
Combined 127 55 19 19.8 6.1 4.3 
Urban 
Vellore 99 22 9 33.4 5.4 4.9 
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3.1.3. Resistance to Other Antimicrobials Amongst the 
Trimethoprim Resistant Isolates 



















Tp Ap Su Tc Cm Sm HgC12 Sp Km Cp 
Antibiotic 
104 trimethoprim resistant bacteria were studied in detail, only those capable of 
transferring trimethoprim resistance were subsequently identified. Almost all the 
trimethoprim resistance was high level, 96 of the strains were resistant to 
> 1024mg /L. Of the other strains, one had an MIC of 256mg /L, five had an MIC 
of 64 mg /L, and two had an MIC of 32 mg /L. 
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Trimethoprim resistant organisms, isolated during the survey were shown, by 
breakpoint sensitivity testing, to be resistant to a wide range of other antimicrobial 
agents (figure 3). Almost all the organisms were also resistant to 
sulphamethoxazole (99), tetracycline (96) and streptomycin (101). Of the 104 
trimethoprim resistant organisms 80 were resistant to ampicillin and 62 were 
resistant to chloramphenicol. The resistance pattern Tpr, Apr, Tcr, Sur was present 
in 67 of the bacterial strains, while 56 showed the pattern Tpr, Apr, Tcr, Sur, 
Cmr. In total 78 isolates were resistant to six or more antimicrobials. Thus many 
of the trimethoprim resistant strains were multiresistant. However, no resistance to 
cefotaxime, ceftazidime or cefuroxime, or to gentamicin or ciprofloxacin was 
encountered. 
3.2. TRANSFERABLE PLASMID MEDIATED 
TRIMETHOPRIM RESISTANCE 
3.2.1. Transfer of Trimethoprim Resistance 
When tested for their ability to transfer trimethoprim resistance to E. coli J62 -2, 36 
of the trimethoprim resistant organisms were found to be capable of transferring 
resistance in broth culture. All the organisms that were capable of transferring 
trimethoprim resistance were subsequently identified as E. coli, by API 20E. The 
E. coli J62 -2 transconjugants were then mated with E. coli K12 and Salmonella 
typhimurium LT2 and the transfer frequencies for the resistance plasmids derived 
from the mating of isogenic strains. Table 15 shows the transfer frequencies for 
these plasmids. 
Seven of the plasmids were not capable of transfer to S. typhimurium. One of the 
strains did not transfer to E. coli K12. The transfer to the E. coli is usually at a 
higher rate than the transfer to the S. typhimurium, although many of the plasmids 
transferred at similar frequencies to the E. coli as they did to the S. typhimurium. 
Thus, 29 of the 36 transferable plasmids encoding resistance to trimethoprim and 
other agents in normal faecal flora were at least capable of replication and 
expression of resistance in S. typhimurium, an enteric pathogen. 
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Table 15. The transfer frequencies of trimethoprim resistance plasmids. 
Strain Transfer frequency to Transfer frequency to 
E. coli K12 S. typhimurium LT2 
2 3.7 x 10-5 5.0 x 10-7 
6 8.2 x 10-4 5.4 x 10-4 
7 4.8 x 10-4 1.9 x 10-4 
9 1.3 x 10-5 
10 1.1x10-3 7.3x10-9 
13 4.5 x 10-4 2.0 x 10-4 
16 9.3 x 10-3 3.1 x 10-9 
20 7.6 x 10-4 1.9 x 10-4 
26 1.1x10'3 5.5x10-4 
29 1.1 x 10-3 5.6 x 10-4 
32 7.3 x 10-4 1.5 x 10-4 
34 1.2 x 10-3 4.0 x 10'7 
35 1.2 x 10-3 7.9 x 10-9 
36 7.6 x 10-4 2.5 x 10-9 
60 5.5 x 10-6 
64 5.8 x 10-7 
91 1.3 x 10-5 2.2 x 10-4 
111 1.2 x 10-3 8.9 x 10-6 
118 8.5 x 10-4 2.8 x 10-4 
120 1.3 x 10-4 8.5 x 10-7 
147 1.1x10-4 1.1x10-4 
160 8.9 x 10'5 - 
163 1.2 x 10-3 8.8 x 10-4 
166 - - 
167 1.2 x 10-3 1.2 x 10-3 
179 1.1 x 10-3 4.5 x 10-8 
185 3.0 x 10-4 5.9 x 10-5 
186 1.0 x 10-5 - 
188 4.3 x 10-4 - 
190 5.1x10'4 3.4x10-5 
192 5.4 x 10-4 1.0 x 10-4 
198 5.0 x 10-4 3.5 x 10-5 
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Table 15. The transfer frequencies of trimethoprim resistance plasmids, continued. 
Strain Transfer frequency to 
E. coli K12 
Transfer frequency to 
S. typhimurium LT2 
199 7.4x10-6 9.9x10-6 
208 1.2 x 10-3 1.2 x 10-3 
217 1.2 x 10-3 1.2 x 10-3 
219 1.3 x 10-3 1.3 x 10-3 
- = No transfer observed. 
3.2.2. MICs for Trimethoprim of the E. coli J62 -2 
Transconjugants 
When the MICs of trimethoprim were derived for the transconjugants (table 16), it 
was shown that those organisms that had low level resistance in the wild -type 
conferred low level resistance in the transconjugant. Only one incidence of low 
level resistance to trimethoprim was recorded that was not transferable, strain 206. 
No wild -type strain possessed high level resistance but conferred low level 
resistance in the transconjugant. The other 29 transconjugants all demonstrated 
high level resistance to trimethoprim. 
3.2.3. MICs of Other Antimicrobials in the Trimethoprim 
Resistant Transconjugants 
MICs of ampicillin, sulphamethoxazole, amoxycillin /clavulanic acid, 
spectinomycin, streptomycin and tetracycline were determined (table 16). 
Breakpoint sensitivities were determined for chloramphenicol (8mg /L), kanamycin 
(8mg /L), cephaloridine (8mg /L) and mercuric chloride (50mg /L) (see tables of 
resistance profiles for resistance markers determined by "break- point "). None of 
the transconjugants were found to be resistant to gentamicin (2mg /L), cefotaxime 
(2mg /L), cephalexin (2mg /L), ceftazidime (mg /L), nalidixic acid (8mg /L) or 
ciprofloxacin (lmg /L). 
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Table 16. MICs of the E. coli J62 -2 transconjugants. 
Strain Tp Su Ap Sm Tc Sp Amox/clav 
2 512 > 1024 1024 32 >128 8 16 
6 512 256 128 64 > 128 16 8 
7 512 > 1024 4 64 8 8 8 
9 512 > 1024 1024 32 > 128 8 16 
10 4 >1024 256 64 > 128 8 8 
13 512 <8 4 <4 8 8 4 
16 4 >1024 256 64 >128 8 8 
20 512 >1024 256 128 > 128 8 8 
26 512 256 256 128 >128 128 8 
29 512 256 128 64 > 128 16 8 
32 512 >1024 4 32 8 8 4 
34 4 >1024 256 64 > 128 8 8 
35 4 > 1024 256 64 >128 8 8 
36 4 >1024 256 64 > 128 8 8 
60 512 >1024 1024 32 >128 8 16 
64 512 <8 4 <4 >128 8 8 
91 512 <8 <4 8 8 8 
111 512 <8 128 64 >128 8 8 
118 16 > 1024 128 128 8 8 8 
120 512 > 1024 256 64 >128 8 8 
147 512 <8 4 <4 8 8 4 
160 512 <8 128 <4 > 128 8 8 
163 512 >1024 128 64 8 16 4 
166 512 <8 128 <4 8 8 8 
167 512 256 128 64 >128 16 4 
179 16 > 1024 4 128 8 8 8 
186 512 >1024 1024 32 >128 8 16 
188 512 <8 4 64 > 128 8 8 
190 512 > 1024 4 32 >128 8 8 
192 512 <8 4 <4 8 8 8 
198 512 >1024 256 128 8 8 8 
199 512 >1024 128 64 >128 8 8 
208 512 1024 128 64 > 128 16 8 
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Table 16. MICs of the E. coli J62 -2 transconjugants, continued. 
Strain Tp Su Ap Sm Tc Sp Amox/clav 
217 512 > 1024 128 64 >128 16 8 
219 512 1024 128 64 > 128 16 8 
Twenty five of the transconjugants were found to be resistant to ampicillin; four of 
these were also found to be resistant to amoxycillin /clavulanic acid and 
cephaloridine and had high MICs of ampicillin, 1024mg /L. 
Surprisingly, only seven strains were resistant to chloramphenicol. Six 
transconjugants were resistant to kanamycin. As might be expected, many of the 
transconjugants were also resistant to sulphamethoxazole; in total 25 were resistant 
to the combination of trimethoprim / sulphamethoxazole. There were 17 different 
antibiotic resistance patterns given by the transconjugants tested against these drugs 
(table 17). This suggested that at least 17 different plasmids were involved in the 
transfer of trimethoprim resistance in this population. 
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Table 17. Resistance profiles of the trimethoprim resistant transconjugants, 
Resistance profile Transconjugant 
Tp 13, 91, 147, 185 
Tp Tc 188 
Tp Ap 166 
Tp Su Sm 7, 32 
Tp (L) Su Sm 179 
TpTcCmHg 64 
Tp Tc Cm Hg Ap 160 
Tp Tc Cm Ap 111 
Tp Su Tc Sm 190 
Tp Su Tc Sm Ap 199 
Tp(L) Su Tc Sm Ap 10, 16, 34, 35, 36 
Tp(L) Su Sm Ap Km 118 
Tp Tc Ap Sp Sm Km 163 
Tp Su Tc Sm Ap 20, 120, 198 
Tp Su Ap Sm Sp 217, 
Tp Su Tc Ap Sm Sp 6, 26, 29, 167, 208,219 
Tp Su Tc Cm Sm Ap Km Cp Hg Ag 186, 2, 9, 60 
L indicates low level resistance to trimethoprim. 
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3.2.4. Restriction Endonuclease Digest Analysis of Transconjugant 
Plasmids 
The plasmids responsible for transferable trimethoprim resistance were analysed by 
restriction endonuclease digestion. The plasmids were grouped according to 
antibiotic resistance pattern so that those sharing the same resistance profile could 
be more easily compared. The plasmids were digested with HindIII. 26 different 
plasmid types were distinguished by this method. This was later confirmed by 
further analysis and restriction endonuclease digestion during identification of the 
mechanisms responsible for trimethoprim resistance in these plasmids. 
Thus trimethoprim resistance in the normal flora of this population was not the 
result of the spread of a few plasmids. Transferable trimethoprim resistance, 
accompanied by a range of other resistance mechanisms, was the result of the 
presence of different plasmids. 
3.3. IDENTIFICATION OF DIHYDROFOLATE 
REDUCTASES RESPONSIBLE FOR TRIMETHOPRIM 
RESISTANCE 
The mechanisms responsible for trimethoprim resistance in the transconjugants 
were identified by means of biotinylated dhfr gene probes as outlined in the 
Materials and Methods. 
All of the plasmids were hybridized with all the probes listed in Materials and 
Methods. None of the plasmids were shown to possess more than one resistant 
DHFR. Eleven of the plasmids were demonstrated to harbour the dhfr type I, 18 
were shown to harbour the dhfr type V and seven carried the dhfr type IV. 
3.3.1. Plasmids Harbouring the Type I dhfr Gene 
All of the plasmids that carried the type I dhfr (figure 4) also gave a positive signal 
when hybridized with the probe for the integrase -like ORF from Tn 7 (figure 5). 
This open reading frame is always associated with the transposon Tn 7; thus all of 
the type I dhfr genes identified here were probably associated with transposon Tn 7, 
the most frequently found location for this gene. Most of the plasmids that carried 
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the dhfr type I also carried spectinomycin resistance which is also normally 
associated with Tn 7. There were three exceptions, 185 and 188 carried only 
trimethoprim resistance and 111, although it also harboured resistance to 
tetracycline, chloramphenicol and ampicillin, was sensitive to spectinomycin. 
All of the remaining plasmids had very similar resistance profiles (table 18) but 
most had different restriction digest patterns. However, 6 and 26 had the same 
BamHl digest patterns (figure 6). The three plasmids 208, 217 and 219 were also 
very similar, although the presence of other smaller plasmids presented a confusing 
picture, 217 was not resistant to tetracycline and seemed to have a large section 
deleted; it was somewhat smaller than 208 and 219 (figure 6). The other plasmids 
were clearly distinguishable from one another. Several of the transconjugants 
harbour two large plasmids which made the task of distinguishing the digest 
patterns of the individual plasmids that much more difficult. The transconjugants 
167 and 188 both carried two large plasmids. The presence of the dhfrl was 
confirmed in a hybridisation with digested plasmid DNA (figure 6 and 7). 
Table 18. Characteristics of plasmids positive for the dhfI probe. 
Plasmid Resistance profile Plasmid 
molecular size 
(Kb) 
185 Tp 40 
188 Tp, Tc 60, 85 
111 Tp, Tc, Cm, Ap 77, 2 
6 Tp, Su, Tc, Ap, Sm, Sp 48, 4 
26 Tp, Su, Tc, Ap, Sm, Sp 48, 4 
29 Tp, Su, Tc, Ap, Sm, Sp 94 
208 Tp, Su, Tc, Ap, Sm, Sp 57, 7, 4 
217 Tp, Su, Ap, Sm, Sp 35, 7, 4 
219 Tp, Su, Tc, Ap, Sm, Sp 57, 7, 4 
167 Tp, Su, Tc, Ap, Sm, Sp 77, 30, 2 
163 Tp, Km, Tc, Ap, Sm, Sp 84 
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Figure 4. Southern blot of plasmid DNA of transconjugants harbouring the dhlìl 
gene hybridised with the probe for the dhfrl gene. 
(A) plasmid pUN433 carries the dhfrV and was included as a negative control; 
plasmid DNA of transconjugants (B) R483 carries the dhfrl gene; (C) R67 carries 
the dhfrl' I and is also included as a negative control; (D) 219; (E) 217; (F) 208; 
(G) 188; (H) 185; (I) 167; (J) 163; (K) 111; (L) 29; (M) 26; (N) 6. 
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Figure 5. Southern blot of plasmid DNA of transconjugants harbouring the dhfri 
gene hybridised with the probe for the Tn 7 integrase -like ORF. 
Tracks are (A) pIJN1053 is a recombinant carrying the dhfrVII; (B) pAZ1is a 
plasmid carrying the dhfrIll, which is not associated with a transposon; (C) R483 
carries the dhfrI gene; (D) R751 carries the dhfrIl and was also included as a 
negative control; (E) R67 carries the dhfll and is also included as a negative 
control; (F) 219; (G) 217; (H) 208; (I) 188; (J) 185; (K) 167; (L) 163; (M) 111; 
(N) 29; (0) 26; (P) 6, 
A B C D E F G H I K L M N O 
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Figure 6. A 0.8% agarose gel of a BamHl restriction endonuclease digest of 
plasmid DNA from transconjugants harbouring the dhfrl gene. 
Tracks are of plasmid DNA from transconjugants (A) 6; (B) 26; (C) 29; (D) 111; 
(E) 163; (F) 167; (G) 185; (H) 188; (I) 208; (J) 217; (K) 219; (L) plasmid 
pUN433 carries the dhfrV and was included as a negative control; (M) X DNA 
HindIII marker. 











Figure 7. Southern blot of a BamH 1 restriction endonuclease digest of plasmid 
DNA of transconjugants harbouring the dhfrI gene hybridised with the probe for 
the dhfrl gene. 
Tracks are digested plasmid DNA of transconjugants (A) 219; (B) 217; (C) 208; 
(D) 188; (E) 185; (F) 167; (G) 163; (H) 111; (I) 29; (J) 26; (K) 6; (L) plasmid 
pUN433, carries the dhfrV and was included as a negative control. 
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3.3.2. Plasmids Harbouring the Type V dhfr Gene 
Many of the 18 plasmids carrying the dhfr V (figures 8 and 9) were very large and 
were responsible for a number of resistance mechanisms other than trimethoprim 
(table 19). The presence of the gene was confirmed by hybridisation of the probe 
with plasmid DNA subjected to restriction endonuclease digestion (figures 10, 11, 
12 and 13). The digest patterns also served to distinguish plasmids that had similar 
antibiotic resistance profiles (figures 10 and 12). The transconjugants of the strains 
13, 91, 147 and 192 all shared similar endonuclease digest patterns (figure 14), 
and were all resistant to trimethoprim only (table 19). They were, however, 
isolated from different areas of the study; 13 was from a strain isolated in 
Kilvayattarrankuppam, 91 from Kavanur, and 192 and 147 from the town of 
Vellore. The plasmids of 91 and 147, although isolated in different areas, had 
digest patterns plasmids which seemed almost identical (figure 14). 
The same antibiotic resistance pattern was also shared by 7 and 32; they also had 
similar digest patterns, although they were not identical (figure 15). The 
preparation and digestion of plasmids 9 and 60 was unreliable, probably because of 
their large size. Although they had the same antibiotic resistance profile, they were 
not identical (figure 15). They did, however, share a number of common bands 
when subjected to restriction endonuclease digestion. Again the presence of more 
than one large plasmid in the transconjugant presented a confusing picture in the 
digest patterns (especially in strains 64, 160 and 186). 
Of the plasmids that possessed the tnpA gene, all but two had sulphonamide 
resistance associated with them. These two plasmids, 64 and 160, were resistant to 
mercuric chloride, another marker commonly associated with the Tn21 -like 
transposons. Four other plasmids also have this marker; these were the "multi - 
resistant" plasmids that were resistant to several antibiotics, including kanamycin, 
amoxycillin /clavulanic acid and cephaloridine (table 20). 
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Table 19. Characteristics of plasmids positive for the dhfrV probe. 
Donor strain Resistance profile Plasmid molecular 
size (Kb) 
13 Tp 69 
91 Tp 46, 2 
147 Tp 53, 13, 4 
192 Tp 54, 8, 3 
166 Tp Ap 64, 13, 6 
7 Tp, Su, Sm 82 
32 Tp, Su, Sm 74, 17, 4, 2 
64 Tp, Tc, Cm, Hg 80, 55 
190 Tp, Su, Tc, Sm 100, 8, 3 
160 Tp, Tc, Cm, Ap, Hg 80, 46 
199 Tp, Su, Tc, Sm, Ap 82 
20 Tp, Su, Tc, Sm, Ap 120 
120 Tp, Su, Tc, Sm, Ap 30 
198 Tp, Su, Tc, Sm, Ap 52 
186 Tp, Su, Tc, Cm, Sm, Ap, Cp, Hg, Km, Ag 70, 63 
2 Tp, Su, Tc, Cm, Sm, Ap, Cp, Hg, Km, Ag 89 
9 Tp, Su, Tc, Cm, Sm, Ap, Cp, Hg, Km, Ag 100 
60 Tp, Su, Tc, Cm, Sm, Ap, Cp, Hg, Km, Ag 108 
Seven of the plasmids carrying the dhfr type V did not have sulphamethoxazole 
resistance associated with them (table 19). Sulphamethoxazole resistance is usually 
found associated with the dhfr type V as part of Tn21. All of the plasmids 
harbouring the dhfrV gave a positive signal when hybridized with the integrase -like 
ORF of Tn21, which indicated the presence of the integrase system commonly 
found associated with this gene (figure 16). In eight of the plasmids, however, 
there was no hybridisation with the probe for the tnpA gene of Tn21 (figures 17 
and 18). This would seem to indicate the lack of a complete and functional 
transposon. The tnpA region may have been deleted or the gene has been inserted 
in the plasmid, by the action of the integrase system, independent of a transposon 
intermediary (information on hybridisation with the transposon probes is 
summarized in table 20). This would seem likely in those five plasmids that did not 
have sulphonamide resistance associated with them and were negative for the tnpA 
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probe, sulphonamide resistance being associated with the Tn2/-like transposons 
(table 20). Four of these plasmids mediated only trimethoprim resistance, whilst 
the fifth mediated only trimethoprim and ampicillin resistance . 
Table 20. Results of hybridization of plasmids positive for the dhfrV probe with 
the probes for the integrase -like ORF of Tn21(In -Tn21) and the tnpA region of 
Tn21 (tnpA). 
Donor strain Resistance profile In -Tn21 tnpA 
13 Tp + 
91 Tp + 
147 Tp + - 
192 Tp + 
166 Tp, Ap + - 
7 Tp, Su, Sm + 
32 Tp, Su, Sm + - 
64 Tp, Tc, Cm, Hg + + 
190 Tp, Su, Tc, Cm, Sm + 
160 Tp, Tc, Cm, Ap, Hg + + 
199 Tp, Su, Tc, Sm, + + 
20 Tp, Su, Tc, Sm, Ap, Cp + + 
120 Tp, Su, Tc, Sm, Ap, Cp + + 
198 Tp, Su, Tc, Sm, Ap, Cp + + 
186 Tp, Su, Tc, Cm, Sm, Ap, Cp, Hg, Km, Ag + + 
2 Tp, Su, Tc, Cm, Sm, Ap, Cp, Hg, Km, Ag + + 
9 Tp, Su, Tc, Cm, Sm, Ap, Cp, Hg, Km, Ag + + 
60 Tp, Su, Tc, Cm, Sm, Ap, Cp, Hg, Km, Ag + + 
aa 
Figure 9. Southern blot of plasmids showing positive hybridisation with the DNA 
probe for the dhfrV gene. 
Tracks are (A) pUN433, plasmid carrying the dhfrV gene. Plasmid DNA from the 
strains (B) 91; (C) 64; (D) 60; (E) 132; (F) 20; (G) 13; (H) 9; (I) 7; (J) 2. 
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Figure 10. EcoR1 restriction endonuclease digest of plasmid DNA from the 
transconjugants harbouring the dhfrV gene. 
EcoR1 digests of plasmid DNA from transconjugants (A) 13; (B) 91; (C) 147; 
(D) 166; (E) 192; (F) 7; (G) 32; (H) 64; (I) 190; (J) 160; (K) 199; (L) 20; 
(M) 120; (N) 198; (0) 186; (P) 2; (Q) 9; (R) 60; (S) X DNA HindIIl digest 
marker. 













Figure 11. Southern blot of EcoR1 restriction endonuclease digest of plasmid DNA 
from the transconjugants harbouring the dhfrV gene hybridised with the probe for 
the dhfrV. 
Tracks are EcoR1 digests of plasmid DNA from transconjugants hybridised with 
the dhfrV probe (A) 60; (B) 9; (C) 2; (D) 186; (E) 198; (F) 120; (G) 20; (H) 199; 
(I) 160; (J) 190; (K) 64; (L) 32; (M) 7; (N) 192; (0) 166; (P) 147; (Q) 91; 
(R) 13. 
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Figure 12. 0.8% agarose gel of the EcoR1 digests of plasmid DNA from 
transconjugants not shown in figure 10. 
Tracks are EcoR1 digests of plasmid DNA from transconjugants (A) 64; (B) 190; 
(C) 160; (D) 199; (E) 20; (F) 120; (G) 198; (H) 186; (I) 2; (J) 9; (K) 60; (L) 64. 
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Fi ure 13. Southern blot of di g ests shown in fi g ure 11 h bridised with the dhfrV 
probe. 
(A) pUN433, plasmid carrying the dhfrV. EcoRl digests of plasmid DNA from 
transconjugants hybridised with the dhfrV probe (B) 60; (C) 9; (D) 2; (E) 186; 
(F) 198; (G) 120; (H) 20; (I) 199; (J) 160; (K) 190; (L) 64. 






Figure 14. A 0.8% ágarose gel of a BamHl restriction endonuclease digest of 
plasmid DNA from the transconjugants of 13, 91,147, and 192, illustrating the 
similarities between these plasmids. 
Tracks are plasmid DNA from transconjugants digested with BamH 1. (A) 13; 
(B) 91; (C) 147; (D) 192. 
A B C D 
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Figure 15. A 0.8% agarose gel of an EcoRl restriction endonuclease digest of 
plasmid DNA from the transconjugants of 7, 32, 9 and 60, illustrating the 
similarities between 7 and 32; and 9 and 60. 
Tracks are of plasmid DNA of transconjugants digested with EcoRl. (A) 7; (B) 32; 





Figure 16. Southern blot of plasmids showing positive hybridisation with the DNA 
probe for the dhfrV gene hybridised with the probe for the Tn21 integrase -like 
ORF. 
Tracks are transconjugant plasmid DNA carrying the dhfrV gene, hybridised with 
the probe for the Tn21 integrase -like ORF. Control plasmids (A) R483, plasmid 
carrying Tn 7; (B) pUN433; (C) 198; (D) 196; (E) 192; (F) 190; (G) 186; (H) 166; 
(I) 160; (J) 147; (K) 120; (L) 91; (M) 64; (N) 60; (0) 32; (P) 20; (Q) 13; (R) 9; 
(S) 7; (T) 2. 




Figure 17. Southern blot of plasmids showing positive hybridisation with the DNA 
probe for the dhfrV gene hybridised with the probe for the Tn21 tnpA gene. 
Tracks are transconjugant plasmid DNA of (A) pUN 1053 a recombinant carrying 
the dh &VII; (B) pUN433; (C) R483, plasmid carrying Tn 7; (D) 199; (E) 198; (F) 
192; (G) 190; (H) 186; (I) 166; (J) 160; (K) 147; (L) 120. 
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Fi ure 18. Southern blot of s lasmids showin ., 
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sitive h bridisation with the DNA 
probe for the dhfrV gene hybridised with the probe for the Tn2ltnpA gene. 
Tracks are transconjugant plasmid DNA from (A) pUN1053 a recombinant 
carrying the dhfrVII; (B) pUN433; (C) R483, plasmid carrying Tn 7; (D) 91; (E) 
64; (F) 60; (G) 32; (H) 20; (I) 13; (J) 9; (K) 7; (L) 2. 
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3.3.3. Identification of dhfrl and dhfrV Genes in Wild -Type 
Strains Unable to Transfer Trimethoprim Resistance 
Those strains that were found not to be able to transfer resistance to trimethoprim 
were tested for the presence of the dhfrl and dhfrV genes by colony blots and 
hybridisation with the probes for these genes labelled with 32P. 
The resistance profiles of the strains that showed positive hybridisation with the 
probes are shown in tables 21 and 22. In total 27 strains, that were not capable of 
the transfer of trimethoprim resistance, gave positive signals when hybridised with 
the dhfrI probe. In most of these strains it is likely that the dhfrl gene is located on 
the chromosome having been transferred to this location as part of the transposon 
Tn 7. In 24 of these strains spectinomycin/streptomycin resistance was also present; 
this is a commonly found resistance marker associated with Tn 7. Only three of the 
strains that showed positive hybridisation with the dhfrl gene were not resistant to 
spectinomycin /streptomycin; this may be the result of loss of this resistance gene 
or the presence of the dhfrl gene on a genetic element other than Tn Z There were 
11 different resistance profiles given by those organisms positive for the dhfrl 
gene; however, 12 of the strains had one of these, and six had another (table 21). 
In those strains that were not capable of transferring trimethoprim resistance, only 
four demonstrated positive hybridisation with the dhfrV probe. Three of these had 
the same resistance profile (table 22) 
Thus the dhfr type I is found very much more frequently in non -transferable 
trimethoprim resistance, as opposed to the dhfr type V which in this survey was 
responsible for 50% of the transferable trimethoprim resistance. 
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Table 21. Strains that demonstrated positive hybridisation with the dhfiì gene 
robe but were not ca s able of transferrin trimetho rim resistance. 
Resistance profile Strain number 
Tp Su Ap Tc Cm Sm/Sp Hg 174 
Km 
Tp Su Ap Tc Sm/Sp Hg Km 203 
Tp Su Ap Tc Cm Sm/Sp 47, 54, 110, 112, 117, 141, 
148, 152, 153, 161, 170, 193 
Tp Su Ap Tc Cm Km 149 
Tp Su Ap Cm Sm/Sp 195 
Tp Su Ap Tc Cm 173 
Tp Ap Tc Sm/Sp 45 
Tp Su Tc Sm/Sp 61, 139, 155, 172, 194, 201 
Tp Su Sm/Sp 162, 171 
Tp 136 
Table 22. Strains that demonstrated positive hybridisation with the dh &V gene 
probe but did not transfer trimethoprim resistance. 
Resistance profile Strain number 
Tp Su Ap Tc Sm 23 
Tp Su Ap Tc Cm Sm Hg 37, 56, 191 
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3.4. IDENTIFICATION OF THE ß- LACTAMASES 
MEDIATING RESISTANCE IN THE AMPICILLIN 
RESISTANT TRANSCONJUGANTS 
Those transconjugants that exhibited resistance to ampicillin were tested for the 
presence of plasmid- mediated ß- lactamases by iso- electric focusing in 
polyacrylamide gels on pH gradient of 3.5 -10 (figures 19 -21), followed by 
detection of the ß- lactamases by staining with nitrocefin. 
This procedure revealed that the presence of the ß- lactamase TEM -1 was 
responsible for ampicillin resistance in all 25 of those transconjugants that 
exhibitted resistance to this drug. This included those transconjugants that were 
resistant to cephaloridine (20, 120, and 198), and those resistant to cephaloridine 
and amoxycillin /clavulanic acid (186, 2, 9 and 60). 
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Figure 19. Iso- electric- focusing polyacrylamide gel (pI 3.5 -10) of ¡3- lactamases 
conferring ampicillin resistance on trimethoprim resistant transconjugants. 
Tracks are ß- lactamase preparations from the transconjugants of (A) 198; (B) 2; 
(C) 6; (D) 9; (E) 10; (F) 16; (G) 20; (H) 26; (I) 29; (J) 34; with 
(K) 'l'EM -1(pI 5.4) and (L) SHV -1(pI 7.6), included as controls. 
pI 7.6 
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Figure 20. Iso- electric focusing polyacrylamide gel (pI 3.5 -10) of ß- lactamases 
conferring ampicillin resistance on trimethoprim resistant transconjugants. 
Tracks are ß- lactamase preparations from the transconjugants of (A) 35; (B) 36; 
(C) 60; (D) 111; (E) 118; (F) 120; (G) 160; (H) 163; (1) 166; with 
(J) SHV -1(pI 7.6), included as a control. 




Figure 21. Iso- electric focusing polyacrylamide gel of (pI 3.5 -10) ß- lactamases 
conferring ampicillin resistance on trimethoprim resistant transconjugants. 
Tracks are /3- lactamase preparations from the transconjugants of (A) 167; (B) 186; 
(C) 199; (D) 208; (E) 217; (F) 219; (G) TEM -1 (pI 5.4) and (H) SHV -1 (pI 7.6), 
included as controls. 
lit pI 7.6 
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THE TYPE IV DIHYDROFOLATE 
REDUCTASE 
The dhfrlV gene confers only low level resistance to trimethoprim, 4 mg /L as 
determined on IST agar, yet it has persisted in this region and has not been 
detected elsewhere. In this area it represented about 20% of the transferable 
trimethoprim resistance. Thus, despite the presence of ostensibly more efficient 
resistance mechanisms, the dhfrl and V, the dhfrWV continues to be responsible for 
mediating resistance to trimethoprim. The properties of this enzyme were, 
therefore, investigated further 
4.1. CHARACTERIZATION OF THE DHFR TYPE IV 
ISOLATED IN THE PRESENT STUDY 
4.1.1. Plasmids that Harboured the Type IV dhfr Gene 
Of those plasmids isolated that harbour the type IV dhfr (figure 22) five were 
identical in their restriction digest patterns (figures 23 and 25) and antibiotic 
resistance profile, 10, 16, 34, 35, 36 (table 23). All of these originated in the same 
village. The other two, one from the village of Melmoil furthest from the town and 
one from Vellore itself, had different antibiotic resistance profiles and restriction 
endonuclease digest patterns (figures 23 and 25). The plasmid of 179 lacked 
ampicillin resistance, and that of 118 had kanamycin resistance but lacked 
tetracycline resistance (table 23). 
These plasmids were not only compared with each other but were also compared 
with those plasmids carrying the type IV dhfr from the study conducted in 1984 
when they were first isolated (Young et al 1986a). There were some similarities 
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between these plasmids and those isolated in 1989, both in resistance profiles and 
molecular size (table 23). 
When probed with the CIaI (1.4 Kb) probe for the type IV gene multiple signals 
were given in both sets of plasmids and in the plasmid from which the probe was 
originally derived. This was seen in digests of the sample plasmids with both CIaI 
(figure 24) and EcoRI (figure 26). This would seem to indicate the presence of 
repeated sequences on the plasmids. 
Table 23. Plasmids positive for the dhfrIV probe in this study. and those plasmids 
isolated in 1984. 
Plasmids Resistance profile Plasmid molecular 
size (Kb) 
Plasmids isolated in 1989 
pUK2005 (10) Tp, Su, Tc, Sm, Ap 65 
pUK2007 (16) Tp, Su, Tc, Sm, Ap 65 
pUK2012 (34) Tp, Su, Tc, Sm, Ap 65 
pUK2013 (35) Tp, Su, Tc, Sm, Ap 65 
pUK2014 (36) Tp, Su, Tc, Sm, Ap 65 
pUK2019 (118) Tp, Su, Sm, Ap, Km 52 
pUK2026 (179) Tp, Su, Sm 77 
Plasmids isolated in 1984 
pUK1123 Tp, Su, Sm 78 
pUK1115 Tp, Su, Sm, Km 81 
pUK1119 Tp, Su, Sm, Ap, Km 79 
pUK1115 Tp, Su, Sm, Ap, Tc, Cm 89 
pUK1109 Tp, Su, Sm, Ap, Tc, Cm 99 
pUK1118 Tp, Su, Sm, Ap, Tc, Cm, Km 100 
pUK1114 Tp, Su, Sm, Ap, Tc, Cm, Km 122 
Numbers in parentheses are the original donor strains. 
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Figure 22. Southern blot of plasmids harbouring the dhfrIV gene, hybridised with 
the DNA probe for the dhfrfV gene. 
Tracks are transconjugant plasmid DNA of; (numbers in parentheses indicate 
original donor strain). (A) pUK2005 (10); (B) pUK2007 (16); (C) pUK2012 (34); 
(D) pUK2013 (35); (E) pUK2014 (36); (F) pUK2019 (118); (G) pUK2026 (179); 
(H) pUK1123; (I) R751; (J) pAZ1. 
A B C D E F GH I J 
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ests of lasmids 
harbouring the dhfrIV gene from this study (1989) and the study by Young et al 
(1986a) (pUK1109- pUK1123). 
Tracks are transconjugant plasmid DNA digested with Cla l , (numbers in 
parentheses indicate original donor strain). (A) pUK2005 (10); (B) pUK2007 (16); 
(C) pUK2012 (34); (D) pUK2013 (35); (E) pUK2014 (36); (F) pUK2019 (118); 
(G) pUK2026 (179); (H) pUK1109; (I) pUK1114; (K) pUK1115; (L) pUK1116; 
(M) pUK1118; (N) pUK1119; (0) pUK1123; (P) dhfrIV probe fragment; 
(Q) X DNA EcoRl /HindIII digest marker. 




Figure 24. Southern _blot of Clal restriction endonuclease digests of plasmids 
harbouring the dhfrlV gene from this study (1989) and the study by Young, et al 
(1986a) (pUK1123- pUK1109), hybridised with the DNA probe for the dhfilV 
gene. 
Tracks are transconjugant plasmid DNA Clal (numbers in parentheses indicate 
original donor strain). (A) dhfrñV probe fragment: (B) pUK1123; (C) pUK1119; 
(D) pUK1118; (E) pUK1116; (F) pUK1115; (G) pUK1114; (H) pUK1109; 
(I) pUK2026 (179); (J) pUK2019 (118); (K) pUK2014(36); (L) pUK2013 (35); 
(M) pUK2012 (34); (N) pUK2007 (16); (0) pUK2005 (10). 
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Figure 25. EcoR1 restriction endonuclease digests of plasmids harbouring the 
dhfrlV gene from this study (1989) and the study by Young et al (1986a) 
(pUK1123 pUK1114). 
Tracks are transconjugant plasmid DNA digested with EcoRl, (numbers in 
parentheses indicate original donor strain). (A) pUK2005 (10); (B) pUK2007 (16); 
(C) pUK2012 (34); (D) pUK2013 (35); (E) pUK2014 (36); (F) pUK2019 (118); 
(G) pUK2026 (179); (H) pUK1123; (I) pUK1116; (J) pUK1119; (K) pUK1115; 
(L) pUK1109; (M) pUK1118; (N) pUK1114; (0) X DNA HindIII digest marker. 








Figure 26. Southern blot of EcoRl restriction endonuclease digests of plasmids 
harbouring the dhfrñV gene from this study (1989) and the study by Young et al 
(1986a) (pUK1123, pUK1114). hybridised with the DNA probe for the dhfrIV 
gene= 
Tracks are transconjugant plasmid DNA digested with EcoRl (numbers in 
parentheses indicate original donor strain). (A) pUK2005 (10); (B) pUK2007 (16); 
(C) pUK2012 (34); (D) pUK2013 (35); (E) pUK2014 (36); (F) pUK2019 (118); 
(G) pUK2026 (179); (H) pUK1123; (I) pUK1116; (J) pUK1119; (K) pUK1115; 
(L) pUK1109; (M) pUK1118; (N) pUK1114. 
B C D E F G H I J K L MN 
fa* voSie ' 4110 
gm. IOW .agaik SIP OD 4,*0 





4.1.2. MICs on Different Media of E. coli J62 -2 Carrying the 
dhfrlV Plasmids 
The MICs of the plasmids carrying the type IV dhfr, in E. coli J62 -2, were 
determined on different media. Thus a comparison could be made between the 
plasmids isolated in 1989 and those isolated in 1984, in which the MICs depended 
on the medium used for testing; the important factors affecting the MIC were 
shown to be methionine, glycine and adenine (Young and Amyes 1986a). 
Table 24. MICs determined on different media for E. coli J62 -2 carrying the type 
IV dhfr plasmids from this study and pUK1123 and pUK1114 from 1984 
Plasmid Donor strain ISTA DSTA Minimal medium MGA 
pUK2005 10 2 8 16 4 
pUK2007 16 2 8 16 4 
pUK2012 34 2 8 16 4 
pUK2013 35 2 8 16 4 
pUK2014 36 2 8 16 4 
pUK2019 118 16 64 64 32 
pUK2026 179 16 64 256 256 
1984 
pUK1123 4 8 16 4 
pUK1114 128 64 128 128 
ISTA is Isosensitest agar; 
DSTA is diagnostic sensitest agar; minimal medium is Davis and Mingioli 
minimal salts containing glucose, proline, histidine and tryptophan; 
MGA is this medium with the addition of methionine, glycine and adenine. 
Again the plasmids carrying the type IV dhfr gave different MICs according to the 
medium used (table 24). Although the same degree of change could not be 
achieved as was shown by Young and Amyes (1986a), there was a marked increase 
in MIC when the assay was conducted on minimal medium as opposed to minimal 
medium containing methionine, glycine and adenine, or in complex medium. 
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4.1.3. Biochemistry of Two of the DHFR Type IV Enzymes 
Identified By the DNA Probe 
One of the plasmids gave MICs that were significantly higher than those given by 
the other plasmids from the 1989 study or most of the plasmids from the 1984 
study, except two that showed similarly raised MICs. The biochemical properties 
of the DHFRs of the plasmids pUK2007 and pUK2026 were investigated for 
comparison with those of the DHFR from plasmid pUK1123, the plasmid in which 
the DHFR type IV was originally characterized. 
Table 25. Summary of properties of DHFRs from pUK2007. pUK2026 and 
pUK1123. 
Plasmid Tp ID50 Mtx IDSO TD50 DHF Km Tp Ki Size MIC in 
µM min µM µM Kd ISTA 
mg/L 
pUK1123 0.20 0.020 >12 37.0 0.063 46.7 4 
pUK2007 0.14 0.002 > 12 9.1 0.020 46.0 2 
pUK2026 0.10 .012 > 12 20.0 0.040 45.0 16 
Tp ID50 is the concentration of trimethoprim required to give 50% inhibition. 
Mtx ID50 is the concentration of methotrexate required to give 50% inhibition. 
TD50 is the time in minutes of exposure of the enzyme to a temperature of 420C 
required to reduce the activity by 50 %. 
DHF Km is the Michaelis constant for DHF. 
Tp Ki is the inhibition constant for trimethoprim against DHF. 
The properties of the DHFRs carried by pUK2026 and pUK2007 were very similar 
to the original DHFR type IV carried by pUK1123 (table 25). There was some 
discrepancy between the methotrexate ID50 of the DHFR of pUK2007, pUK2026 
and the original type IV. The methotrexate ID50 of pUK1123 and pUK2026 were 
much closer than pUK2026 and pUK2007. The other biochemical data, however, 
combined with the hybridisation results, indicated that these enzymes are very 
similar. Although pUK2026 had a higher MIC than pUK1123, the enzyme encoded 
by pUK2026 seemed to have very similar properties to the enzyme carried by 
pUK1123. Indeed it showed very slightly less resistance to trimethoprim, although 
this was probably experimental error. 
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4.2. INDUCTION OF THE DHFR TYPE IV 
4.2.1. Induction of the DHFR Encoded by pUK2007 
The DHFR of plasmid pUK2007 was very like the type IV DHFR of pUK1123. 
This enzyme has been shown to be inducible when challenged with trimethoprim. 
In order to determine if this mechanism has persisted in the plasmids isolated in 
1989, induction of the DHFR encoded by pUK2007 was compared to that of 
plasmid pUK1123. Both plasmids were in E. coli J62 -2 transconjugants (table 26). 
Table 26. Induction of the DHFR of E. coli J62 -2 (pUK2007) in comparison to 
that of E. coli J62 -2 (pUK1123). 
DHFR of Trimethoprim Specific activity 
plasmid (mg /L) (nmol DHF reduced /min /mg protein) 
pUK1123 0 2.6 
pUK1123 50 834.7 
pUK1123 150 1047.4 
pUK2007 0 3. 8 
pUK2007 50 362.2 
pUK2007 150 578.2 
The specific activity of both DHFRs increased dramatically in response to 
challenge with increasing concentrations of trimethoprim (table 26). Thus that 
unusual property of the DHFR type IV, of being inducible, has been maintained in 
the plasmid pUK2007. 
This initial experiment was performed in transconjugants, to provide an isogenic 
background for the experiments. The following experiment was performed on the 
wild -type strain harbouring pUK2007, strain 16T, in order to determine if this 
system also operated in the wild -type, as isolated from the normal flora (table 27). 
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Table 27. Induction of the DHFR in the wild -type strain 16T. 
Trimethoprim Specific activity 





Challenging the wild -type strain harbouring plasmid pUK2007 with trimethoprim 
produced higher levels of DHFR but to a lesser degree than was seen in the 
standard E. coli J62 -2 (table 27). The wild -type strain had a higher MIC on IST 
agar, 32mg /L as compared to 4mg /L for the transconjugant, which may reflect 
decreased permeability to trimethoprim. This and other factors may influence the 
expression of the DHFR, thus all further experiments were carried out in the 
standard laboratory strain. 
4.2.2. Expression of the DHFR of pUK2026 Compared to 
pUK1123 
The E. coli J62 -2 transconjugant carrying pUK2026 had a higher MIC than those 
carrying pUK1123 or pUK2007, although it had very similar properties, hybridised 
with the type IV probe and displayed the differential MICs when these were 
performed on different media. The expression of the DHFR from this plasmid was 
compared to that of the DHFR type IV of pUK1123 (table 28). 
The DHFR of plasmid pUK2026 did not appear to be as inducible as the other 
DHFR type IVs of pUK1123 and pUK2007. It is produced constitutively at 
moderate levels compared to the expression of the DHFR of pUK1123 (table 28). 
This may account for the greater MIC, the constitutive production of moderate 
levels of DHFR type IV resulting in a higher MIC than that given by low level 
expression in the plasmids carrying the inducible enzyme. This assumes that no 
induction takes place on the agar plate, a matter that will be considered later. 
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Table 28. Comparison of DHFR expression from pUK2026 and pUK1123. 
Plasmid Trimethoprim Specific activity 













4.2.3. The Effect of Thymine Starvation on the Induction of the 
DHFR Type IV 
Thomson et al (1993) demonstrated that the presence of thymidine, the 
ribonucleoside derivative of thymine, abolishes the induction of the type IV DHFR 
of pUK1123. Trimethoprim has the effect of producing thymine starvation in 
bacterial cells when methionine, glycine and a purine are present in the medium. 
The role of thymine may thus be central to the induction of the type IV DHFR. 
Therefore, in order to investigate whether thymine starvation was sufficient to 
produce induction of the DHFR type IV, a thymine requiring auxotroph of E. coli 
J62 -2 was selected, and the plasmid pUK1123 was transferred into it. 
To produce the auxotroph, E. coli J62 -2 was grown in Davis and Mingioli minimal 
medium containing proline, histidine and tryptophan, together with trimethoprim at 
40mg /L and thymidine at 50mg /L. Thymidine was used in preference to thymine 
because it is more readily taken up by the cell. This was cultured for five days to 
allow thymine requiring cells, which are resistant to trimethoprim, to grow 
through. From this culture, 0.1m1 was spread on agar containing the same 
concentration of supplements. Colonies from this medium were tested for thymine 
auxotrophy and E. coli J62 -2 auxotrophic markers. 
Plasmid pUK1123 was transferred to this E. coli J62 -2, confirmed as a thy mine 
requiring auxotroph, from E. coli J53. Streptomycin at 20mg /L was used as the 
selective agent for plasmid transfer. 
111 
The resulting transconjugant, E. coli J62 -2 thy (pUKI 123), was then subjected to 
growth in minimal medium containing decreasing concentrations of thymidine, and 
the specific activity of the DHFR from the cell free extract measured (table 29). 
When the thymine requiring strain was grown in reduced thymidine concentrations, 
an increase in DHFR specific activity of up to ten -fold could be seen between cells 
grown in 10mg /L and in lmg /L thymidine (table 29). This effect is reversed in 
cells grown in of thymidine, 0.5mg /L; however, this may be as a result of the 
over -growth of thy+ revertants in a medium which is very low in thymidine. 
Table 29. DHFR specific activity of thymine requiring auxotroph in decreasing 









Thymine depletion produced an increase in the expression of DHFR which 
confirms the role of thymine in the induction mechanism of the type IV DHFR; 
thymine starvation was sufficient to induce greater expression of the DHFR type 
IV. 
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4.3. INDUCTION OF TEM -1 IN E. COL1 J62 (pUK2007) 
4.3.1. Induction of TEM -1 with Trimethoprim or Amoxycillin 
The plasmid pUK2007 as well as harbouring the dhfrIV gene also carries the bla 
gene of the TEM -1 ß- lactamase. It was speculated that the expression of this gene 
might also be affected in the same way as the expression of the dhfr IV gene. The 
expression of TEM -1 can be measured by spectrophotometry and the specific 
activity assayed. The MIC of ampicillin for E. coli J62 -2 (pUK2007) is 256mg /L. 
This strain was challenged with varying concentrations of ampicillin and 
trimethoprim at 80mg /L. The overnight culture was then prepared for the assay of 
both DHFR and ß- lactamase specific activity; TEM -1 activity was assayed by the 
use of the chromogenic ß- lactam substrate, nitrocefin (table 30). 
Table 30. Specific activity of DHFR and 8- lactamase from E. coli J62 -2 
(pUK2007) when challenged with ampicillin and trimethoprim. 
Antibiotic Concentration 
(mg /L) 
0- lactamase specific 
activity' 
DHFR specific activity2 
control 0 0.50 1.6 
ampicillin 80 0.98 1.3 
ampicillin 160 1.14 
ampicillin 240 1.93 4.0 
trimethoprim 80 15.8 244.5 
1 µmol nitrocefin hydrolysed /min /mg protein. 
2 nmol DHF reduced /min /mg protein. 
There were indications of a rise in ß- lactamase specific activity after challenge with 
high concentrations of ampicillin, an increase of almost four -fold could be seen 
when the cells are challenged with 240mg /L of ampicillin. More surprisingly, 
however, is the rise in TEM -1 specific activity after challenge with trimethoprim, a 
very significant rise of 30 -fold was recorded when the cells were challenged with 
80mg /L of trimethoprim. This compared with an approximate increase of 150 -fold 
in the DHFR specific activity (table 30). 
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4.3.2. Induction of the TEM -1 ß- Lactamase and the DHFR Type 
IV with High Concentrations of Amoxycillin or 
Trimethoprim 
From the previous experiment it was found that trimethoprim concentrations very 
much higher than the MIC, as derived on IST agar by the agar dilution method, 
are required to induce the DHFR type IV and the TEM -1 ß- lactamase. Very high 
concentrations of the ß- lactam may then be required to produce the induction of the 
TEM -1 enzyme. Therefore, the specific activity of the TEM -1 ß- lactamase and the 
DHFR type IV from E. coli J62 -2 (pUK2007) was assessed after challenge with 
trimethoprim at 40mg /L and amoxycillin at 500mg /L and 1000mg /L (table 31). 
Table 31. Specific activity of the TEM -1 and DHFR type IV of E. coli J62 -2 
(pUK2007) after challenge with trimethoprim and high concentrations of 
amoxycillin. 
Antibiotic Concentratio 





control 0 9.9 0.01 
trimethoprim 40 238.4 0.81 
amoxycillin 500 6.6 0.34 
amoxycillin 1000 37.3 1.46 
inmol DHF reduced /min /mg protein. 
2µmo1 nitrocefin hydrolysed /min /mg protein. 
Challenge with a high concentration of amoxycillin was capable of inducing 
increased specific activity in both the TEM -1 ß- lactamase and the DHFR type IV 
(table 31). As in the case of induction with trimethoprim, induction with 
amoxycillin required the presence of levels of drug higher than those given by 
MICs derived by the agar dilution method. The observed increase in specific 
activity of the enzymes with the two drugs was not proportional, i.e. the rise in 
activity of each enzyme was not the same; for instance, challenge with amoxycillin 
at 500mg /L increases the specific activity of the TEM -1 g- lactamase but not that of 
the DHFR, and the observed rise in specific activity after challenge with 
trimethoprim was significantly higher in the case of TEM -1. 
114 
4.3.3. Induction of the TEM -1 ß- Lactamase and the Type IV 
DHFR by Amoxycillin /Clavulanic Acid 
The MIC of amoxycillin /clavulanic acid for E. coli J62 -2 (pUK2007) was 8mg /L. 
The inhibition of TEM -1 by clavulanic acid, which is a competitive inhibitor of 
TEM -1, allows amoxycillin to take effect on the cell. Thus, considerably reduced 
concentrations of amoxycillin are required to produce cell death in the presence of 
clavulanic acid. The ability of amoxycillin in combination with clavulanic acid to 
produce induction of the TEM -1 ß- lactamase and the DHFR type IV enzymes was 
tested (table 32). 
Table 32. Specific activity of TEM -1 ß- lactamase and DHFR type IV after 





ß- lactamase specific 
activity2 
control 0 0.29 0.33 
trimethoprim 40 24.44 5.5 
amox /clav* 8 5.35 1.06 
amox /clav* 12 16.04 3.74 
*Amoxycillin: clavulanic acid was used in a 2:1 ratio. 
lnmol DHF reduced /min /mg protein. 
2µmol nitrocefin hydrolysed /min /mg protein. 
Much lower concentrations of the amoxycillin/clavulanic acid combination were 
capable of producing the induction of both enzymes (table 32). Significant 
increases in the specific activity of both enzymes were seen at 
amoxycillin /clavulanic acid concentrations around the MIC, as derived by agar 
dilution. 
4.3.4. The Over -Expression of TEM -1 Is Reversible 
Young et al (1993) demonstrated that the DHFR type IV in E. coli J62 -2 
(pUK1123) was induced by challenge with trimethoprim and that this was a 
reversible condition and not the result of the selection of an over -expressing 
mutant. Levels of DHFR type IV returned to basal levels when cells that had been 
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over -producing the enzyme in broth containing trimethoprim were sub -cultured 
into broth containing no drug. 
To determine if this were true for the induction of the TEM -1 ß- lactamase, a 
similar experiment was performed on E. coli J62 -2 (pUK2007). Cells were 
challenged with of amoxycillin /clavulanic acid, 8mg /L, in a total volume of 200m1 
of IST broth; a control containing no drug was also included. After overnight 
culture, 1 ml of the culture was added to fresh IST broth, containing no drug; the 
remainder was prepared for ß- lactamase and DHFR specific activity assays. The 
fresh culture containing no drug was again incubated overnight with vigorous 
shaking as in all other assays, after which this was also prepared for ß- lactamase 
and DHFR specific activity assays (table 33). 
Table 33. ß- lactamase and DHFR specific activities after challenge with 








after sub -culture 
DHFR1 0- lactamase2 DHFR1 0- lactamase2 
0 





lnmol DHF reduced /min /mg protein. 
2 µmol nitrocefin hydrolysed /min /mg protein. 
Although the specific activities were variable, it can be seen that the levels of 
enzyme activity of both the DHFR and the ß- lactamase returned to basal levels in 
the equivalent cultures containing no drug challenge after they have achieved 
activities 10 -fold greater (table 33). This would indicate that the over -expression is 
not by the selection of mutants. In support of this, it would also seem unlikely that 
an unrelated antimicrobial such as trimethoprim could select for mutants resistant 
to ß- lactam agents, by the over -expression of a ß- lactamase, and vice -versa. 
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4.4. THE El'HECT OF INDUCTION ON THE MIC 
4.4.1. Increase in MIC After Challenge with Antimicrobials 
The MICs given on IST agar are significantly lower than the concentrations in 
which induction takes place and in which the cells will subsequently grow, at least 
in the case of trimethoprim and amoxycillin as a single agent. This would indicate 
that the enzymes are not induced when the cells are grown on agar. To investigate 
the possible affect of induction on the MIC, the test organism E. coli J62 -2 
(pUK2007) was incubated overnight with vigorous shaking in different 
concentrations of antimicrobials, in order to produce induction of the enzymes 
before the MIC assays were performed. The MICs were then determined by the 
normal agar dilution method. E. coli J62 -2 (Rl), which also carries TEM -1 was 
included as a control (table 34). 
After challenge with antimicrobial, at a sufficiently high concentration of drug to 
produce induction of the enzymes, the MICs of trimethoprim, amoxycillin and 
amoxycillin/clavulanic acid rose substantially. A very large increase in the MIC of 
trimethoprim was seen, the cells being rendered resistant to what would be 
considered high levels of trimethoprim by an initial challenge with both 
trimethoprim and amoxycillin /clavulanic acid. No equivalent rise was seen in the 
MICs of amoxycillin or amoxycillin /clavulanic acid in the case of the R1 carrying 
strain (table 34). 
The challenge by amoxycillin did not appear to be sufficient to produce the very 
large increase in MIC displayed when the cells were challenged with trimethoprim 
or the combination of amoxycillin and clavulanic acid. Thus, it can be seen that the 
cells do not induce the resistance enzymes on agar plates under normal 
circumstances. However, if the cells are challenged prior to assay, the induced 
enzymes allow the cells to grow in greatly increased concentrations of 
antimicrobial. As might be expected from the induction studies, challenge by one 
antimicrobial results in increased resistance to both types of agent, i.e. challenge 
by ß- lactam resulted in increased resistance to both the ß- lactam agents and 
trimethoprim, and challenge with trimethoprim resulted in increased resistance to 
both trimethoprim and the ß- lactam agents. 
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Table 34. The MICs of trimetho i rim amox cillin and amox cillin /clavulanic acid 
determined after challen ' e with antimicrobials. 
Plasmid Drug concentration 











R1 0 - 512 8 
Rl amoxycillin 250 - 512 8 
R1 amoxycillin 500 - 512 8 
R1 amoxycillin 1000 - 512 8 
R1 amox/clav 4* - 512 8 
R1 amox/clav 8* - 512 8 
pUK2007 0 4 512 8 
pUK2007 trimethoprim 40 128 1024 16 
pUK2007 trimethoprim 80 > 128 > 1024 16 
pUK2007 trimethoprim 160 > 128 > 1024 16 
pUK2007 amoxycillin 250 4 512 8 
pUK2007 amoxycillin 500 4 512 8 
pUK2007 amoxycillin 1000 16 1024 16 
pUK2007 amox/clav 4* 4 512 8 
pUK2007 amox/clav 8* 128 1024 16 
pUK2007 amox/clav 12* 128 1024 16 
*Amoxycillin:clavulanic acid was used in a 2:1 rato. 
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4.4.2. MICS by Tube Assay for E. coli J62 -2 (pUK2007) 
MICs were assayed in 5ml of IST broth by overnight incubation at 37°C with 
vigorous shaking, the last tube showing no growth was taken as the MIC (table 
35). 
Table 35. MICs as determined by broth "tube" assay_ 
Plasmid Amoxycillin MIC Amox/clav* MIC Trimethoprim MIC 
(mg/L) (mg/L) (mg/L) 
pUK2007 > 2048 512 64 
Rl 2048 16 - 
*Amoxycillin: clavulanic acid was used in a 2:1 ratio. 
Again, under conditions when the enzymes can be induced, the MICs were raised 
substantially (table 35). This was shown to greatest effect in the case of 
amoxycillin /clavulanic acid where the MIC was 64mg /L, making the cells resistant 
to amoxycillin /clavulanic acid, whilst the strain carrying the R1 plasmid had an 
MIC of 16mg /L, as determined by this method, whereas if assayed by agar dilution 
both strains had an MIC of 8mg /L. 
4.5. THE EFFECT OF GROWTH PHASE AND CELL 
NUMBERS ON INDUCTION 
4.5.1. The Affect of Growth -Phase on the Induction by 
Trimethoprim and Amoxycillin /Clavulanic Acid of 
E. coli J62 -2 (pUK2007) 
E. coli J62 -2 (pUK2007) was grown for two hours, to approximately mid -log 
phase, and then challenged with amoxycillin/clavulanic acid (12, 32 or 64mg /L) or 
trimethoprim (40 and 512mg /L). The cells were harvested after two and 24 hours 
and assayed for TEM -1 ß- lactamase or the DHFR type IV specific activity 
(table 36). 
Table 36. S . ific activities of TEM -1 and DHFR I 
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IV after challenge of 
log -phase cells with various concentrations of drug after two or 24 hours. 
Drug concentration 
(mg /L) 










amox /clav 12 




























lnmol DHF reduced /min /mg protein. 
2µmol nitrocefin hydrolysed /min /mg protein. 
No induction of either the TEM -1 ß- lactamase or the DHFR type IV was seen 
under these conditions. At high concentrations of amoxycillin /clavulanic acid, i.e. 
32 or 64mg /L, the cells were killed. Gram -stains of these cultures after two hours 
showed lysed cells, few were intact, in the culture containing 32 mg /L, while the 
culture containing 64mg /L showed only cell debris after two hours. After 24 hours 
both showed only cell debris. These cells seem, however, to be able to overcome 
trimethoprim when high cell densities, in log -phase are challenged. A similar result 
was achieved in E. coli J62 -2 (pUK1123) with trimethoprim as the challenge 
(results not shown). 
4.5.2. The Effect of Cell -Phase on the Induction Mechanism 
Experiments were performed to separate the effect of cell numbers and the effect 
of cell phase on the induction mechanism of the type IV DHFR. A culture of E. 
coli J62 -2 (pUK2007) was grown overnight in IST broth. Of this culture 0.1m1 was 
diluted in 10m1 of IST broth and incubated with vigorous agitation for two hours to 
approximately mid -log phase. The remainder of the culture was maintained at 
370C. Of the two hour mid -log phase culture, one ml was treated with carbonyl 
cyanide m- chlorophenyl hydrazone (CCCP) to a final concentration of 5mM. (This 
is an uncoupler of the electron motive force, and thus inhibits cell metabolism). 
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The treated cells were incubated on ice for five minutes; they were then washed in 
Davis and Mingioli medium before being resuspended in one ml of IST broth. 
The overnight culture was diluted to approximately the same cell density as the 
mid -log phase cells, as measured at O.D. 540nm. IST broths containing 
trimethoprim with 0 or 40mg /L, were then inoculated with 0.1 ml of each of the 
three cell suspensions. The cell numbers at inoculation and after two hours were 
checked by performing viable counts (table 37). The broths were cultured 
overnight and DHFR assays performed on the cell extracts (table 38). 
Table 37. Cell counts of overnight, carbonyl cyanide m-chlorophenyl hydrazone 
treated and log phase inocula. 
Cell suspension Inoculum Cell concentration after two hours 
(cfu /ml) (cfu /ml) 
trimethoprim 
0 mg /L 
trimethoprim 
40 mg /L 
overnight 3x103 6x107 7x103 
CCCP 2x103 6x107 2x104 
log phase 8x103 8x107 4x104 
The overnight culture, which was presumably in stationary phase, induced high 
levels of both the TEM -1 ß- lactamase and the DHFR. Those cells that had their 
metabolism disrupted, and were forced back into stationary phase by the action of 
CCCP, also produced a considerable increase of both enzymes. However, 
challenge of cells during mid -log phase resulted in a very much reduced induction 
of the DHFR type IV and showed a decrease in the production of the TEM -1 
enzyme (table 38). 
If the figures were expressed in terms of relative increase in DHFR type IV and 
TEM -1 ß- lactamase specific activity between challenged and unchallenged cultures 
in each of the three inoculum types, the low level of induction in log phase cells 
could be seen. In the overnight cells the increase was 1458 -fold in the DHFR, 
six -fold in the 13-lactamase; in the CCCP treated cells induction was less marked 
being some 20 -fold in the DHFR and four -fold in the ß- lactamase; in the log phase 
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cells there was only a three -fold increase in DHFR activity and a reduction in ß- 
lactamase activity. 
The cell numbers in the inocula were similar (table 37), thus inoculum size could 
not be affecting the induction process. The cells treated with CCCP seemed to 
recover after two hours when cell numbers were similar to the other cultures; the 
log -phase cells grew slightly more rapidly than the cells inoculated at stationary 
phase. 
Table 38. DHFR specific activities of cultures inoculated with cells in different 
phases. 
Cells in Trimethoprim 























inmol DHF reduced /min /mg protein 
2µmol nitrocefin hydrolysed /min /mg protein 
The CCCP, although not a complete inhibitor of metabolism was sufficient to 
reduce the metabolic processes so that the cells behaved like stationary phase cells. 
The enzymes were induced in these cells on treatment with trimethoprim, although 
not to the same extent as the overnight culture. This presumably resulted from the 
incomplete action of the CCCP treatment on the cells. The cells challenged during 
log -phase showed little induction of the DHFR type IV, and none of the TEM -1 ß- 
lactamase. Thus, cell phase seems to be very important in the induction 
mechanism; induction did not take place in log -phase cells. 
4.5.3. The Effect of Inoculum Size on the Induction Mechanism 
Cell numbers in the inoculum may also have an effect on the induction process. In 
order to investigate the effect of inoculum size, 100m1 of IST broth was inoculated 
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with E. coli J62 -2 (pUK2007) and cultured overnight. The cells were harvested and 
resuspended in 10m1 of Davis and Mingioli medium. Aliquots of 5, 0.5 and 
0.05m1 of this cell suspension were used to inoculate IST broth containing 
trimethoprim, 40mg /L; 0.05m1 was also inoculated into IST broth containing no 
trimethoprim. Viable counts were performed on these cultures, and after overnight, 
growth cell free extracts were assayed for enzyme activity (table 39). 
Table 39. Enzyme activity in cultures inoculated with differing inoculum sizes after 
challenge with trimethoprim. 






ß- lactamase specific 
activity2 
0.05 4.6x106 26.7 1.04 
0.5 5.2x107 12.8 0.13 
5.0 5. 4x108 1.3 0.07 
0.05 control no 3.3 0.18 
trimethoprim 
'nmol DHF reduced /min /mg protein. 
2gmol nitrocefin hydrolysed /min /mg protein. 
Cell numbers clearly had an effect on the induction of the DHFR and TEM -1. 
When a large inoculum was used (5.4x108cfu /m1), induction of the DHFR and ß- 
lactamase was abolished, whilst inoculation with moderate cell numbers 
(5.2x107cfu /ml) resulted in reduced induction (table 39). Thus both cell numbers 
and the growth phase of the cells when challenged with drug influence the 
induction of the type IV DHFR and TEM -1 ß- lactamase. 
123 
4.5.4. DHFR Specific Activity and Cell -Phase 
Samples of an untreated culture were taken at four hour intervals and assayed for 
DHFR specific activity (table 40). 
The specific activity of the DHFR dropped with time of culture (table 40 and 
figure 27). Unfortunately sufficient material could not be obtained to allow assay 
before four hours. At four hours, however, there was more activity than at eight or 
twelve hours when activity is reduced six -fold. In mid -log phase the cells appeared 
to produce more DHFR. This may have contributed to the reduction of the 
response in log -phase cells to treatment with trimethoprim, resulting in the 
abolition of the induction of DHFR. However, even at high concentrations of 
trimethoprim no induction was observed; thus other factors may be involved in the 
response of the cells in log- phase. 
Table 40. The correlation of DHFR specific activity with cell growth. 
Time cell numbers DHFR specific activity* 
(hours) (cfu /ml) 
4 2.9x106 2.5 
8 2.1x108 0.8 
12 8.0x108 0.4 
*nmol DHF reduced /min /mg protein 
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Figure 27. Graph of increasing cell numbers with time against DHFR specific 
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4.6. THE EFFECT OF THE METABOLITES METHIONINE, 
GLYCINE, ADENINE AND THYMINE 
4.6.1. Induction of the Type IV DHFR in the Presence and 
Absence of Methionine, Glycine and Adenine 
The MICs in the absence of methionine, glycine and adenine were higher than 
when these were present, as shown in table 24 above. The induction mechanism 
has also been shown to be dependent on several factors, including cell phase, 
inoculum size and amount of DHFR present. The effect of methionine, glycine and 
adenine is to reduce levels of thymine to produce "thymineless" death of the cell in 
the presence of trimethoprim. This was perhaps the cause of the reduction of MIC 
in the presence of these metabolites. So can the same response be obtained in the 
cells, in the absence of methionine, glycine and adenine, by increasing the 
concentration of trimethoprim to further inhibit the DHFR and presumably bring 
about "thymineless" stress? Is the DHFR induced by higher levels of trimethoprim 
despite the absence of methionine, glycine and adenine? 
E. coli J62 -2 (pUK2007) was grown overnight in various concentrations of 
trimethoprim in single strength Davis and Mingioli minimal medium containing 
proline, histidine and tryptophan or this medium with the addition of methionine, 
glycine and adenine, each at a concentration of 50mg /L. Specific activities were 
then determined (table 41). 
In order to compare this set of results they can be expressed more easily in terms 
of the relative increase in specific activity between the unchallenged and those 
challenged with trimethoprim in each case (table 42). 
In media containing methionine, glycine and adenine, less trimethoprim was 
required to bring about induction of both the DHFR type IV and TEM -1 (3 
-lactamase, although the reaction of the 0- lactamase was not as pronounced (table 
42). Even with trimethoprim at a concentration of 240mg /L, the induction of the 
DHFR was not as great in media lacking the metabolites as it was at a 
trimethoprim concentration of 40mg /L in media containing methionine, glycine 
and adenine. 
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Table 41. Specific activities of cells challenged with trimethoprim in the presence 
or absence of methionine, glycine and adenine. 
Medium Trimethoprim DHFR 0- lactamase 
(mg /L) specific activity 1 specific activity2 
PHT 0 0. 88 0.09 
PHT 40 1.40 0.17 
PHT 120 4.40 0.52 
PHT 240 5.56 1.26 
MGA 0 0.30 0.09 
MGA 40 3.48 0.39 
PHT is Davis Mingioli media containing proline, histidine and tryptophan. 
MGA is this media with methionine, glycine and adenine. 
lnmol DHF reduced /min /mg protein. 
2µmo1 nitrocefin hydrolysed /min /mg protein. 
Table 42. Relative increase in specific activity between challenged and 
unchallenged cultures. 
Medium Trimethoprim Relative increase in Relative increase in ¡3- 
(mg/L) DHFR specific activity. lactamase specific activity. 
PHT 0 1 1 
PHT 40 1.6 1.7 
PHT 120 5.0 5.8 
PHT 240 6.3 14 
MGA 0 1 1 
MGA 40 11.6 4.3 
PHT is Davis Mingioli media containing proline, histidine and tryptophan. 
MGA is this media with methionine, glycine and adenine. 
4.6.2. The Effect of Methioinine, Glycine and Adenine on the 
Expression of the TEM -1 ß- Lactamase E. coli J62 -2 
(pUK2007) 
The metabolites, methionine, glycine and adenine, influence the expression of the 
type IV DHFR. Will the presence of these metabolites have the same influence on 
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the expression of the TEM -1 0- lactamase and will they have any influence on the 
ability of amoxycillin /clavulanic acid to produce induction of the resistance 
enzymes? 
The MIC for the combination of amoxycillin /clavulanic acid on media containing 
methionine, glycine and adenine and media lacking these metabolites, with and 
without challenge prior to performing the assay, was first determined (table 43). 
Table 43a. The MIC of amoxycillin /clavulanic acid for E. coli J62 -2 (pUK2007) in 
minimal medium and medium containing methionine, glycine and adenine. with 
and without prior challenge. 
Drug and concentration 
of challenge (mg /L) 
MIC in minimal medial 
(mg /L) 
MIC in methionine, glycine 
and adenine (mg /L)2 
0 4 4 
trimethoprim 40 16 16 
amox/clav 8 16 16 
amox/clav 12 16 16 
1 This is Davis and Mingioli (DM) minimal medium containing proline, histidine 
and tryptophan.2 DM medium containing the additives methionine, glycine and 
adenine. 
There was no difference in the MICs of amoxycillin /clavulanic acid when the 
assays were carried out in the presence or absence of methionine, glycine and 
adenine. The MICs were again raised when the cells were challenged and the 
resistance enzymes induced prior to assay of the MIC (table 43a). 
To investigate the effect of the presence of the metabolites on the expression of 
TEM -1 ß- lactamase, cells were challenged with trimethoprim in the presence and 
absence of the three metabolites and the specific activity of the TEM -1 /3- lactamase 
assayed. In a further experiment, cells were challenged with amoxycillin /clavulanic 
acid also in the presence and absence of methionine, glycine and adenine, and 
again the specific activity of the /3- lactamase was assayed (table 43b). 
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'i'able 43b. ß- lactamase specific activities after challenge with trimethoprim in the 
presence and absence of methionine 11 cine and adenine. The relative increase in 
specific activity from unchallenged cells is also shown. 
Media Concentration of 
challenge with 
trimethoprim (mg /L) 
ß- lactamase 
specific activity 1 
Relative increase 
PHT 0 0.09 1 
PHT 40 0.17 1.9 
PHT 120 0.52 5. 8 
PHT 240 1.26 14.0 
MGA 0 0.09 1 
MGA 40 0.39 4.3 
PHT is Davis Mingioli medium containing proline, histidine and tryptophan. 
MGA is this medium with methionine, glycine and adenine. 
1µmo1 nitrocefin hydrolysed /min /mg protein. 
ß- lactamase expression reacted in the same manner as the DHFR when the cells 
were challenged with trimethoprim in the presence of methionine, glycine and 
adenine (table 43b). Significantly less drug was required to bring about a similar 
rise in specific activity of TEM -1 ß- lactamase when methionine, glycine and 
adenine were present in the media. 
This feature of trimethoprim action was not repeated in the case of challenge with 
the amoxycillin /clavulanic acid combination. A greater increase in enzyme specific 
activity, both ß- lactamase and DHFR, was seen when the cells were challenged in 
the absence of methionine, glycine and adenine (table 44). This possibly resulted 
from the greater effect of the drug in a nutrient depleted medium. It would be 
expected that the action of the ß- lactam would not be influenced by the presence of 
the metabolites since their action is on the metabolic pathway on which 
trimethoprim acts. Once again both resistance mechanisms responded in the same 
way. Both the ß- lactamase and the DHFR specific activities were not influenced by 
the presence of methionine, glycine and adenine when the cells were challenged 
with amoxycillin/clavulanic acid. 
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Table 44. ß- lactamase and DHFR specific activities after challenge with 
amox cillin /clavulanic acid in the sresence and absence of methionine 1 cine and 
adenine. The relative increase in s s ific activi from unchallen ed cell is al 
shown. 
Media Concentration of 











PHT 0 2.8 1 0.14 1 
PHT 4 12.7 4.5 0.36 2.5 
PHT 8 660.9 236.0 5.3 38.0 
PHT 12 no growth - - - 
MGA 0 4.4 1 0.21 1 
MGA 4 3.5 0.8 0.28 1.3 
MGA 8 41.9 9.5 2.1 10 
PHT is Davis Mingioli medium containing proline, histidine and tryptophan. 
MGA is this medium with methionine, glycine and adenine. 
lnmol DHF reduced /min/mg protein. 
2 mmol nitrocefin hydrolysed /min /mg protein. 
4.6.3. The Effect of Thymine Starvation on the Induction of 
TEM -1 ß- lactamase 
The plasmid pUK2007 was transferred, by conjugation, into the thymine requiring 
mutant of E. coli J62 -2, as was outlined previously in the transfer of plasmid 
pUK1123 to this same strain. 
This strain was then subjected, as in the previous experiment, to growth conditions 
of decreasing concentrations of thymidine. The specific activities of both the TEM- 
1 (3- lactamase and the type IV DHFR were then assayed (table 45). 
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'fable 45. The specific activities of DHFR and TEM -1 in the thymine requiring 





ß- lactamase specific 
activity2 
1 1.3 0.28 
2 1.1 0.27 
5 0.6 0.17 
10 0.8 0.20 
50 0.8 0.14 
lnmol DHF reduced /min /mg protein. 
2mmol nitrocefm hydrolysed /min /mg protein. 
The specific activity dropped slightly for both the ß- lactamase and the DHFR, 
although the amounts were not very large, when the amount of thymidine in the 
growth medium was increased (table 45). However, both enzymes react in a 
similar way; both fell when thymidine, 5mg /L, was present, which may lend some 
credibility to the result. Thus, thymine deficiency seems to influence the expression 
of both enzymes. 
4.7. THE EFFECT OF AMOXYCILLIN /CLAVULANIC ACID 
AND TRIMETHOPRIM ON THE GROWTH AND 
MORPHOLOGY OF E. COLT J62 -2 (PUK2007) 
E. coli J62 -2 (pUK1123) undergoes an initial phase of cell death after inoculation 
in IST broth containing trimethoprim. In this phase, numbers dropped and the cells 
became elongated, a change in morphology that has been associated with 
thymineless- death; the cells then recovered to grow normally (Thomson et al 
1993). To test if this response was also demonstrated in E. coli J62 -2 (pUK2007), 
and if amoxycillin /clavulanic acid had a similar effect, three 200m1 flasks of IST 
broth containing either no drug, trimethoprim 40mg /L or amoxycillin /clavulanic 
acid 12mg /L, were inoculated with E. coli J62 -2 (pUK2007). These were 
incubated at 37 °C with vigorous shaking for 24 hours. Samples were taken at 4 
hour intervals for viable count and gram -film (figures 28 and 29). 
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Both the cells treated with trimethoprim and amoxycillin /clavulanic acid underwent 
an initial period of cell -death; cell numbers dropped from the numbers inoculated 
into the media (figure 28). The cells treated with trimethoprim started to recover at 
about four to eight hours, when the cell numbers began to increase steadily. The 
cells treated with amoxycillin /clavulanic acid, however, continued to fall in 
number until about 12 hours when there was a dramatic increase in cell numbers. 
The cells presumably started to recover when the amount of enzyme was sufficient 
to overcome the antibiotic, thus allowing normal cell growth to continue (figure 
28). The cells themselves underwent morphological changes. E. coli J62 -2 
(pUK2007) was a small rod at inoculum; after four hours without drug the cells 
were slightly larger, however, with drug treatment the cells were greatly elongated 
(figure 29). The trimethoprim treated cells were elongated; as demonstrated by 
Thomson et al (1993). Those cells treated with amoxycillin /clavulanic acid are also 
elongated but they also appeared to have a bulge in the middle of the cell, perhaps 
where the cells may have divided. This feature was not apparent in the 
trimethoprim treated cells. On recovery, after 24 hours, the cells returned to the 
normal morphology, as shown by the untreated cells, although some elongated 
cells were also seen (figure 29). 
The cells reacted in a similar, but not identical, manner to treatment with 
trimethoprim or amoxycillin /clavulanic acid. Both drugs brought about cell -death 
and morphological changes, involving cell elongation, before induction of the 
resistance mechanisms. 
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Figure 28. Growth of E. coli J62 -2 t U1(2007 after challen . e with trimetho s rim 
or amoxycillin / clavulanic acid. 
0 2 4 6 8 10 12 14 16 18 20 22 24 
Time (in hours) 
No drug 
iz Amoxycillin clavulanic acid 
a, Trimethoprim 
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figure 29. Photomicrographs of E. coli J62 -2 (pUK2007) with (A) no drug (B) 
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4.8. DO OTHER ANTIBIOTICS PRODUCE INDUCTION OF 
THE DHFR TYPE IV AND TEM -1? 
The MIC of nalidixic acid for E. coli J62 -2 (pUK2007) is 8mg /L, the strain being 
sensitive to nalidixic acid. The MIC of streptomycin for this strain is 256mg /L, the 
resistance mechanism being located on the plasmid pUK2007. Induction was 
attempted with both of these agents. 
Table 46. Specific activity of Type IV DHFRin E. coli J62 -2 (pUK2007) after 
challenge with nalidixic acid. 





16 no growth 
*nmol DHF reduced /min /mg protein. 
There was an indication of increased specific activity when the cells were 
challenged with nalidixic acid at a concentration of 4mg /L. However, growth of 
the cells was inhibited by 8mg /L and the specific activity was affected by the much 
reduced growth of the cells. No growth was obtained with nalidixic acid at 16mg /L 
(table 46). The strain was sensitive to nalidixic acid and thus no possible 
mechanism could be induced to allow it to grow in increasing concentrations of 
nalidixic acid, as it could when treated with trimethoprim or amoxycillin. The cells 
perhaps died before any significant increase in DHFR could be achieved. 
The plasmid pUK2007 carried a streptomycin resistance gene conferring an MIC of 
256mg /L on E. coli J62 -2. Is streptomycin capable of inducing the plasmid 
mediated resistance mechanisms? To test this, E. coli J62 -2 (pUK2007) was 
challenged with streptomycin at concentrations of 256 and 512mg /L, and 
trimethoprim at 40mg /L, as a control (table 47). 
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'fable 47. Specific activities of DHFR type IV and TEM -1 in E. coli J62 -2 
(pUK2007) after challenge with streptomycin. 
Challenge (mg /L) DHFR specific ß- lactamase 
activity' specific activity2 
0 1.00 
streptomycin 256 0.02 
streptomycin 512 0.20 





1 nmol DHF reduced /min/mg protein. 
2 µmol nitrocefin hydrolysed /min /mg protein. 
Challenge with streptomycin produced no increase in specific activity of either the 
DHFR type IV or the TEM -1 ß- lactamase (table 47). Thus, of the agents tested 
only trimethoprim, amoxycillin and amoxycillin /clavulanic acid were capable of 
inducing high levels of the resistance enzymes. 
4.9. THE bla GENE OF TEM -1 AND THE dhfiiV GENE ARE 
NOT CLOSELY ASSOCIATED ON PLASMID pUK2007 
The probe for the dhfr IV gives multiple bands; therefore the use of this probe and 
a probe for the TEM -1 bla gene could not be used to establish whether the two 
genes are linked. To try and demonstrate an association, a number of recombinants 
were created from different restriction digests of pUK2007 by selecting for 
recombinants with trimethoprim or ampicillin, and then checking for 
cross -resistance (table 48). 
Of the six different recombinants formed from digests using "six- cutter" 
endonuclease restriction enzymes, no recombinant was formed that was resistant to 
both trimethoprim and ampicillin. It seemed likely, therefore, that they were not 
closely associated on the plasmid; if they had been it might be expected that they 
would have been inserted together during the cloning procedure. It seemed very 
unlikely indeed that the genes were transcribed from the same promoter. However, 
there remains the possibility that a mutation has occurred in one of the two genes 
forming a site for one of the above enzymes. Thus, the genes could have been cut 
by the enzyme. 
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Table 48. The following recombinants, formed from pUK2007, were created and 
characterized. 
Plasmid Enzyme Vector Approximate size of 
insert (Kb) 
Resistance pattern 
of insert only 
pUK2047 HindlIl pSU18 5 TpR, ApS 
pUK2048 HindlI pSU18 4 TpS, ApR 
pUK2049 Pstl pSU18 4 TpR, ApS 
pUK2052 EcoRI pSU18 6 TpS, ApR 
pUK2053 Sall pSU18 2 TpS, ApR 
pUK2054 Aval pSU 18 3 TpS, ApR 
The 5Kb fragment of pUK2047, after separation and labelling with biotin, showed 
positive hybridisation with the 4Kb ampicillin resistance fragment of pUK2048. 
This would indicate the existence of repeated sequences associated with both the 
dhfrlV gene and the bla gene of TEM -1. These repeated sequences may be 
associated with the control of the induction mechanism, however, this would 
require further investigation (figures 30 and 31). 
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figure 30. A 1% agarose gel of recombinant plasmids digested with Hindill. 
(A) pUK2049; (B) pUK2047; (C) pUK1216, recombinant plasmid containing the 
dhfrIV gene; (D) pSU18; (E) X Hindl ldigest. 









Figure 31. Southern blot of recombinant plasmids digested with Hindi!I and 
hybridised with the dhfrIV insert of pUK2049. 
(A) pSU18; (B) pUK1216, recombinant plasmid containing the dhfiIV gene; (C) 
pUK2047; (D) pUK2049. 
A B C D 
pUK2047 insert 5.5Kb 
pUK2049 inserb4.8Kb 
pUK1216 insert 2.7Kb 
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4.10. THE SPECIFIC ACTIVITIES OF RECOMBINANTS OF 
pSC101 CARRYING THE dhfiIV FROM pUK1123. 
The following clones were created containing the dhfr IV gene inserted into the 
low copy number plasmid pSC101 (table 49). A low copy number vector was used 
in order that copy number of the recombinants would not influence expression of 
the DHFR. 




pUK2043 6.5 sub -clone of pUK2041, a pUC18 recombinant containing 
an EcoRl insert from pUK1123. 
pUK2044 1.2 sub -clone of pUK1227, a pUC18 recombinant with a 
HindIII /HindII insert from pUK1123. A blunt -ended 
fragment from this recombinant was ligated with an 
EcoRl linker and subsequently ligated with pSC101. 
These recombinants were initially used to transform E. coli DH5a, from which 
plasmid DNA was purified and used to transform E. coli J62 -2. The strains E. coli 
J62 -2 (pUK2043) and E. coli J62 -2 (pUK2044) were then used in induction 
experiments as before, being challenged with trimethoprim 50mg /L. 
The recombinant plasmids were not capable of the induction response on challenge 
with trimethoprim (table 50). The DHFR was expressed at constitutive high levels, 
despite being on low copy number plasmids. Therefore, it may be that a repressor 
is present in the wild -type plasmid, that is not present in the recombinants, which 
suppresses the DHFR expression in the absence of trimethoprim. 
The wild -type plasmid pUK1123, harbouring the original dhfrIV gene, was 
transfered into the strains harbouring the recombinant plasmid pUK2043. 
Transconjugants harbouring both plasmids were then selected and specific activities 
measured after challenge with trimethoprim (table 51). 
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Table 50. DHFR specific activities from recombinant plasmids in E. coli J62 -2 
after challenge with trimethoprim. 
Plasmid Trimethoprim (mg /L) DHFR specific activity* 
pUK1123 0 1.7 
pUK1123 50 99.6 
pUK2043 0 88.6 
pUK2043 50 96.1 
pUK2044 0 126.6 
pUK2044 50 127.0 
*nmol DHF reduced /min /mg protein. 
Table 51. DHFR specific activities in E. coli J62 -2 (pUK2043; pUK1123). 
Plasmids Trimethoprim (mg /L) DHFR specific activity* 
pUK2043 0 74 
pUK2043 50 50 
pUK1123; pUK2043 0 126 
pUK1123; pUK2043 50 129 
pUK1123; pUK2043 500 48 
pUK1123; pUK2043 1000 25 
*nmol DHF reduced /min /mg protein. 
Again no induction was observed (table 51), thus no suppressor is present that will 
act in trans on the recombinant. It may be that this is a complex mechanism, as the 
results that have been presented would suggest, that requires large amounts of the 
plasmid DNA or is a property of the plasmid as a whole. 
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CHAPTER 5 
THE NUCLEOTIDE SEQUENCE OF 
THE dhfrIV GENE 
The nucleotide sequence of the dhfrlV structural gene was determined from 
pUK1227 (from Dr H -K Young) and an M13 sub -clone of the insert from 
pUK1227. The plasmid pUK1227 contained an insert from the original plasmid 
pUK1123 of approximately 1.2 Kb. 
The nucleotide sequence of the dhfrIV gene was found to be 432 base pairs long, 
giving a translation product with a molecular weight of 17, 195. This is a similar 
size to the other plasmid mediated dhfr genes and their products, with the 
exception of the type Ils, and to the chromosomal DHFRs. A ribosomal binding 
site was identified which terminated 9bp upstream of the initiation codon ATG. A 
-10 promoter sequence was identified 12 bp upstream of this site, and a possible - 
35 promoter sequence was taken as being 17bp upstream of this sequence (labelled 
a). Both of these sequences show reduced homology with the E. coli consensus 
promoter sequences. Further possible -10 and -35 regions were identified (labelled 
b), with the -10 region starting 28bp upstream of the initiation codon, and the 
possible -35 sequence starting 20bp upstream of this region. This again is only a 
weak promoter in terms of the E. coli consensus promoter sequences. 
A termination codon was identified which would give a protein of a size similar to 
the other DHFRs; however, no stem loop structure was seen associated with the 
termination of transcription. 
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figure 32. Nucleotide sequence of the dhfrlV dihydrofolate reductase showing 
translation of amino acids numbered from the initial methionine residue. 
indicates the ribosomal binding site. 
-35b -35a -10b 
TAACTGAACA CGCGCTTAAT GAAGCCGGCATTAATTCATC 
-l0a . . . . Met Ile Arg 
CAACCCTAAACT CCATTAAGGAAACATC ATG ATT CGT 
10 
Met Ile Leu Ala Ile Asn Asn Gln Cys Phe 
ATG ATT CTT GCA ATT AAC AAC CAA TGC TTT 
20 
Ile Gly Lys Asn Asn Thr Leu Met Tyr Arg 
ATC GGT AAA AAC AAC ACA CTG ATG TAT CGT 
30 
Leu Lys Asp Asp Met Leu Asn Phe Lys Lys 
TTG AAA GAC GAT ATG TTG AAC TTC AAA AAG 
40 
Met Ihr Gln Asn Asn Ile Val Val Met Gly 
ATG ACA CAA AAC AAC ATC GTG GTG ATG GGG 
50 
Arg Lys Thr Phe Glu Ser Leu Asn Asn Arg 
CGT AAA ACA TTT GAG TCG TTG AAT AAT CGC 
60 
Gly Leu Pro Asn Arg Leu Asn Val Val 
Val 




Thr Ser Lys Ala Glu 71ír Phe Glu Asp Ile 
ACA TCA AAA GCG GAA ACG TTT GAA GAC ATT 
80 
Gln Thr Ile Thr Ihr His Asp Met Lys Arg 
CAG ACC ATC ACA ACC CAT GAC ATG AAA CGT 
90 
Ser Glu Thr Phe Thr Lys Glu Gly His Val 
TCT GAA ACC '1' 1"1 ACC AAA GAA GGT CAT GTC 
100 
Val Tyr Ile ihr Pro Asp Ser Phe Ile Asn 
GTC TAC ATC ACT CCT GAT AGC TTT ATC AAT 
110 
Gln Phe Leu Pro Phe His Arg Asp Ser Glu 
CAG TTT CTT CCT '1°1'1' CAT CGT GAC AGC GAA 
120 
Asp Glu Ile Trp Val Ile Gly Gly Trp Arg 
GAT GAA ATC TGG GTC ATT GGT GGT TGG CGC 
130 
Arg Tyr Met Arg Gln Pro Leu His Val His 
AGG TAT ATG AGG CAG CCA CTC CAT GTG CAT 
140 
Lys Ser Phe Val His Leu Trp Met Met Ihr 
AAA TCA TTT GTA CAT TTG TGG ATG ATG ACG 
Arg End 
AGG TGA TGTAGCGCTAAACTAACTCTTTGGCGG 
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Homology between the nucleotide sequences of the dhfrIV and the E. coli K12 
chromosomal gene is 37% over the first 210 residues. Over the first 146bp, 
homology was greatest with the gene for the chromosomal DHFR, iìÒ/A, of 
Klebsiella aerogenes, at 51% (comparisons made with the EMBL database); the 
homology with the E. coli IÒJA over this region was 47 %. 
Table 52. Homologies between the DHFR type IV amino acid sequence and other 
plasmid- encoded DHFRs. 
DHFR Over whole enzyme 
% Homology % Similarity 
First 70 residues only 
% Homology % Similarity 
Chromosomal 26 38 37 54 
type IIIa 26 30 43 54 
type Inc 28 36 46 57 
type IX 19 30 30 47 
type I 30 32 34 47 
type V 24 33 37 51 
type VI 20 31 33 50 
type VII 22 32 36 50 
A search using the SWISSPROT database revealed homologies with the DHFRs of 
other species at the protein level. However this was only at the N- terminal 
sequence. The DHFR of Bacillus subtilis is 33 %, homologous 56% similar, over 
the first 78 residues. Lactobacillus casei showed 43% identity, 63% similarity, 
over a region from amino acid 13 to 67. The DHFRs of Enterococcus faeciurnand 
Neisseria gonorrhoeae gave similar levels of homology over various regions at the 
N- terminal sequence. The percentage homologies and similarities over the entire 
protein and the first 70 amino acids are summarised in table 52. The DHFRs show 
greatest homology at the N- terminal sequence (table 52); when conservative amino 
acid changes are considered, the similarity between the type IV and the other 
plasmid - mediated trimethoprim- resistant DHFRs is approximately 50% in this 
region. This figure falls to just over 30% if the entire sequence is considered. The 
type IV DHFR is most like the type IIIc in sequence, being 57% similar over the 




Very high rates of carriage of gram -negative lactose- fermenting rods resistant to 
the commonly used antimicrobials, chloramphenicol, trimethoprim and ampicillin, 
were recorded in the normal faecal flora of the population in the town of Vellore 
and three surrounding villages. Almost all of the sample population carried bacteria 
resistant to these antibiotics. As such, these results demonstrate the highest 
recorded incidence of carriage of antibacterial resistant organisms in the normal 
faecal flora of a population. In studies of trimethoprim resistance, for example, 
resistance in E. coli causing infections has been shown in the west usually to be 
below 20% (Heikkilä et al 1990a; Amyes et al 1986; Towner and Slack 1986). 
Even in special locations such as geriatric and long -stay hospitals, resistance to 
trimethoprim has not approached the level found in the present study. Bendall et al 
(1989) showed 50% resistance in a geriatric ward in the UK; Heikkilä et al 
(1990b) showed 40% in a similar situation in Finland, whilst Amyes et al (1986) 
showed 64% resistance in urinary tract isolates in a long -stay unit. In developing 
countries, higher levels of resistance have been recorded; for example 63.3% of 
urinary tract isolates were found to be resistant to trimethoprim in Nigeria 
(Lamikanra and Ndep 1989), and in Vellore resistance in urinary tract isolates was 
shown to be 64% (Young et al 1986a). In studies of normal flora in the Sudan, 
96% resistance to ampicillin and 77% resistance to trimethoprim was recorded in 
faecal coliforms from children (Shears et al 1988). In two studies in the 
Netherlands, high levels of resistance in faecal flora were recorded; 89% resistance 
to ampicillin and 28% resistance to trimethoprim were the highest figures recorded 
(Bonten et al 1990; 1992). 
In direct comparisons of developed countries to developing countries higher rates 
of carriage of resistant organisms have been recorded in normal faecal 
146 
gram- negative rods; for example, in a sample of children in Boston, only 1 in 39 
carried a trimethoprim resistant organism whilst 25 of 41 in Peru and 34 of 53 in 
China carried trimethoprim resistant E. coli. (Lester et al 1990). Although only 
small sample numbers were used, this does give an indication of the scale of the 
problem in the developing world. 
This study demonstrated almost universal carriage of resistant coliforms in the 
normal faecal flora, and this must influence the resistance rates seen in enteric 
pathogens. Of the trimethoprim resistant wild -type strains, 35% were capable of 
transferring trimethoprim resistance to the standard E. coli K12; of these most 
were capable of transferring trimethoprim resistance, along with resistance to any 
other antimicrobials situated on the plasmids, to a strain of Salmonella 
typhimurium. Thus, the resistance plasmids are capable of transfer to an enteric 
pathogen and expressing the resistance genes. It, therefore, seems feasible that 
transfer of these resistance mechanisms is possible to other enteric pathogens in the 
wild, as has been demonstrated by Griffin et al (1989) who identified a plasmid 
mediating resistance to trimethoprim- sulphamethoxazole in a Shigella outbreak as 
having originated in an E. coli from a urinary tract infection. 
Such high rates of resistance in the normal flora are reflected in high rates of 
resistance in pathogenic isolates. In this region high levels of resistance are seen in 
pathogenic isolates. In isolates from urinary tract infections, resistance to 
trimethoprim was found to be high, at 64% (Young et al 1986a). Reports have also 
been made of high levels of resistance to trimethoprim amongst Shigella flexneri 
isolates, 84% resistant, and S. shigae, 88% resistant, in Vellore (Jesudason et al 
1989). Transferable resistance to trimethoprim has also been seen in Vibrio 
cholerae in this area (Jesudason and John 1990). 
What are the possible contributory factors in this high rate of carriage of faecal 
organisms resistant to these antimicrobials? A high level of consumption of 
antibiotics is an obvious source for the promotion of resistance in all categories of 
bacteria. In India there is very little control over the use of antibiotics; in general 
the only constraint is perhaps financial. Many of the commonly used 
antimicrobials, such as trimethoprim, co- trimoxazole, chloramphenicol, nalidixic 
acid and ampicillin, can be bought from the many pharmacies without prescription, 
although by law these are necessary to obtain antimicrobials. This results in 
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self- dosing, probably with incorrect doses since the tablets may be bought singly 
and many of the people are very poor; possibly for inappropriate reasons when 
bacterial infection is not the cause or the wrong agents are used for the causative 
infecting organism. The bacteria, particularly commensal bacteria, are therefore 
exposed to sub -optimal doses of antimicrobial which promotes the development of 
resistance mechanisms (Thomson and Amyes 1993) and the maintenance and 
spread of these mechanisms in the bacterial population via plasmids (Anderson et 
al 1973; Petrocheilou et a11977) and possibly transposons and integrons. 
This is not, however, the only factor contributing to the propagation and 
maintenance of antibiotic resistant bacteria in the faecal flora. General hygiene and 
living conditions in Third world areas are low and this must promote the 
transmission of faecal bacteria. High levels of faecal bacteria were found to 
contaminate the drinking water of both the urban and rural populations; these 
bacteria were also very often resistant to antimicrobial agents and carried 
transferable resistance plasmids (Young and Jesudason 1990). Cramped living 
conditions without proper facilities and a population perhaps ignorant of basic 
hygiene must also contribute to the transmission of resistant organisms. 
The high incidence of illness and enteric disease, in particular, that is evident in the 
population of this study, is also of importance. The causative bacteria of the enteric 
diseases that are prevalent in this region are, by their very nature infectious, and 
unhygienic and poor living conditions obviously support their transmission and any 
resistance genes that they may carry. If resistance can be transferred from 
commensals to pathogens then the opposite is likely to be true. Thus, a cyclical 
promotion of resistance genes is possible between commensals and pathogens, 
encouraged by an ever -present challenge with antimicrobials at sub -optimal 
concentrations. 
The resistance to nalidixic acid seen in this study perhaps illustrates some of these 
points. Resistance to nalidixic acid is at a much lower rate than resistance to the 
other antibacterials, trimethoprim, ampicillin and chloramphenicol. Nalidixic acid 
resistance, unlike resistance to the other three agents, is never plasmid- mediated. 
Thus, transmission of resistance between strains via plasmid- transfer and the 
subsequent movement of other mobile genetic elements that have been shown to 
contribute to the distribution of resistance genes is not possible. A difference 
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between the urban and rural populations in their carriage of nalidixic acid resistant 
organisms was also recorded but was not observed in resistance to any of the other 
antibacterials. The urban population had significantly higher rates of carriage of 
nalidixic acid resistance than was shown in the rural population. This is perhaps the 
result of the greater use of nalidixic acid by the urban population in the treatment 
of shigellosis; thus the organisms in the town are exposed to the drug more 
frequently, with the subsequent increase in resistance rates. The non -transferable 
nature of the resistance means that resistance to nalidixic acid is more limited and 
the rates of carriage do not reach the levels seen with the other antimicrobials. 
The transferable, plasmid- mediated nature of trimethoprim resistance in this study 
no doubt contributed to the levels of resistance to this agent seen in this population. 
Approximately 35% of trimethoprim resistance was mediated by plasmids capable 
of transfer by conjugation. Most of these plasmids were capable of transfer, 
replication and expression of resistance in Salmonella typhimurium. They are then 
capable of mediating resistance in a known enteric pathogen, although proving a 
direct link between resistance in commensal organisms and pathogens may be 
difficult, this provides evidence that there is the potential for such a link. 
The plasmids mediating trimethoprim resistance were not of one or even a few 
types, but many different plasmids were responsible for resistance, showing a 
diverse population of resistance plasmids capable of spreading and maintaining 
both themselves and the resistance mechanisms that they harbour in the commensal 
and pathogenic enterobacteria. Many of these plasmids also carried resistance 
mechanisms to other agents, and a few could be characterized as multiresistance 
plasmids. This provides for possible co- selection of diverse resistance mechanisms 
situated on the same plasmid so that treatment with one agent not only selects for 
resistance to that agent but also to those other agents located on the plasmid 
(Amyes 1989). Sulphamethoxazole resistance is present on most of the plasmids, 
rendering them resistant to the commonly used trimethoprim- sulphamethoxazole 
combination. The TEM -1 ß- lactamase, mediating resistance to ampicillin, was also 
identified in all of those plasmids mediating resistance to ampicillin, of which there 
were 25. Worldwide, this is the most frequently identified of the plasmid- mediated 
,ß- lactamases and is the progenitor of many of the extended spectrum ß- lactamases 
that are responsible for resistance to the third generation cephalosporins. The 
change from TEM -1 to the extended spectrum ß- lactamases involves only a very 
149 
few mutations (Payne and Amyes 1991). The potential is therefore present in the 
plasmid population for rapid evolution to resistance to the third generation 
cephalosporins if the challenge of the use of these agents becomes frequent. 
Resistance to the first generation cephalosporin, cephaloridine, and to the 
amoxycillin /clavulanic acid combination was also seen to be mediated by TEM -1 in 
a few of the plasmids. This was probably by hyper -production of the enzyme 
which produces low level resistance to these agents. As was later shown, the 
induction of TEM -1 associated with those plasmids harbouring the type IV DHFR 
was also responsible for resistance to amoxycillin /clavulanic acid that was not 
identified initially. 
Fortunately no resistance was seen to the third generation cephalosporins or 
gentamicin; this is perhaps because these are very expensive drugs and are 
delivered by the I.V. route and are therefore limited mostly to hospital use. If the 
use of the newer oral cephalosporins were to become more common, the potential 
for the rapid evolution of resistance mechanisms is present in the form of TEM -1. 
Resistance to these agents was also absent from the original wild -type isolates. The 
original isolates did, however, have a wide -range of other resistance to other 
agents, most of the strains being resistant to sulphamethoxazole, ampicillin, 
tetracycline and streptomycin. Many of the wild -types were multiresistant, being 
resistant to six or more antibacterial agents. 
Half of the plasmid -mediated trimethoprim resistance resulted from the presence of 
the dhfrV gene. This gene, mediating high level resistance to trimethoprim, has 
been found in many locations around the world, although its prevalence is not as 
high, in other locations, as that of the dhfrI. It was, however, first isolated in Sri 
Lanka, which is very close to Tamil Nadu where this study was conducted. In Sri 
Lanka also it was shown to be the most common cause of plasmid- mediated 
trimethoprim resistance. This study was also conducted on the commensal faecal 
flora, although only in children (Sundström et al 1987). There are thus two 
possibilities, either the dhfrV is more prevalent in this part of the world or is more 
common in normal faecal flora. Unfortunately there is no information on its 
prevalence in pathogenic isolates in this area, although in other studies of normal 
faecal flora in the US the dhfrV is not commonly found. It may be, then, that the 
dhfrV is more common in plasmids in this part of the world. When the original 
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wild -type strains were tested for the presence of the dhf l and the dhfrV, the dhfrl 
was shown to be very much more common in strains that were not capable of 
transferring resistance to trimethoprim. In total, 37% of trimethoprim resistance 
was shown to be mediated by the dhfrI gene, while approximately 22% was 
mediated by the dhfrV. However, only 10% of this resistance was as the result of 
transferable dhfrl but 18% of resistance was due to transferable dhfrV. The 27% 
of trimethoprim resistance as a result of "non -transferable" dhfrl is a likely 
consequence of the transposition of Tn 7, carrying the dhfrI gene, onto the E. coli 
chromosome. The transposon is preferentially inserted into a locus on the E. coli 
chromosome (Lichtenstein and Brenner 1982) and this has been shown to be an 
increasing trend in trimethoprim resistance (Towner 1982; Kraft et al 1986; 
Heikkilä et a1 1991). 
In total, 35% of trimethoprim resistance was as the result of transferable 
plasmid- mediated enzymes and a further 30% was as the result of identifiable 
non -transferable resistance genes, most of which were dhfrI. 
The transposon and integron systems associated with the Tn21 -like transposons 
were also shown to be present, although some of the plasmids were shown not to 
possess a fully functional transposon. Positive hybridisation with the probe for the 
tnpA transposase gene was not obtained in eight of the plasmids carrying the 
dhfrV, indicating the absence of the transposase. All the dhfrV genes were, 
however, associated with the integrase -like ORF of Tn21 responsible for 
integration of "gene- cassettes" into the Tn21 -like group of transposons (Sundström 
and Sköld 1990). Whether those genes not associated with the tnpA gene had 
undergone direct integration into the plasmid by the action of the 
integron/integrase, as is the case in the type II genes encoded by plasmids R751 
and R388 (Sundström et al 1988) or that the tnpA had been deleted was not 
established. It is interesting to note that those plasmids possessing a tnpA gene 
had, in general, more resistance mechanisms associated with them, whereas those 
without the transposase gene had fewer, in four cases only the trimethoprim 
resistance determinant, perhaps indicating integration into the plasmid without the 
presence of the transposon, which commonly has more than one resistance 
mechanism associated with it. Further examination of the plasmids would be 
necessary to confirm this. 
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Ir those plasmids harbouring the dhfrl gene, all carried the ORF for the integrase 
of the Tn 7 transposon, the transposon usually associated with the dhirl gene. 
Spectinomycin resistance is also usually carried by this transposon. In those 
plasmids isolated in this study, however, three are sensitive to spectinomycin. In 
these cases rearrangements or deletions, possibly mediated by the integrase, may 
have resulted in the loss of the resistance phenotype, or the replacement of 
spectinomycin resistance with another resistance gene, as has been recorded 
previously (Tietze et al 1987; Sundström et al 1991). 
In seven plasmids, all responsible for low level resistance to trimethoprim, the 
dhfrlV gene was identified as mediating trimethoprim resistance. The dhfrIV was 
first characterized in E. coli isolated from urinary tract infections from Vellore in 
1984 (Young et al 1986b). Since then it has not been identified in any other study 
and this is the first report of the DHFR type IV since the initial report. Five of the 
plasmids harbouring the gene were shown to be identical in both their resistance 
profile and their restriction endonuclease digest pattern; these plasmids were all 
isolated from samples from the same village. It might be expected that since both 
studies were conducted in the same area that the same resistance mechanism might 
be found; however, the dhfrIV mediates only very low level resistance, as assayed 
by commonly used methods (MIC 4mg /L) and would appear to be a fairly 
inefficient resistance mechanism when compared to enzymes such as the types I 
and V. It has survived this competition; thus the enzyme's unique property 
amongst the DHFRs of being inducible may be important in the resistance 
produced by this enzyme. 
The induction mechanism was shown to be present, although one plasmid was 
capable of mediating higher levels of resistance by constitutive expression of 
moderate levels of the enzyme. The plasmid pUK2007 was shown to be inducible, 
and as had been shown in the plasmids reported previously, the enzyme was 
expressed in increased amounts when the cells harbouring it were challenged with 
increasing concentrations of trimethoprim. Thomson et al (1993) have shown that 
this is a metabolic effect that is abolished by the presence of thymidine in the 
growth medium. Thymidine, being the ribonucleoside of thymine, is an antagonist 
of trimethoprim, which acts by depleting thymine in the cell, producing thymine 
starvation and subsequent thymine -less death (Amyes and Smith 1974a). 
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It was shown in this study that deprivation of thymidine in a thymine requiring 
auxotroph of E. coli J62 -2 carrying the plasmid pUK2007 resulted in the increased 
expression of the DHFR type IV. Thus, thymine -less stress is sufficient for the 
induction of the DHFR type IV and the metabolic basis for the production of the 
induction response by trimethoprim. 
Thomson et al (1993) speculated that the presence of methionine, glycine and 
adenine was necessary for the induction of the DHFR type IV to occur. This was 
presumed because at 40mg /L no induction of the enzyme is produced when these 
metabolites are not present in the media. Amyes and Smith (1974a) had also 
previously shown that these metabolites are necessary, because of their role in the 
DHF - thymine pathway (figure 32) conserving the THF pool by acting to inhibit 
its conversion to 10- formyl THF, a necessary step towards the formation of 
thymine (figure 32), to bring about thymineless cell death. It has been shown here, 
however, that increased concentrations of trimethoprim will bring about induction 
of the DHFR type IV in the absence of methionine, glycine and adenine. Increased 
concentrations of trimethoprim were tried initially because it was shown that in 
minimal medium, the MIC is considerably higher than in media containing 
methionine, glycine and adenine. So given that significantly higher concentrations 
of trimethoprim than the MIC, as derived by the agar dilution method on IST agar, 
were necessary to produce induction it seemed that because higher MICs are 
obtained in minimal media higher concentrations of trimethoprim would be 
necessary to produce induction. The higher MICs and the higher concentration 
required to bring about induction of the type IV, as will be seen, both reflect the 
involvement of the pathway shown below in which DHF is reduced to THF then 
regenerated in the production of thymine. 
Increased concentrations of trimethoprim are required to bring about induction of 
the DHFR type IV in the absence of the metabolites, methionine, glycine and 
adenine. Thymine production is prevented in the presence of methionine, glycine 
and adenine, by the inhibitory effect of these metabolites on the reactions after the 
formation of THF. Methionine, glycine and adenine act to conserve the THF pool 
which is depleted by the action of trimethoprim on the dihydrofolate reductase. 
This then results in depletion of the precursors, specifically 5,10 methylene THF, 
that lead to thymine formation, and therefore thymine depletion and subsequent 
cell death. This also has the effect of halting the regeneration of DHF, further 
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contributing to the action of trimethoprim which is a competitive analogue of 
DHF. Thus rapid thymine starvation occurs and induction of the DHFR takes 
place. 
Although THF production is inhibited some will be produced; because 
trimethoprim is a competitive inhibitor of dihydrofolate reductase there is a 
statistical likelihood that some reduction of DHF will take place. This will be 
dependant upon the Ki of the enzyme, i.e. the sensitivity of the enzyme to 
trimethoprim, the concentration of trimethoprim, the concentration of DHF 
available and the amount of enzyme present. If methionine, glycine and adenine 
are not present the THF which is produced may be enough to maintain thymine 
production, which would in the presence of methionine, glycine and adenine have 
been prevented by their inhibition of the formation of 5,10- methylene THF. In 
minimal medium, growth and protein synthesis will be slower; protein synthesis 
being a necessary factor in thymine -less death this will result in cell survival and 
possible continued slow growth. In the presence of the type IV DHFR which is 
moderately resistant to trimethoprim, and will be produced in larger amounts even 
without induction, being encoded as it is by a plasmid, enough THF may be 
produced to allow thymine synthesis and regeneration of DHF. 
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Figure 32. The pathway of 5,10- methylene THF formation from THF on which 
methionine, glycine and adenine act to produce thymine starvation in the presence 
of trimethoprim 
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The regeneration of DHF will contribute to the resistance of the cell to the effects 
of trimethoprim, competing as it will with the available trimethoprim, contributing 
to the maintenance of thymine synthesis and thus raising the MIC of trimethoprim. 
In the presence of methionine, glycine and adenine, DHF will become trapped in 
the form of THF; thus regeneration is prevented and competition with the 
trimethoprim present is reduced. The limitation of the supply of DHF is a major 
factor in the action of trimethoprim. Under normal circumstances the action of 
trimethoprim will result in the build up of DHF and thus it will increasingly lose 
effectiveness as a competitive inhibitor as a result of the build up of substrate 
(Hitchings 1973). It is probably at this level that the sulphonamides have most 
effect, i.e. in limiting the supply of newly synthesized DHF. This then may 
account for the increased MIC of trimethoprim in minimal medium when compared 
to the MIC in media containing methionine, glycine and adenine. 
It also indicates why increased concentrations of trimethoprim are necessary to 
bring about induction of the DHFR type IV in the absence of methionine, glycine 
and adenine. Raised concentrations of trimethoprim are required to bring about 
saturation of the DHFR in order to limit further the reduction of DHF to THF and 
thus eliminate the synthesis of thymine; this will then result in the induction of the 
DHFR type IV. Indeed trimethoprim has been shown previously to be bactericidal 
if high enough concentrations are present, even in minimal medium (Bushby 
1973). This is possibly the result of saturation of the DHFR and subsequent 
elimination of any thymine synthesis. 
In log -phase cells, induction of the enzyme did not occur or occurred only at very 
low levels. It was demonstrated that such cells have increased amounts of DHFR 
present and thus larger numbers of available sites with which to bind trimethoprim; 
this then increases the chances of THF being formed and the synthesis of thymine 
via the pathway in figure 32. The cells are thus perhaps able to cope with the 
concentrations of trimethoprim present. The same is true of cells in high numbers; 
greater cell numbers will mean larger numbers of DHFR molecules will be 
available to "soak -up" the trimethoprim present and THF formation will again be 
more likely. The effect of inoculum size on MICs has been documented. Bushby 
(1973) observed up to 300 -fold increase in MIC when the inoculum was raised 
from 5 organisms to 5x105 organisms, and no doubt this is the same process at 
work. Thus, in log -phase cells induction is abolished, despite high concentrations 
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of trimethoprim. However, it may be that other factors are also involved; 
log -phase cells may contain more thymine or DHF or both. It would seem 
reasonable that in rapidly dividing cells higher concentrations would be present, 
not only of DHFR, but also of thymine and DHF. The presence of increased 
concentrations of these factors and the enzyme would act to decrease the effect of 
trimethoprim and reduce the induction of the DHFR type IV. 
This may go some way to explaining the route whereby trimethoprim produces a 
metabolic effect which results in the increased expression of the DHFR type IV. It 
was, however, shown that the gene for the TEM -1 ß- lactamase was present on the 
plasmid that harboured the dhfrlV, and that this mechanism of resistance was also 
inducible. This has never before been demonstrated in TEM -1 or any other 
plasmid- mediated ß- lactamase in gram- negative bacteria. 
The inducible chromosomal ß- lactamases possessed by many species of 
gram -negative rod are induced as a direct response to the antibiotic, although 
intervening cell wall breakdown products may act as intermediates (Korfmann and 
Sanders 1989), with a response being seen almost immediately on addition of the 
antibiotic to the medium in log -phase cells. This is not true of the mechanism 
described here; the response to the antibiotic is not seen in log -phase cells or cells 
in high numbers, as was seen to be true of the response to trimethoprim. High 
concentrations of ampicillin, far in excess of the MIC, were necessary to produce 
the induction response, as was also shown in the response of the DHFR type IV to 
trimethoprim. The high concentrations of antibiotic are probably necessary to 
swamp the available TEM -1 and thus allow ampicillin to take effect. However, 
much lower levels are necessary when clavulanic acid is present to inhibit the ß 
-lactamase. Thus, it would also seem likely that the induction of both the TEM -1 
and the DHFR type IV by the ß- lactam antibiotics described is a result of a 
metabolic stress brought about by the action of the drugs, as is the case with 
trimethoprim. 
The most surprising aspect of this mechanism is that the ß- lactam drugs are able to 
produce induction of the DHFR type IV and that trimethoprim is able to produce 
induction of the ß- lactamase. 
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The increased effectiveness of trimethoprim in the presence of methionine, glycine 
and adenine is also apparent in the increased expression of the ß- lactamase, as 
would be expected in a response triggered by the metabolic stress imposed by 
trimethoprim. The presence of methionine, glycine and adenine has no effect on 
the ability of amoxycillin /clavulanic acid to produce induction of either the TEM -1 
or the DHFR type IV. 
The role of thymidine was, however, more difficult to assess. Thy mine starvation 
produced induction of both mechanisms and thus a general metabolic response 
producing induction of both mechanisms is implicated. The 0- lactams and 
trimethoprim have little in common and it is difficult to imagine a mechanism that 
could link them other than a general metabolic response to the stress brought about 
by the treatment with these antimicrobials. It was noted that neither treatment with 
nalidixic acid nor streptomycin was capable of producing a similar response. 
However, nalidixic acid resistance is not present on the plasmid and hence no 
induction of a resistance mechanism is possible that would permit recovery of the 
cells. Streptomycin, on the other hand, is an inhibitor of protein synthesis which 
may be necessary for the induction response. 
In treatment with both amoxycillin /clavulanic acid and trimethoprim the 
morphology of the cells changed, and in a similar way. The cells elongate and 
become much larger, before they recover and grow normally. Cells treated with 
amoxycillin/clavulanic acid also displayed a bulge in the centre of the elongated 
cells. This is often seen in cells treated with ;ß- lactam agents, and may be an 
intermediate in the formation of spheroplasts. This change in cell morphology was 
associated with concomitant cell death after inoculation of the antimicrobial 
containing media. The resumption of normal cell growth must be brought about 
when sufficient levels of enzyme have been induced to circumvent the effect of the 
drug in the media. 
Thus a general response would seem to be implicated, perhaps involving the whole 
plasmid. A close link between the genes of the two resistance mechanisms could 
not be demonstrated by the failure to co- select recombinants resistant to both 
agents after restriction digest and cloning. This combined with the finding that the 
resistance mechanisms are not increased proportionally would seem to indicate that 
they are not transcribed from the same promoter. It might be possible to select 
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constitutive over -expressing mutants of one enzyme and show that the other is not 
over -expressed; this may assist in ruling -out transcription of both genes from a 
common promoter. Dorman (1991) has demonstrated the modification of gene 
expression as a result of metabolic stress on bacterial cells effecting supercoiling of 
plasmid DNA which in turn modifies gene expression. Such a mechanism is 
possibly acting here. However, the failure to clone the mechanism makes 
investigation of the molecular basis of this mechanism difficult, although the 
possibility of a trans acting suppressor seems to have been eliminated. 
Although the molecular mechanism of induction is unclear, the phenotypic effect 
has been characterized. When the cells were challenged before the MIC assays 
were performed, a dramatic increase in the MIC of trimethoprim, ampicillin and 
amoxycillin /clavulanic acid was observed, and the MICs observed in broth assays, 
with enzyme induction, were also very much higher. So under normal 
circumstances the enzymes are not induced on agar plates. The resistance to 
trimethoprim was increased to levels comparable with high level resistance 
mechanisms such as the DHFRs I and V. Resistance to amoxycillin/clavulanic acid 
is increased to levels which may be clinically significant and result in a failure of 
therapy. 
Such a resistance mechanism has important implications. It has been reported 
previously that transferable low level resistance mechanisms to trimethoprim may 
be overlooked (Towner and Pinn 1981). In this mechanism resistance to both 
trimethoprim and amoxycillin /clavulanic acid is low as assessed by normal assay 
conditions. When hyper- production of the enzymes occurs, resistance is 
significantly increased. It may be important to monitor low level resistance to 
indicated the levels of such mechanisms and assess the significance of low level 
resistance producing failure of therapy. 
The structural gene of the dhfrlV that mediates resistance to trimethoprim is 432 
base pairs and gives a translation product of Mr 17 195. This is of a size similar to 
other dhfr genes, both plasmid mediated and the chromosomal genes of many 
species. It does not, however, agree with the findings of Thomson, Young and 
Amyes (1990) that the DHFR type IV had a Mr of 33 000 as given by SDS -PAGE, 
under even the most strenuous of de- naturing conditions. The amino acid sequence 
given by the translation of the nucleotide sequence when compared to that given by 
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the partial N- terminal sequence (Thomson, Young and Amyes 1990) shows only 
one difference which occurs at position 12. Automatic N- terminal amino acid 
sequencing determined a threonine residue at this position but a cysteine residue 
was shown at this position by nucleotide sequencing. This may be significant in the 
structure of the DHFR type IV enzyme. Cysteine residues are rarely substituted for 
other amino acids without specific cause, because of their role in the conformation 
of proteins (Dayhoff et al 1978), and no other DHFR possesses a cysteine at this 
position. Given that the Mr is 33 000 as determined by SDS -PAGE and 17 200 by 
the nucleotide sequence it would seem likely that the protein occurs as a dimer and 
that the sub -units are joined by a di- sulphide bridge formed by the cysteine residues 
at position 12. So even under de- naturing conditions the sub -units would not be 
separated and the molecular weight of only the dimer could be determined. 
Table 53. Homologies between the DHFR type IV amino acid sequence and other 
plasmid- encoded DHFRs. 
DHFR Over whole enzyme 
Homology Similarity 
First 70 residues only 
Homology Similarity 
E. coli 
chromosomal 26 38 37 54 
type IIIa 26 30 43 54 
type IIIc 28 36 46 57 
type IX 19 30 30 47 
type I 30 32 34 47 
type V 24 33 37 51 
type VI 20 31 33 50 
type VII 22 32 36 50 
At the level of the nucleotide sequence the gene is 47% homologous to the E. coli 
chromosomal gene (Smith and Calvo 1980) over the first 210 nucleotides. 
However, homology in the amino acid sequence over the same region was only 
37 %, similarity being 54 %, so many of the changes in the nucleotide sequence 
must be significant and result in a difference in the amino acid sequence. The 
greatest homology at the level of the amino acid sequence was with the 
chromosomal DHFR of Klebsiella aerogenes, being 51% homologous to the 
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DHFR type IV, but again only at the N- terminal sequence. The type IV DHFR 
amino acid sequence shows homology with other DHFRs, both plasmid encoded 
genes and the chromosomal DHFRs of diverse species; however, this is seen only 
at the N- terminal sequence, for approximately the first 70 amino acids. Beyond this 
point comparisons could not be made. The DHFR IV has a region of some 45 
amino acids, from amino acid 70 to 115, that bears no resemblance to the other 
DHFRs in which this region is usually shorter, approximately 20 residues long. In 
this region, between the NADPH binding site at amino acids 63 -66 and the 
NADPH/trimethoprim binding site at positions 115 -119, the other DHFRs all show 
very much reduced homology; this area seems not to be associated with any 
specific function and this may account for the reduced homology. 
The DHFR type IV is rather unusual in that this region is somewhat extended. This 
may have resulted from the insertion of a section of DNA from another location. 
Only at the NADPH/trimethoprim binding site associated with the amino acids in 
the region 119 -124 is there any homology at the C- terminal end. The type IV 
DHFR is somewhat shorter after this region than is seen in the other DHFRs, 
stretching only 19 residues whereas other DHFRs are approximately 40 residues 
longer than this and form another NADPH binding site which seems to be 
completely absent in the dhfrlV gene. 
When comparing the translation to amino acid sequence of the nucleotide sequence 
with the other DHFR amino acid sequences before and after amino acid 70, the 
lack of homology after amino acid 70 is revealed. For instance, the similarity 
between the DHFR IV and the E. coli chromosomal gene is 54% over the first 70 
amino acids but only 38% over the entire gene, and in the type Inc the similarity is 
57% over the first 70 amino acids but only 36% over the entire protein, while the 
similarity in the IIIa drops in these regions from 54% to 30 %. Thus it would seem 
that the type IV has been conserved in the N- terminal region but is very unlike the 
other DHFRs at the C- terminal end, except around the NADPH /trimethoprim 
binding site. Since the N- terminal region is most heavily associated with enzyme 
function (Rouch et al 1989) it seems reasonable that the C- terminal region can 
undergo considerable change without affecting the function of the enzyme. This 
raises the question of how to compare sequences and assess degrees of relatedness 
between proteins; certainly in this case it would seem inappropriate to take the 
percentages for homology over the entire gene as reflecting the DHFR type IV's 
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relationship to other DHFRs since this would demonstrate a very low degree of 
relatedness that would not reflect the considerable homology demonstrated at the 
N- terminal end, which is more important for enzyme function. The considerable 
differences in the C- terminal region may be associated with the induction 
mechanism; however, this may be unlikely since TEM -1 is also inducible in this 
plasmid, and from the pI derived for this enzyme it would not seem to be 
considerably different from other TEM -1 enzymes, so inducibility is most likely 
associated with structures outwith the resistance genes themselves. 
If the N- terminal region only is considered, the type IV is most similar to the type 
IIIc, the h a, the E. coli chromosomal DHFR and the K aerogenes chromosomal 
DHFR. It is significant that the type IV is most similar to chromosomal and low 
level trimethoprim resistance DHFRs since this enzyme is only moderately resistant 
to inhibition by trimethoprim. 
If the amino acid sequences of the type IV, other plasmid- mediated DHFRs, and 
the E. coli chromosomal DHFR (figure 33) are aligned, considerable conservation 
of homology can be seen at sites associated with the function of the enzyme, i.e. 
with NADPH binding sites, methotrexate and trimethoprim binding sites that are 
analogous with DHF binding sites. There are, however, a number of changes 
identifiable in these regions that may be associated with changes in function or 
resistance of the enzyme. It is, however, difficult to identify specific changes that 
result in an increase in resistance to trimethoprim, as can be done in the TEM 
enzymes such that a change in single amino acids has been identified with a change 
in specificity and function of the enzyme (Payne and Amyes 1991). The 
differences in the DHFRs are more gross and the effect of a difference in single 
amino acids can only be speculated upon. There are changes in sequence that may 
be identified at important regions and may be significant in changes of enzyme 
function. Often these differences are conservative between similar amino acids, and 
such changes are often consistent between different DHFRs. The type IV also has a 
number of changes in amino acids that are normally highly conserved in the other 
DHFRs (figure 33). 
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Figure 33 Amino acid sequence of the DHFR type IV compared with other DHFR 
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Figure 33. Amino acid sequence of the DHFR type N compared with other DHFR 
amino acid sequences from the E. coli chromosomal (Chr) enzyme and plasmid 
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ure 33 Amino acid se s uence of the DHFR . IV com . ared with other DHFR 
amino acid sequences from the E. coli chromosomal (Chr) enzyme and plasmid 
mediated enzymes, continued. 
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° Indicates an amino acid associated with an NADPH binding site. 
Indicates an amino acid associated with a trimethoprim binding site. 
V Indicates an amino acid associated with a methotrexate binding site. 
(Rouch et al 1989) 
Shaded residues are homologous. 
Shaded residues are similar. 
At amino acids 5 -7, associated with an NADPH and trimethoprim binding site, the 
sequence is conserved, although at position 6 there is some variation. At position 7 
alanine is completely conserved. The complete conservation of isoleucine and 
glycine at positions 14 and 15 is seen in all the plasmid- encoded DHFRs and across 
species, this again being involved in NADPH binding. From position 18 to 
22, 
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associated with both NADPH and trimethoprim -DHF binding, several interesting 
differences are seen. At position 18, although not directly associated with a binding 
site but perhaps close enough to exert an influence, the low level resistance 
enzymes and the E. coli chromosomal enzyme have an asparagine residue, the high 
level resistance mechanisms having a proline or leucine. Proline, in particular, may 
be important since it will cause a change in strand direction, because of the 
residues shape, and thus cause a change in conformation perhaps altering 
trimethoprim binding. Then at position 20, which is directly associated with both 
trimethoprim and NADPH binding, the sensitive E. coli enzyme has a methionine 
whilst the resistant enzymes have either a leucine or isoleucine substitution. So 
although there is a difference it is between similar amino acids, which is perhaps 
significant at an area associated with both NADPH and trimethoprim binding; 
NADPH binding must be preserved whilst trimethoprim binding is perhaps 
reduced. There are at positions 21 and 22 two substitutions in the type IV that are 
otherwise completely conserved in the other DHFRs included here, and in other 
species. Methionine is substituted for proline which again will result in a 
conformational change as outlined above, and position 22 tyrosine is substituted for 
tryptophan, which is a conservative change. 
The region from amino acids 27 to 32 is a region which has been associated with 
methotrexate, trimethoprim and thus DHF binding (Rouch et al 1989). The 
aspartate residue has been implicated as an important residue in differentiating 
between trimethoprim resistant and sensitive DHFRs (Sundström et al 1993). In 
the sensitive and low level resistance mechanisms the aspartate is conserved, as it 
is in the chromosomal enzymes of other species. In the highly resistant DHFRs, 
however, the aspartate is substituted for a glutamic acid residue. This residue is 
also seen in mammalian DHFRs which are resistant to the action of trimethoprim. 
Although this is a conservative substitution, these amino acids being very similar, 
glutamic acid has a larger side -chain and this may be the significant difference, 
preventing trimethoprim binding by steric hinderance. Also at position 28 in the 
low level resistance mechanisms either leucine or methionine, similar amino acids, 
are present but in highly resistant DHFRs a glutamine is found. The residues 
phenylalanine and lysine are highly conserved at positions 31 and 32, indicating a 
significant role in DHF binding. 
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From position 40 stretching to 51 there is a region that is concerned with NADPH 
binding and, towards the end of this region, with trimethoprim binding. Within this 
region is a highly conserved glycine, arginine, lysine, threonine, phenylalanine 
motif (although conservative substitutions of lysine with histidine or arginine and 
phenylalanine for tryptophan or tyrosine are found). This highly conserved region 
is also present in the DHFR type IV. Serine at position 50 is also highly conserved, 
being directly involved with both NADPH and trimethoprim binding; however, at 
position 51 there are conservative substitutions with possible significance in 
trimethoprim binding, i.e. leucine or methionine for isoleucine. 
The leucine, proline residues of positions 55 and 56, and the arginine at position 
58 are highly conserved. At position 63, although there is involvement with 
NADPH binding, there is consistent substitution of leucine in the chromosomal E. 
coli enzyme, as well as the chromosomal DHFRs of other species, for a valine 
residue in the resistant plasmid- mediated DHFRs; this is a conservative substitution 
which may have implications for enzyme function, being consistent throughout 
many genes encoding trimethoprim resistant dihydrofolate reductases. There then 
follows the region of reduced homology in which it is not feasible to make 
comparisons between the type IV and the other DHFRs. 
At the region associated with NADPH and trimethoprim binding at amino acids 
119 -125, homology is again seen when the sequence of the type IV is aligned with 
the other DHFRs. The glycine doublet which is entirely conserved throughout the 
DHFRs is present in the DHFR type IV, and over the length of this short region 
the type IV resembles both the E. coli chromosomal enzyme and the other 
plasmid- mediated DHFRs. After this region, homology once again disappears and 
the DHFR ends earlier than the other DHFRs. 
Many of the changes mentioned above may affect function and therefore resistance 
conferred by the enzyme. This, however, can only be speculation as effects on the 
binding as it relates to specific amino acid changes of the two substrates, NADPH 
and DHF, and trimethoprim, are very difficult to understand. Mutation studies or 
site directed mutagenesis would have to be undertaken in order to investigate the 
effect of single changes on enzyme function and sensitivity to trimethoprim. 
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In the region immediately upstream of the structural gene of the dhfrlV two 
possible -10 and -35 promoter regions were identified, along with a single 
ribosomal binding site terminating 9bp upstream of the initiation codon, ATG. 
Of the two possible -10 and -35 promoter regions, one of the -10 regions 
(TAAACT) was identified 12bp upstream of the ribosomal binding site and the 
complementary -35 (CCGGCA) region was taken as being 17bp upstream of the 
-10 region, as a 17bp separation is the most common between these promoter 
regions (Harley and Reynolds 1987). Neither of these sites showed a high degree 
of homology with the E. coli consensus promoter sequences as shown by Harley 
and Reynolds (1987), and as such are possibly weak promoters. 
The other -10 and -35 promoter regions that were identified were further upstream 
than those described above. The -10 site (TTCATC) starts 28bp from the ribosomal 
binding sequence and a possible -35 region (CACGCG) was identified 20bp 
upstream of the -10 sequence. Although this is not ideal spacing between the two 
promoter regions, such separation is seen and these possible promoters have more 
in common with the E. coli consensus promoter sequences (Harley and Reynolds 
1987) than those described above. This may, however, represent only a weak 
promoter of the dhfrIV gene. The weak similarity to E. coli promoters may reflect 
a possible role in the induction mechanism; an investigation of the promoters of the 
other DHFR type IV gene that did not show induction, that of plasmid pUK2026, 
may indicate the part played by these promoter regions in induction. The 
dissimilarity between the promoter region of the dhfrIV gene and the E. coli 
consensus promoters may also reflect the origins of the enzyme in a species 
unrelated to E. coli or indeed the Enterabacteriaceae. 
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CONCLUSIONS 
There was almost universal carriage of gram -negative rods resistant to the 
commonly used antimicrobial agents, ampicillin, chloramphenicol and 
trimethoprim in the normal faecal flora of the population in and around the town of 
Vellore, in Tamil Nadu. 
It could be speculated that this was as a result of poor hygiene and general living 
conditions combined with the indiscriminate use of antimicrobials. This presents a 
threat to the continued use of these antimicrobials and presents a basis for the 
evolution of novel resistance mechasisms. 
Transferable trimethoprim resistance was mediated by a number of plasmids that 
were also responsible for resistance to a range of other antimicrobial agents. The 
responsible for plasmid- resistance 
the type V DHFR, and this is an unusual finding. When non -transferable resistance 
is also considered, however, the dhfrl gene is the most prevalent trimethoprim 
resistance gene, probably as a result of transposition into the E. coli chromosome, 
as has been widely reported by other workers. This makes the resistance gene more 
stable, being less likely to be lost from the chromosome but remaining available 
for transposition into any plasmid entering the cell. 
In all the plasmids that encoded the DHFR type I, the transposon Tn 7 was also 
identified; this is the most frequently found location for the dhfrl gene. In all of 
those plasmids that harboured the dhfrV, gene the integrase -like ORF of Tn21 was 
present, but in several plasmids the tnpA gene of the Tn21 transposase was not 
identified, indicating that Tn21 was not present in a fully functional form. 
The dhfrfV was identified in all of those plasmids that mediated low level 
trimethoprim resistance. The inducible nature of this resistance mechanism was 
shown to be a result of thymine starvation imposed on the cell by the action of 
trimethoprim. The plasmid on which the dhfrlV was characterized also carried the 
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TEM -1 ß- lactamase. As part of this plasmid the TEM -1 (3-lactamase was also 
shown to be inducible; such a response has never been demonstrated previously in 
this enzyme. Trimethoprim and the ß- lactam agents, amoxycillin and 
amoxycillin/clavulanic acid, were capable of producing induction of both the 
DHFR type IV and the TEM -1 ß- lactamase. 
It was speculated that this was perhaps a general response to the metabolic stress 
imposed on the cell by these agents; however, a mechanism to account for this 
could not be established. This response did, however, produce dramatic increases 
in resistance to trimethoprim and amoxycillin/clavulanic acid that would not 
normally be detected by commonly used assay methods for determining 
antimicrobial sensitivities. 
The dhfrlV is related to the other plasmid mediated dhfr genes and to the 
chromosomal gene, foVA, of E. coli and other species, both gram -positive and 
gram -negative. Homology was greatest at the active sites that have been identified 
in these enzymes. There were, however, great differences in sequence towards the 
C- terminal end that perhaps indicates a genetic origin, of this unusual DHFR, 
removed from the Enterobacteriaceae. 
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